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Abstract 
 
CD is a chronic transmural inflammatory disease of the gut. The aetiology of CD 
is unknown, but is likely to result from dysregulated innate immune responses to 
gut microbiota leading to over activation of the acquired immune system in a 
genetically susceptible host. Inflammation occurs anywhere from mouth to anus, 
in addition to extra-intestinal sites. This compartmentalisation of the 
inflammatory process is linked to tissue-specific innate immune mechanisms 
and immune cell homing. DCs play a key role in discriminating between gut 
commensal microbiota and harmful pathogens, directing T-cell polarisation and 
directing immune cells to specific anatomical locations by expressing and 
imprinting homing markers. 
 
Improved understanding of the immunopathogenic basis of inflammation in CD 
has led to the development of more efficacious medical therapy, in particular, 
targeting the pro-inflammatory cytokine TNFα. The precise mechanism of action 
of TNFα blockade in CD remains unclear.  
 
We found homing marker expression on circulating DCs in patients with CD 
closely correlates with anatomical phenotype of inflammation. When immune 
cells are cultured with IFX we found homing marker expression on monocytes 
and T-cells changed from a gut-homing to skin-homing phenotype., perhaps 
explaining the phenomenon of ‘paradoxical inflammation’ seen in some patients 
treated with anti-TNFα therapy.   
 
Blood-enriched DCs isolated from patients with active CD had higher levels of 
pro-inflammatory cytokines in culture medium. IFX culture resulted in reduced 
concentrations of pro-inflammatory cytokines and decreased gut-homing 
marker expression. 
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Finally, we examined the functional effects of IFX-pre-treated-LDCs on T-cells. 
There was a dose-dependent reduction in LDC stimulatory capacity with 
increasing concentrations of IFX, but no changes in T-cell phenotype.     
 
The effect of IFX on the immune system goes beyond TNFα blockade alone. This 
work has identified several mechanisms by which IFX interacts with immune 
cells in vitro, which may result in changes to CD inflammatory process in vivo.  
 
Abbreviations:  
CD  Crohn’s disease 
DCs   Dendritic cells 
TNFα  Tumour necrosis factor alpha 
IFX  Infliximab  
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1.1  Crohn’s disease 
 
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal 
tract characterised by a relapsing-remitting course. The earliest description of 
chronic transmural inflammatory bowel disease was provided by Dalizel in 1913, 
but the disease was first recognised as a pathological and clinical entity in 1932 
by Burril Crohn and colleagues, who described a regional ileitis (Crohn, Ginzburg 
et al. 1984). The inflammatory process in CD can involve any part of the digestive 
tract from the mouth to the anus, but predominantly affects the distal ileum and 
colon (figure 1). It is unclear why different patients develop Crohn’s disease in 
different anatomical locations.  
 
 
 
 
Figure 1. Anatomical distribution of Crohn’s disease in the human gastrointestinal 
tract. The ileocaecal region is the most commonly affected location in the adult 
Crohn’s disease population. Isolated colonic disease is the most common phenotype 
in paediatric populations (approximately 80% of patients under the age of 16 
years). 
 
 
17 
 
1.1.1   Epidemiology  
 
The incidence of CD varies depending on the region studied. The highest 
incidence is seen in the United Kingdom, North America and northern parts of 
Europe. Studies have consistently identified a North-South gradient in the 
incidence of CD within Europe, with higher disease incidence in Northern 
countries, and furthermore the same incidence trends are seen within individual 
countries, including the UK (Economou, Zambeli et al. 2009). More recently, the 
ECCO-EpiCom inception cohort has shown the existence of an East-West gradient 
in the incidence of CD, with higher incidence rates in West Europe compared to 
East Europe (Burisch, Pedersen et al. 2014).   
 
The incidence of CD has been increasing over time in most countries, although it 
now seems to have reached a plateau in the North America (Loftus, Loftus et al. 
2007), Sweden (Lapidus 2006) and in the UK (Gunesh, Thomas et al. 2008).   
 
CD can occur at any age, although there are two peaks of incidence. The first 
peak is seen in teens and early twenties with a second peak in the fifties to 
seventies (Baumgart and Sandborn 2007). There is a slight female predominance 
in CD, which has been shown by several studies (Moum, Vatn et al. 1996; Vind, 
Riis et al. 2006; Ramadas, Gunesh et al. 2010).  
 
The prevalence of CD in North America is estimated as ranging from 26 to 198 
cases per 100,000 persons, equating to 400,000 to 600,000 patients with CD 
(Loftus, Schoenfeld et al. 2002). Prevalence estimates from Northern Europe are 
lower, ranging from 27 to 48 persons per 100,000 (Bernstein, Wajda et al. 2006). 
A study carried out in the UK, using data obtained from primary care, reported 
the prevalence of CD to be 145 cases per 100,000 population (Rubin, Hungin et al. 
2000).   
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1.1.2   Aetiology  
 
The exact aetiology of CD remains unclear. It is likely that the disease is caused 
by a complex interplay of genetic, microbiological, immunological and 
environmental factors. 
 
Genetic factors 
There is now ample evidence that CD is, in part, the result of a genetic 
predisposition. Familial aggregation of IBD was first reported in the 1930s 
(Russell and Satsangi 2004). A positive family history is still the largest 
independent risk factor for the disease. The estimated lifetime risk of developing 
IBD for a first-degree relative of a CD patient is 4.8-5.2% (Russell and Satsangi 
2004). This figure rises to 7.8% in the Jewish population, which has the highest 
prevalence of CD of any ethnic group and displays the phenomenon of genetic 
anticipation. Identical twin studies have shown a concordance rate of 50-60% 
(Orholm, Binder et al. 2000; Halfvarson, Jess et al. 2006).  
 
CD is a polygenic disease and there are now many genes that have been 
identified as being linked to the condition. Of major interest is the 
CARD15/NOD2 gene, located on chromosome 16, first described by Economou et 
al. in 2004 (Economou, Trikalinos et al. 2004). Mutations in this gene (including 
amino acid substitutions or a frame shift resulting in insertion of a cysteine 
residue) account for 10-15% of patients with CD (Hugot, Chamaillard et al. 2001), 
and homozygous expression of variant NOD2 confers a 20 fold increased risk of 
developing CD (Cuthbert, Fisher et al. 2002). CARD15/NOD2 mutations interfere 
with the ability of NOD2 to recognise ligand and a reduced capacity to activate 
nuclear factor kappaB (NF-κB) in response to stimulation with muramyl 
dipeptide (Inohara, Ogura et al. 2003). It is not clear exactly how these mutations 
give rise to developing CD, although they are thought to result in a disturbance in 
the equilibrium maintained between the mucosal immune system and 
commensal intestinal microbiota. Furthermore, NF-κB mediates the 
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transcription of numerous inflammatory cytokines, including tumour necrosis 
factor alpha (TNFα), interleukin-1 (IL-1), IL-6 and IL-12.  
 
To date, 163 loci have been identified as being associated with the development 
of IBD, mainly involved with mucosal homeostasis and innate immune responses 
(Jostins, Ripke et al. 2012). A meta-analysis of all genome-wide association 
studies in CD has identified 71 regions of susceptibility to CD (Franke, McGovern 
et al. 2010), including IL-23R (dysregulated adaptive immunity), ATG16L1 and 
IRGM (defects in autophagy) and XBP1 and ORMDL3 (endoplasmic reticulum 
stress).      
 
Microbiological factors 
Microbial agents appear to be intimately involved in the pathogenesis of CD. 
Several microbes have previously been implicated, including Mycobacterium 
paratuberculosis, the measles virus and Listeria monocytogenes. However, 
despite extensive investigations over the past four decades, no single, specific 
pathogen has been shown to be critical in the pathogenesis of CD.    
 
The intestine harbours the largest and most diverse microbiota in the human 
body, consisting of more than 500 species of bacteria. Sequencing of 16S RNA 
has shown that patients with CD have an overall reduction in the diversity of gut 
microbiota with increased abundance of Fusobacteriaceae, Veillonellaceae and 
Enterobacteriaceae Pasteurellacaea and reduced levels of Clostridiales, 
Bacterioidales and Erysipelotrichales (Gevers, Kugathasan et al. 2014). 
Interestingly, this dysbiosis was only seen in mucosal biopsies and not in stool 
samples, indicating that CD pathogenesis involves mucosa-associated microbiota 
more than luminal bacteria. Commensal enteric bacteria provide constant 
antigenic stimulation, thereby continuously activating pathogenic T-cells to 
cause chronic intestinal injury in CD (Eckburg and Relman 2007). 
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Immunological factors 
The gut houses a large part of the mucosa-associated lymphoid tissue in the 
human body. The mucosal surfaces are the physical interface between the 
immune system and the high antigenic load within the gut lumen. Under normal 
conditions, the intestinal mucosa is in a state of ‘controlled inflammation’, being 
regulated by a delicate balance maintained by the innate and acquired immune 
systems.   
 
In CD, this well-controlled balance of the intestinal immune system is disturbed 
at all levels. Luminal antigens gain access to the underlying mucosal tissue via a 
‘leaky’ luminal barrier. There are deficiencies in the innate immune system and 
an exaggerated T-cell driven adaptive immune response. In active CD, effector T-
cells (Th1 and Th17) predominate over T-cells with a regulatory phenotype 
(Treg). Activated effector T-cells produce pro-inflammatory cytokines and 
influence macrophages to do the same. Tissue damage results from the release of 
numerous noxious mediators.     
 
Other environmental factors 
Cigarette smoking is associated with an increased risk of developing CD 
(Lindberg, Tysk et al. 1988). Smoking also negatively influences the clinical 
course of CD and is associated with clinical recurrence of CD after surgical 
resection in CD patients (Kane, Flicker et al. 2005).  
 
Vitamin D is increasingly being recognised as important in the pathogenesis of 
CD. A large prospective study of 72,719 women enrolled in the Nurses’ Health 
Study in the USA examined vitamin D status and the risk of developing IBD. The 
authors showed that higher predicted levels of serum vitamin D were associated 
with a reduced risk of developing CD, but not UC (Ananthakrishnan, Khalili et al. 
2012). Another study has shown that lower plasma vitamin D levels in patients 
with CD is associated with increased risk of hospitalisation and surgery 
(Ananthakrishnan, Cagan et al. 2013).  
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The relationship between appendicectomy and the risk of developing CD has also 
been investigated. A systemic review of the literature in 2008 found the relative 
risk (RR) of having CD diagnosed following an appendicectomy was significantly 
elevated (Kaplan, Jackson et al. 2008). Within the first year after surgery, the RR 
was 6.69 (95% CI: 5.42-8.25). An increase risk in developing CD was also seen 1-
4 years after appendicectomy. However, data from 4 years post-appendicectomy 
and onwards shows no increase in the risk of developing CD.  
 
A recent population-based case-control study in Asia-Pacific identified several 
environmental factors that confer protection against developing CD (Ng, Tang et 
al. 2015). These included being breast fed (aOR 0.10; 95% CI 0.04 to 0.30), 
antibiotic use (aOR 0.19; 0.07 to 0.52), having dogs (aOR 0.54; 0.35 to 0.83), daily 
tea consumption (aOR 0.62; 0.43 to 0.91) and daily physical activity (aOR 0.58; 
0.35 to 0.96).  
 
Ultimately, it is likely that CD is the result of continuous microbial antigenic 
stimulation of pathogenic immune responses as a consequence of host genetic 
defects in mucosal barrier function, innate bacterial killing and 
immunoregulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
 
1.1.3   Clinical Features  
 
CD is a disease with a broad spectrum of clinical manifestations, and the initial 
presentation is seldom a good predictor of the clinical course (Katz 1994). It is 
clinically useful to classify CD according to the site, extent and pattern of disease, 
since this influences medical management. This has been formalised by the 
Montreal Classification (table 1).  
 
The site of the disease influences presentation; however symptoms of abdominal 
pain, diarrhoea and weight loss are ubiquitous among all phenotypes of CD. 
When patients are experiencing active disease, patients may also experience 
symptoms of fever, malaise and anorexia. The frequency of anatomical locations 
of inflammation in CD is shown in figure 1 (section 1.1), with the terminal ileum 
being the most commonly affected region.  
 
Small bowel (SB) CD is often associated with colicky abdominal pain, which may 
also suggest a local stenotic lesion. Extensive ileal disease (>100cm), is 
associated with more profound weight loss and poor nutrition. Specific vitamin 
deficiencies, such as vitamin B12 and folic acid, may also be seen.  
 
Colonic CD is associated with diarrhoea more commonly than SB CD. Perianal 
Crohn’s disease is common, occurring in approximately 50% of patients (Cosnes 
2008). Perianal disease is characterised by recurrent abscesses, fistulae and 
fleshy skin tags, with or without ulceration. This occurs more commonly in 
patients with ileocolonic disease and less so in isolated SB disease. Anal and 
rectal stenosis are complications of perianal CD and may cause symptoms of 
constipation and spurious diarrhoea.  
 
The pattern of CD also influences patient presentation. Fibrostenotic disease 
pattern is commonly associated with disease in the ileocaecal region or SB. This 
can lead to localised strictures and obstructive symptoms. Inflammatory disease 
pattern is more commonly colonic, causing profuse diarrhoea, pronounced 
23 
 
weight loss and marked elevation in serum inflammatory markers. CD is a 
transmural inflammatory disease and therefore has the capability to penetrate 
the full thickness of the gut wall, leading to severe clinical consequences.    
 
 
Age at diagnosis Site of disease  Disease behaviour 
A1: <16yrs L1: Ileal  B1: Non-stricturing, non-penetrating 
A2: 17-40yrs  L2: Colonic B2: Stricturing 
A3: >40yrs L3: Ileocolonic B3: Penetrating 
 L4: Upper GI tract P: Perianal disease 
 
Table 1. The Montreal Classification for Crohn’s disease. This classification system 
takes into account the patient’s age at diagnosis, site of disease and behaviour 
(pattern) of disease. It is useful in the clinical setting as these factors influence the 
medical management, likelihood of surgery and patient’s prognosis. L4 is a 
modifier and can be added to L1-3 if the patient has concomitant upper GI CD. ‘P’ is 
also a modifier and can be added to B1-3, if concurrent perianal disease is present.    
 
 
1.1.4   Extra-intestinal manifestations 
 
Extra-intestinal manifestations (EIMs) occur in about 30% of individuals with 
IBD (Veloso 2011). They are slightly more common in CD compared to UC, and 
patients with CD affecting the colon have a higher incidence of EIMs. The clinical 
spectrum of EIMs varies from mild transitory to very severe lesions, the latter of 
which can be more incapacitating than the intestinal disease itself.     
 
Immune-mediated EIMs can occur in the joints (peripheral and axial arthritis), 
skin (erythema nodosum and pyoderma gangrenosum), mouth (apthous 
stomatitis), eyes (epislceritis and uveitis) or liver (primary sclerosing cholangitis, 
PSC). Often, immune-mediated EIMs are related to disease activity and therefore 
will respond to treating the underlying disease process. However, some patients 
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experience EIMs, which are unrelated to disease activity and run their own 
course. For example, PSC, a chronic inflammatory liver disease characterised by 
progressive bile duct destruction, is a known EIM of IBD. In PSC, liver and bowel 
inflammatory are rarely concomitant, to the extent that PSC may develop in IBD 
patients whose diseased colons have been removed many years previously.  A 
summary of EIMs associated with CD is shown in table 2.  
 
 Common (5-20%) Unusual (<5%) 
Relate to disease activity Erythema nodosum 
Finger clubbing 
Ocular involvement: 
- conjunctivitis 
- episcleritis 
- iritis 
Arthritis (large joints) 
Osteoporosis 
Pyoderma gangrenosum 
Unrelated to disease 
activity 
Gallstones 
Sacroilitis 
Arthralgia (small joints) 
Nutritional deficiency 
Liver disease (fatty liver, 
PSC)  
Ankylosing spondylitis 
Renal stones (oxalate) 
Osteomalacia 
Sweet’s syndrome 
Systemic amyloidosis 
 
Table 2. Extra-intestinal manifestations associated with Crohn’s disease.  
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1.1.5   Diagnosis  
 
There is no single test for CD, and a positive diagnosis requires several different 
modalities including clinical assessment and endoscopic, radiological and 
histological investigation. Internationally accepted criteria for the diagnosis of 
CD were defined by Lennard-Jones in 1989 (Lennard-Jones 1989). The criteria 
can be applied after excluding infection, ischaemia, irradiation and malignancy as 
causes for intestinal inflammation and comprises a variety of clinical 
examination, radiological, endoscopic and histological findings. The presence of 
3 or more of these features is diagnostic of CD.   
 
Initial assessment of CD needs to establish the site, extent and pattern of 
inflammation, as well as the presence of disease complications, as these factors 
directly influence management and prognosis.  
 
 
1.1.6   Medical therapy  
 
The medical treatment of patients with CD is difficult. The heterogeneity of 
patients, including the disease location and pattern, presence of EIMs and 
response to therapy – promotes challenges when recommending optimal 
treatment. The principles of management are a consistent approach, attention to 
nutrition, medical treatment of active disease and surgical management of 
complications.  
 
Dietary therapy is an established treatment option for CD. The use of elemental 
or polymeric diets has been shown to be effective in reducing gut inflammation 
in CD. Unfortunately, this treatment modality is frequently unpalatable and is 
restrictive to the patient, and therefore its use is limited. Dietary therapy is more 
widely used in paediatric populations where adherence is better and it offers a 
good alternative to the use of corticosteroids.   
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Historically, the medical treatment of CD has been with non-specific 
immunosuppression, including corticosteroids and immunomodulator therapies 
(such as thiopurines and methotrexate). These medications are used to modify 
the pattern of disease, but expose patients to systemic side effects of 
immunosuppression.  
 
The discovery of immunological mechanisms and pathways that underlie 
inflammation in CD, has led to the development of therapies that target specific 
molecules and pathways in the inflammatory cascade, thereby maximising 
benefit and minimising harm to patients (Melmed and Targan 2010). This form 
of therapy is currently available in the form of the anti tumour necrosis factor 
alpha (anti TNFα) drugs. This class of drug has revolutionised the medical 
management of CD thanks to their ability to induce and maintain remission, heal 
mucosa, reduce hospitalisations and surgical operations and restore quality of 
life (Di Sabatino, Liberato et al. 2011). These therapies, their mechanisms of 
action and therapeutic targets are discussed further in section 1.3 of this 
introduction.    
 
 
1.1.7   Complications  
 
In addition to EIMs, CD can give rise to a variety of complications within the gut, 
some of which can be potentially life-threatening. Small intestinal obstruction 
can result from active disease and also by a food bolus becoming impacted on a 
fibrostenotic stricture. Toxic dilatation (toxic megacolon) can occur, although 
this is much less common than in UC. Bowel perforation rarely presents acutely 
because an abscess cavity is likely to form and usually requires surgical 
intervention.  
 
Massive rectal bleeding is rare (1% of patients with colonic disease and very rare 
in SB CD). Colonic carcinoma occurs in <5% of patients with colonic disease and 
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is related to the extent and duration (>10 years) of Crohn’s colitis. The risk of 
small intestinal carcinoma is increased, but remains very rare.  
 
Abdominal, pelvic or ischiorectal abscesses can occur and are usually treated 
with radiological or surgical drainage and antibiotics. Fistulae can occur at any 
point along the GI tract, including from gut to gut, skin, bladder, vagina and 
perianal fistulae. The management of fistulae involves ensuring local sepsis has 
been excluded by imaging and/or surgical examination under anaesthetic and 
then biological drug therapy with or without immunomodulator therapy should 
be considered along with surgical options.  
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1.2  Dendritic cells 
 
1.2.1   Overview of the innate and adaptive immune systems 
 
The key to a healthy immune system is the interaction between the innate and 
adaptive immune response to foreign and self-antigens. The initial encounter 
with an antigen occurs within the innate immune system. Innate immunity is a 
primitive system which produces a rapid, but non-specific response. Cellular 
mediators include macrophages, dendritic cells (DCs), granulocytes and natural 
killer (NK) cells. Macrophages and DCs produce high levels of cytokines when 
foreign antigens are encountered, resulting in increased vascularity, 
permeability and elevated expression of adhesion markers and leukocyte 
recruitment. The function of the innate response is to limit the early replication 
and spread of infectious agents. 
 
The adaptive immune system responds to signals from the innate response and 
is antigen-specific. After a lag period of several days, there is a clonal expansion 
and differentiation of naïve lymphocytes into effector T-cells and antibody-
secreting B-cells, usually eliminating the pathogen. On repeated exposure to a 
particular antigen, the response adapts and becomes more rapid and specific – a 
phenomenon known as ‘immunological memory’. The nature of the adaptive 
immune response is dependent on the quality and size of the innate response.  
 
DCs are professional antigen presenting cells and therefore play a pivotal role in 
the immune system by linking the innate and adaptive immune responses. 
Antigen presentation by DCs can occur in one of two ways. Endogenous antigens 
(including viral antigens), processed by the endoplasmic reticulum, are 
presented by Major Histocompatability Complex (MHC) class I-bearing cells. 
These MHC/antigen complexes are recognized exclusively by CD8+ (cytotoxic) T-
cells. Once activated, CD8+ T-cells release the cytotoxins perforin, granzymes 
and granulysin, which enter the cytoplasm of the target cell and trigger the 
caspase cascade, ultimately resulting in apoptosis (programmed cell death). 
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CD8+ T-cells can also induce apoptosis via cell surface interactions with the 
infected target cell.   
 
Exogenous antigens are processed by the lysosomal (endosomal) route and are 
presented by MHC class II-bearing cells to CD4+ (helper) T-cells. Following 
activation, CD4+ T-cells differentiate into several distinct subgroups depending 
on the cytokine profile (Th1, Th2, Th17, regulatory T-cells). The characteristics 
and functions of these subgroups is discussed later in the introduction (section 
1.2.7).     
 
By bridging the innate and adaptive immune responses, DCs act as 
immunological guardians of the immune system. Although monocytes, 
macrophages and B-cells are also able to present antigens to stimulate T-cells, it 
is the ability of DCs to stimulate naïve T-cells that makes them unique 
(Banchereau, Briere et al. 2000).  
 
 
1.2.2   Definition and origin of dendritic cells  
 
In 1868, the German anatomist Paul Langerhans identified Langerhan’s cells in 
the skin, which he mistook for nerve endings. These are now known to be 
epithelial DCs, crucial in the initiation of immune responses to epidermal 
pathogens. Later, in 1973, Steinman and colleagues found cells in the mouse 
spleen that were potent stimulators of the immune system (Steinman and Cohn 
2007). These were called DCs because of their appearance of spikey arms or 
dendrites. This morphology is ideally suited to facilitate interaction with T-cells.  
 
DCs originate from haematopoietic stem cells in the bone marrow, and are 
widely present throughout all tissues in the human body with the exception of 
the cornea and testes (Steinman 1991). Despite this, they constitute only a 
fraction of circulating leucocytes in human blood with values in the literature 
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varying from 0.1% - 2% (Van Voorhis, Hair et al. 1982; Knight, Farrant et al. 
1986; Hart 1997).  
 
Progenitors of DCs in bone marrow migrate via the blood stream to peripheral 
tissues where they encounter several essential growth factors such as GM-CSF, 
IL-4, IL-15, TNFα, TGFβ, and IL-3 secreted by various cell types (including 
endothelial cells, mast cells, keratinocytes and fibroblasts). Such growth factors 
determine the fate of the progenitor and what type of DC it will become. The 
capacity to react to innate immune factors places DCs in a pivotal position at the 
interface between the innate and adaptive immune systems allows DCs to shape 
the ultimate immune response to a vast range of antigenic stimuli.  
 
 
1.2.3   Dendritic cell subsets 
 
Human blood contains two major DC subsets, identified by the presence or 
absence of the adhesion molecule, CD11c.  
 
Plasmacytoid dendritic cells 
The CD11c- DC subset are called plasmacytoid DC (pDC). In addition to the 
absence of CD11c, they are phenotypically distinguished from CD11c+ DCs by 
expression of the IL-3 receptor (CD123), CD45RA, CD62L, BDCA2, BDCA4 and by 
lack of expression of CD33 and CD16 (Dzionek, Fuchs et al. 2000). pDCs also 
exclusively express toll-like receptors (TLRs) 7 and 9 (Ng, Kamm et al. 2010). 
 
Unlike their CD11c+ counterparts, pDCs develop fully within the bone marrow 
and then travel to the thymus and secondary lymphoid organs via the blood in 
the healthy state (Colonna, Trinchieri et al. 2004). Prior to antigenic stimulation, 
pDCs are often referred to as ‘pre-pDCs’ (Shortman and Naik 2007) and migrate 
to specific tissues (such as LNs or gut) under the control of chemokine receptors 
such as CCR7 and CCR9 respectively.      
 
31 
 
Myeloid dendritic cells 
The CD11c+ DC subset follows a myeloid differentiation pathway and are 
therefore termed myeloid DC (mDCs). In addition to CD11c, mDCs express CD13, 
CD33, CD11b and a high level of HLA DR. They also express TLR1 to 6 and TLR8 
(Ng, Kamm et al. 2010). Monocytes are thought to serve as a circulating reservoir 
of mDC precursors.  
 
Recently, mDCs have been further subdivided into two groups. Type 1 mDCs are 
identified by BDCA1+ (also known as CD1c+) and represent the vast majority of 
mDC in the human body (>90%). These DCs are involved in presenting MHC 
class II antigens, leading to activation of CD4+ T-cell responses. Type 2 mDCs 
(<10% total mDC) are BDCA3+ (also known as CD141+) and carry out MHC class 
I antigen presentation to CD8+ T-cells with antigen-cross presenting capabilities 
(Collin, Bigley et al. 2011).  
 
 
 
Figure 2. Human dendritic cell subsets and their distribution in blood, epithelial 
tissues and lymph nodes (Collin, McGovern et al. 2013). 
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1.2.4   Antigen detection by intestinal dendritic cells 
 
A single layer of epithelial cells separates the intestinal lamina propria from the 
gut lumen. On the luminal surface of the epithelial layer is a thick layer of mucus 
containing bactericidal defensins, neutrophils and large amounts of antigen 
specific IgA (Sansonetti 2004). There are several mechanisms by which intestinal 
DCs can sample the antigenic material within the intestinal lumen. Microfold (M) 
cells transport luminal antigens to the sub-epithelial dome of Peyer’s patches for 
DCs to sample. Lamina propria DCs can directly sample luminal antigenic 
material by extending dendrites through the epithelial layer under the control of 
CX3CR1 expression. DCs can internalise apoptotic epithelial cells and thereby 
acquiring antigens contained within the apoptosed cell. In addition, breakdown 
of the epithelial barrier may allow DCs direct access to the luminal antigenic load 
(Stagg, Hart et al. 2003).  
 
DCs are able to sense microbes by a series of surface receptors (pattern 
recognition receptors, PRRs), which recognise microbial molecular patterns 
known as pathogen-associated molecular patterns (PAMPs). Examples of PRR 
families on DCs include TLRs, cell surface c-type lectin receptors and 
intracytoplasmic NOD-like receptors. Microbes can directly activate DCs through 
PRRs, or indirectly, through the internalisation of apoptotic or necrotic cells 
dying in response to microbial stimuli.   
 
To date, at least ten TLRs have been identified in humans. These are largely 
characterised by their cellular location (surface or intracellular), differential 
expression by DC subsets and the microbial product they detect (Akira 2001). Of 
particular importance are TLR2 and TLR4. TLR2 recognises peptidoglycan 
lipoteichoic acid from gram-positive bacteria and lipoproteins from both gram-
positive and gram-negative organisms and stimulates DCs to secrete IL-10, 
leading to a Th2 response. TLR4 is required for recognition of lipopolysaccharide 
(LPS) from Escherichia Coli and stimulates IL-12 production from DCs, giving rise 
to a Th1 response.   
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A study by Hart et al. has shown that DCs isolated from human lamina propria 
express lower TLR2 and TLR4 compared with blood from the same healthy 
individuals. This may serve to limit recognition of commensal flora in healthy gut 
and prevent aberrant immune responses. Expression of both TLR2 and TLR4 
was raised in inflamed IBD gut tissue, likely leading to increased recognition of 
bacterial products and an enhanced response to them (Hart, Al-Hassi et al. 2005).  
 
 
1.2.5   Dendritic cell maturation and migration  
 
In the steady state, DCs are immunologically immature and therefore do not have 
the capacity to prime naïve T-cells (Banchereau, Briere et al. 2000). Immature 
DCs have a high endocytic potential with MHC class II molecule accumulation in 
the endosomal compartments and a low T-cell activation potential with low 
surface expression of co-stimulatory markers (CD80 and CD86) (Villadangos and 
Schnorrer 2007). 
 
DC activation and subsequent maturation occurs via the PRRs, cytokine and 
chemokine receptors that recognise potential stimulatory molecules. Factors 
that can stimulate DCs include:  
 
 Host-derived molecules such as CD40 ligand, TNFα, IL-1, IL-6 and IFNα.  
 Microbial products stimulating TLRs expressed on the surface of DCs. 
 Signals released from distressed or dying cells. 
 
The result of DC maturation is down regulation of materials involved in antigen 
acquisition and upregulation of MHC Class II, MHC Class I and co-stimulatory 
molecules (CD40, CD80 and CD86). The exact nature of the maturation process 
and the cytokines secreted vary depending of the type of PRR encountered and 
are specific to each pathogen (Guermonprez, Valladeau et al. 2002). Phenotypic 
properties of immature and mature DCs are shown in table 3.  
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Simultaneously, the maturing DCs up-regulate the chemokine receptor CCR7 and 
therefore acquire responsiveness to the CCL19 and CCL21 ligands. This process 
promotes the migration of lamina propria DCs to mesenteric lymph nodes (MLN) 
via the afferent lymph system (Dieu, Vanbervliet et al. 1998). The lymph nodes 
are rich in memory and naïve T-cells. Indeed, both memory and naïve T-cells also 
express CCR7, encouraging their own migration to the MLN.  
 
The chemokine receptor, CCR5, controls the DC’s ability to migrate to areas of 
inflammation. Immature DCs are CCR5highCCR7low and are therefore likely to 
migrate to sites of inflammation where they are required to sample antigenic 
material. Following antigen acquisition, the maturation process reverses the 
ratio of expression of these two chemokine receptors (becoming 
CCR5lowCCR7high), thereby encouraging migration to draining lymph nodes to 
trigger the adaptive immune response (Sallusto, Schaerli et al. 1998).   
 
 
DC characteristic Immature Mature 
Function Antigen capture Antigen presentation 
Morphology Stellate Multiple veil-like projections 
Adhesion molecules Low CD54 High CD54 
Co-stimulatory 
molecules 
Low CD40, CD80, CD86 High CD40, CD80, CD86 
Maturation marker Low CD83 High CD83 
Chemokine receptors Low CCR7, High CCR5 High CCR7, Low CCR5 
Macropinocytosis High Low 
Stimulatory capacity Low High 
 
Table 3. Immature and mature dendritic cell phenotype. Immature DCs capture 
antigens in the peripheral tissue. As they migrate to lymphoid organs, they mature 
and prepare for antigen presentation to T-cells.  
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1.2.6   Antigen presentation 
 
Naïve T-cells require two signals from DCs to become fully activated. The antigen 
(bound to MHC-II molecule) provides the first signal and interacts with the T-cell 
receptor (TCR). The second signal is antigen non-specific and is provided by co-
stimulatory molecules on the surface of the DC binding with their corresponding 
receptors on the naïve T-cell. Examples of such co-stimulatory molecules are 
CD40, CD80 and CD86. This double signal is necessary for T-cell proliferation, 
differentiation, survival and cytokine secretion. Activation of T-cells without co-
stimulation results in suppression of the immune response, and, in some cases, 
induces antigen-specific tolerance (Lenschow, Walunas et al. 1996).  
 
Matured or activated DCs also provide a third signal to the T-cells via secretion of 
cytokines. The cytokines produced by DCs determine the type of effector T-cell 
response that occurs. This signal is the most important factor inducing the 
effector functions in T-cells (de Jong, Smits et al. 2005).  
 
 
Figure 3. Antigen presentation by dendritic cells. Signal 1 is provided by the antigen 
itself, bound to MHC-II molecule. Signal 2 represents the co-stimulatory molecules 
and signal 3 is cytokine production. The quality and quantity of these 3 signals 
regulates the subsequent T-cell response.  
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1.2.7   T-lymphocyte differentiation and effector function 
 
DCs can contribute to the expansion and differentiation of most classes of 
lymphocytes. In addition to T-cells, they also play a role in the differentiation of 
B-cells and NK cells (section 1.2.8). The type of DC and its maturation status 
influences the subsequent T-cell response and therefore the effect on adaptive 
immunity. DCs drive both T-cell proliferation and the functional differentiation 
of T-cells. The type of T-cell differentiation depends on multiple factors, such as 
the antigen dose, types of cytokines secreted by the DC and co-stimulatory 
molecule expression.  
 
 
 
Figure 4. Proposed mechanisms of control of T-cell responses by intestinal dendritic 
cells. Once antigen acquisition by the DC has occurred, the DC begins to mature and 
migrates to the MLN to interact with the T-cell population. Cytokines produced by 
the activated DC play a role in polarising the T-cell response resulting in distinct 
effector CD4+ T-helper cell subsets. 
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Production of IL-12 by DCs promotes a Th1 response (Macatonia, Hosken et al. 
1995). Two further members of the IL-12 family have been described; IL-23 
which induces proliferation of memory T-cells (Oppmann, Lesley et al. 2000) and 
IL-27 which induces proliferation of naïve T-cells (Pflanz, Timans et al. 2002). 
Both IL-23 and IL-27 are produced by DCs and polarise T-cells to a Th1 response 
(Smits, van Beelen et al. 2004). 
 
Prior to the characterisation of Th17 lymphocytes, Th1 T-cells were thought of 
as the main mediators of the pathogenesis of CD. Evidence for this includes the 
observation that DCs and macrophages in CD produce large amounts of IL-12 
(Monteleone, Biancone et al. 1997). In addition, there is enhanced production of 
IL-18 (a cytokine that perpetuates Th1 cell responses) in the intestinal mucosa of 
patients with active CD (Pizarro, Michie et al. 1999), and T-cells isolated from 
areas of active CD have been shown to express increased amounts of IFNγ and 
decreased amounts of IL-4 (a Th2 cytokine) compared with healthy control 
subjects (Fuss, Neurath et al. 1996). Further evidence for the importance of Th1 
cells in the pathogenesis of CD comes from a study of fontolizumab (an anti-
IFNγ-antibody) in patients with CD, where the study drug was associated with a 
clinical response in CD patients (Hommes, Mikhajlova et al. 2006). 
  
Effector Th1 cells produce high levels of IFNγ and TNFβ cytokines, which are 
required for cell-mediated immunity against intracellular pathogens through 
macrophage activation and the promotion of cytotoxic activity in NK and CD8+ 
T-cells. While mucosal T-cells mount a strong Th1 response in the early stages of 
CD with high IFNγ production and IL-12Rβ2 chain expression, in the latter stages 
of CD, this appears to be lost (Kugathasan, Saubermann et al. 2007). This 
suggests that mucosal T-cell immunoregulation varies with the course of IBD and 
may have implications on the therapeutic efficacy of drug treatment in different 
stages of CD. 
 
The production of IL-4 and IL-10 by DCs, polarise a Th2 cell response. Th2 cells 
drive humoral immunity directed towards clearing extracellular pathogens. They 
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stimulate B-cells to produce IgE, enhance the maturation of eosinophils and 
promote degranulation of mast cells and basophils. Th2 cells produce high levels 
of IL-4, IL-5 and IL-13 cytokines.   
 
More recently, a new subset of IL-17-producing Th17 cells with different 
effector functions from Th1 and Th2 cells have been identified (Bettelli, Korn et 
al. 2008). In contrast to Th1 and Th2 cell differentiation, which depend on 
effector cytokines for differentiation (IFNγ and IL-4 respectively), Th17 cells do 
not require IL-17 for their differentiation (Brand 2009). Murine Th17 cells 
originate from naïve CD4+ T-cells in the presence of IL-6 and TGFβ and their 
ongoing development is supported by IL-21 and IL-23 (Aggarwal, Ghilardi et al. 
2003; Bettelli, Carrier et al. 2006). Wilson et al. demonstrated that Th17 cells are 
characterised by an increased expression of IL-17a, IL-17F, IL-22, IL-26, IFNγ 
and CCL20 (Wilson, Boniface et al. 2007). These cytokines and chemokines are 
highly expressed in active CD, therefore supporting their role in CD pathogenesis.  
 
Regulatory T-cells (Tregs) express the phenotype CD4+CD25high and the 
intracellular forkhead box transcription factor p3 (FoxP3).  Tregs play a crucial 
role in the maintenance of self-tolerance and prevention of autoimmune disease. 
Treg differentiation occurs via a mechanism dependent on retinoic acid and 
TGFβ (Coombes, Siddiqui et al. 2007). Cytokines that induce differentiation of 
Th1, Th2 and Th17 cells antagonise Treg cell differentiation (Zhou, Bailey-
Bucktrout et al. 2009). The production of immunosuppressive cytokines TGFβ 
and IL-10 have been implicated in the effector function of Tregs, with immature 
DCs secreting IL-10 on contact with Tregs which in turn induces the Tregs to 
suppress immune activity by secreting IL-10 (Jonuleit, Schmitt et al. 2000). 
However, some recent evidence suggests that Tregs phenotype, or at least the 
expression of their regulatory-associated FoxP3 transcription factor, may be 
more dynamic than was initially thought (Bernardo, Al-Hassi et al. 2012).  
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1.2.8   Effect of dendritic cells on other lymphocytes 
 
DCs also have the capacity to stimulate other lymphocytes, including NK T-cells, 
by secretion of IL-12p70 upon microbial contact (Munz, Steinman et al. 2005) 
and naïve B-cells, by producing pro-inflammatory cytokines such as IL-12, 
thereby stimulating B-cell antibody production.  
 
 
1.2.9   Completing the dendritic cell lifecycle 
 
Following migration to LNs, DCs have a life expectancy of up to 72 hours. The 
lifecycle of DCs ends by a process of cellular apoptosis, mediated by T-
lymphocytes. The process of DC apoptosis triggers signaling pathways that lead 
to the next wave of DCs migrating from local tissues to the lymphoid tissue 
(Parajuli, Nishioka et al. 1999).  The lifecycle of DCs is shown in figure 5. A small 
percentage of DCs leave the secondary lymphoid organs via efferent lymphatics 
and accumulate in the thoracic duct. From here they are seeded back into the 
systemic circulation. These DCs have an antigen load and therefore spread the 
antigenic stimulus to the thymus, spleen and the bone marrow. This results in 
adequate adaptive immunity with the ability to mount a future effective defence 
as well as contribute to long term immunological memory.  
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Figure 5. The lifecycle of the dendritic cell. Immature DCs in the circulation enter 
the tissues and encounter pathogens directly or indirectly to induce cytokine 
secretion. DC maturation and migration occurs resulting in mature DCs arriving at 
the lymphoid organs displaying peptide-MHC complexes and recruiting antigen-
specific T lymphocytes (Ueno, Schmitt et al. 2010). 
 
 
1.2.10  Principles of T-lymphocyte migration  
 
Every day, nearly a trillion lymphocytes leave the circulation, enter the tissues 
and then re-enter the blood. By continually migrating around the body, 
lymphocytes optimise the chances of encountering an antigen. Cell migration on 
this massive scale must be tightly controlled. Lymphocytes express homing 
molecules which recognise specific ligands on the vascular endothelium, thereby 
enabling lymphocytes to migrate to their target tissue.  
 
Naïve T-cells tend to migrate to lymphoid organs and are generally excluded 
from peripheral tissues due to high levels of CCR7 expression. Once activated by 
antigen, naïve T-cells alter their homing marker expression, thereby enabling 
migration to peripheral tissues.  
41 
 
Recruitment of immune cells to sites of inflammation is a complex process 
mediated by adhesion molecules, chemokines and receptors. This interaction can 
be divided into several steps, including; rolling and tethering on the vascular 
endothelium; activation and adhesion to the endothelium; locomotion from the 
site of adhesion to the endothelial cell junction; and transmigration across the 
endothelial barrier into the tissue compartment (figure 6). This series of steps 
happen in sequence and not in parallel and occur rapidly, with a leukocyte stuck 
to the endothelium only taking a few minutes to reach the subendothelial 
basement membrane (Muller 2003).   
 
The recruitment of leukocytes to a specific site of inflammation is dependent 
upon localised endothelial cell activation, a major part of which is an increase in 
the expression of adhesion molecules (Carlos and Harlan 1994). Examples of 
these adhesion molecules are the endothelial selectins (E- and P-selectin) and 
endothelial immunoglobulin superfamily proteins (ICAM-1, VCAM-1, PECAM-1 
and MadCAM). The expression of adhesion molecules is rapidly increased in 
response to inflammatory stimuli. Chemokines also play an important role in the 
conversion of rolling behaviour to firm integrin-dependent cell arrest (Campbell, 
Hedrick et al. 1998). This change in behaviour occurs in seconds following 
chemokine stimulation of leukocytes (Alon and Feigelson 2002).    
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Figure 6. Leukocyte recruitment to sites of inflammation. Leukocyte recruitment 
from blood to sties of inflammation occurs in a stepwise process; Rolling and 
tethering on the vascular endothelium, mediated by selectins and their respective 
ligands; Activation and adhesion to the endothelium, mediated by the interaction of 
leukocyte integrins with ICAMs and VCAM-1; Locomotion from the site of adhesion 
to the endothelial cell junction; Diapedisis across the endothelial cell and basement 
membrane into the tissue (Garton, Gough et al. 2006). 
 
 
1.2.11  Dendritic cells influence T-lymphocyte homing 
 
An efficient system would ensure that responder cells return to the site where 
the antigen was originally acquired in order to carry out their response. In 
addition to activating naïve T-cells, DCs also direct T-cells to the site where the 
antigen was encountered. This is done at the time of antigen-acquisition by way 
of a fourth signal; a ‘homing’ signal.  
 
Studies have shown that murine DCs obtained from mesenteric LN, but not from 
peripheral LN, induced the gut-homing molecule α4β7 on T-cells following 
stimulation, therefore targeting those T-cells back to the gut tissue (Stagg, Kamm 
et al. 2002). Other experiments have shown a similar picture when using murine 
intestinal DCs obtained from Peyer’s patches and gut lamina propria, resulting in 
expression of gut-homing α4β7 and CCR9 on activated T-cells (Mora, Bono et al. 
2003; Johansson-Lindbom, Svensson et al. 2005). Conversely, DCs obtained from 
skin-draining LN specifically induce expression of skin-homing markers on 
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activated T-cells (Campbell and Butcher 2002). These studies have shown that 
DCs are essential for imprinting lymphocytes with tissue-specific properties. A 
variety of homing molecules on immune cells have been identified:  
 
 
Gut-homing molecules 
 
Beta7 (β7) integrin 
Effector T-cells homing to intestinal sites express high levels of the gut-homing 
molecule α4β7 integrin (Lefrancois, Parker et al. 1999). The ligand for this 
integrin is mucosal vascular addressin cell-adhesion molecule 1 (MAdCAM-1) 
and is expressed by post-capillary endotheial cells in the small intestinal lamina 
propria (Berlin, Berg et al. 1993) and the colonic lamina propria (Berg, McEvoy 
et al. 1993). Studies performed with β7-deficient mice or utilising antibodies to 
α4β7 or MAdCAM-1 have shown β7 integrin expression is mandatory for 
lymphocyte recruitment to intestinal tissues (Wagner, Lohler et al. 1996).  
 
In addition to mediating lymphocyte homing to the gut, the presence of β7-
expressing DCs in the gut is required to induce Treg and IL-10 producing T-cells, 
resulting in tolerogenic properties. Furthermore, lack of the α4β7 integrin in the 
innate immune compartment leads to a reduction in retinoic acid-producing DCs 
and accelerates T-cell-mediated colitis (Villablanca, De Calisto et al. 2014). 
 
The αE integrin (also known as CD103) serves as a mucosal DC subset marker.  
These cells mediate essential immune activities such as antigen presentation (del 
Rio, Rodriguez-Barbosa et al. 2007) and Treg induction. Although only 2% of 
circulating lymphocytes express CD103, expression is greater than 90% on 
intraepithelial lymphocytes (IELs) (Cepek, Parker et al. 1993). The ligand for 
αεβ7 is e-cadherin, which is expressed on epithelial surfaces, including the gut, 
lungs and skin. CD103+ DCs are able to synthesise retinoic acid (RA), resulting in 
the generation of Tregs at the expense of Th17 cells (Coombes, Siddiqui et al. 
2007).  
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Throughout this thesis, cells which have positive β7 expression have been 
assumed to be expressing the molecule α4β7 and therefore taken to have a gut-
homing phenotype. It is accepted that a proportion of these β7 positive cells will 
actually be expressing αεβ7 and therefore have a different homing phenotype. 
However, in view of the tiny proportion of αεβ7 expression on circulating 
lymphocytes (2%, as described above), cells staining positive for β7 in the 
experimental work in this thesis are assumed to have gut-homing properties.  
 
CCR9 chemokine receptor 
CCR9 is a chemokine receptor, selectively expressed on T-cells homing towards 
intestinal sites and on the majority of T-cells in the small intestine (Zabel, Agace 
et al. 1999). The ligand for CCR9 is CCL25/TECK, which is expressed by epithelial 
cells within the small intestine (Wurbel, Philippe et al. 2000). Together, CCR9 
and CCL25/TECK play a selective role in effector T-cell homing to the small 
intestine. This has been demonstrated by Stenstad et al., who showed the 
reduced ability of CCR9-deficient CD4+ murine T-cells to enter the small 
intestinal lamina propria compared to their wild-type counterparts (Stenstad, 
Ericsson et al. 2006). 
 
Despite CCR9 being considered a small bowel homing marker, we have recently 
shown that it is expressed on DC from the small bowel and the colon, albeit in 
higher quantities in the former group (Mann, Landy et al. 2013). Furthermore, 
differences in CCR9 expression have also been reported on a gradient between 
human DC isolated from the ascending and descending colon (Dr David Bernardo, 
personal communication).  
 
Studies have shown the expression of α4β7, MAdCAM-1 and CCR9 to be 
dysregulated in humans with IBD (Souza, Elia et al. 1999; Hart, Kamm et al. 
2004). We recently demonstrated that human colonic DCs generate gut-homing 
T-cells when cultured together (Mann, Bernardo et al. 2012). Although murine 
studies have identified the default pathway for stimulated T-cells is skin-
trophism, we found that in the presence of signals provided by intestinal DCs, 
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gut-homing properties can be acquired by T-cells. Furthermore, we have 
demonstrated that, in humans, blood and cutaneous DCs, but not intestinal DCs, 
induced expression of cutaneous lymphocyte antigen (CLA) on stimulated T-cells, 
a molecule involved in leucocyte homing to the skin (Mann, Bernardo et al. 2012).  
 
Lymph node homing molecules 
 
As previously described, CCR7 expression is dramatically increased on DC after 
stimulation and maturation (Sallusto, Schaerli et al. 1998). CCR7 expression 
promotes homing to local draining lymph nodes by acquired responsiveness to 
the CCR7-ligand, macrophage inflammatory protein 3β (MIP-3β), also known as 
CCL19, and CCL21. These ligands attract CCR7-expressing mature DC and naïve 
T-cells to the lymph nodes. CCL19 expression is spread over the T-cell zone, 
driving maturing DC and naïve T-cells into the paracortical areas for antigen 
presentation and subsequent T-cell stimulation (Dieu, Vanbervliet et al. 1998).    
 
 
Skin homing molecules 
 
Cutaneous lymphocyte antigen  
CLA arises from specialised glycosylation of P-selectin glycoprotein ligand-1 
(CD162) (Fuhlbrigge, Kieffer et al. 1997). CLA interacts with E-selectin 
(endothelial receptor) which is expressed on post-capillary venules in the skin. 
Under physiological conditions, the majority of T-cells in the skin compartment 
express high levels of CLA (Clark, Chong et al. 2006). Recent work in our 
laboratory has shown aberrant CLA expression on γδ T-cells in patients with 
cutaneous manifestations of IBD (Mann, McCarthy et al. 2012).  
 
Skin-associated chemokine receptors 
CCR4 (ligand CCL17) is likely to confer skin-homing of immune cells under 
physiological conditions (Campbell, O'Connell et al. 2007). Under physiological 
conditions, the vast majority of T-cells in the skin compartment are CCR4+ (Clark, 
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Chong et al. 2006). CCR10 (ligand CCL27) also promotes skin-homing 
(Sigmundsdottir, Pan et al. 2007). However, some evidence shows CCR10 is 
implicated in homing to mucosal sites. The mucosal epithelium within the gut 
expresses an alternative CCR10 ligand (CCL28), which mediates CCR10-
dependent recruitment of IgA secreting cells to the gut mucosa (Lazarus, Kunkel 
et al. 2003).  
 
CCL17 and CCL27 have been identified in inflamed and non-inflamed skin 
endothelium (Campbell, Haraldsen et al. 1999), further supporting the skin-
homing function of these chemokine receptors. 
 
The role of CCR8 (ligand CCL1) remains poorly understood. It is thought that 
CCR8 expression on lymphocytes confers a homing preference towards human 
skin (although lung-homing properties also remain a possibility). CCR8-
expressing, skin-derived lymphocytes promote the production of the pro-
inflammatory cytokines IFNγ, TNFα and IL-12 after ex-vivo stimulation (Schaerli, 
Ebert et al. 2004).  
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47 
 
Cell surface receptor Receptor/Ligand Target tissue 
α4β7 MadCAM1 Gut 
CLA E-selectin Skin 
CCR4 CCL17 Skin 
CCR7 CCL19/21 Lymph node 
CCR8 CCL1 Skin 
CCR9 CCL25 Small bowel 
CCR10 CCL27/28 Skin / mucosal surfaces 
 
 
 
Figure 7. Induction of T-lymphocyte homing by dendritic cells. DCs deliver 4th 
homing signal to T-cells at the time of antigen presentation in the MLN. This signal 
is a reflection of where the DC has originated from and directs T-cell migration 
back to that site to enact their response (Courtesy of Dr Elizabeth Mann, APRG, 
Imperial College London). The incorporated table shows the molecules and 
receptors involved in lymphocyte homing.  
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Other factors promoting immune cell homing 
 
The vitamin A metabolite, retinoic acid (RA), plays an important role in gut-
homing. This was demonstrated by Iwata and colleagues, who identified that 
mucosal DCs, but not spleen or skin DCs, express relatively high levels of retinal 
dehydrogenase (RALDH), an enzyme required for the production of RA. They 
went on to demonstrate that, while vitamin A deficiency in mice results in 
decreased expression of α4β7 integrin on effector and memory T-cells and 
reduced lamina propria lymphocyte numbers, it has no effect on E- or P- selectin 
ligand expression on skin-homing effector cells. The authors also showed that 
pharmacological inhibition of RALDH inhibits DCs originating in GALT from 
imprinting gut trophism (Iwata, Hirakiyama et al. 2004).   
 
The presence of RA has a similar effect on B-cell homing. Mora et al. studied this 
by stimulating B-cells with and without RA and then re-stimulated the cells 
under reversed imprinting conditions. B-cells that were activated with RA 
expressed few gut-homing receptors, but became α4β7highCCR9+ upon re-
stimulation with RA. Conversely, B-cells initially exposed to RA and then re-
stimulated without RA down-regulated CCR9 expression but remained α4β7high. 
Thus, effector B-cells adjust their homing phenotype according to changing 
microenvironmental conditions (Mora, Iwata et al. 2006).   
 
Furthermore, RA in combination with TGFβ has been implicated in the 
generation of T-cells with a regulatory phenotype (Tregs) from naïve T-cells 
(Sun, Hall et al. 2007). Peripheral induction of Tregs is also accompanied by up-
regulation of α4β7 and CCR9 homing markers, directing Treg migration to gut 
tissue (Benson, Pino-Lagos et al. 2007).   
 
Vitamin D influences DC-mediated homing marker expression in activated 
human T-cells, favouring a skin-homing phenotype. Human in vitro studies have 
shown the vitamin D3 precursor is efficiently processed to the active molecule 
1,25(OH)2D3 by DCs in the skin. This active form of vitamin D up-regulates the 
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expression of the skin-homing marker CCR10 on activated T-cells while down-
regulating the expression of the gut-homing markers, α4β7 and CCR9 
(Sigmundsdottir, Pan et al. 2007).  
 
 
1.2.12  The role of dendritic cells in intestinal homeostasis 
 
The intestine represents the largest and most complex component of the human 
immune system. In health, the gut mucosal immune system maintains a disease-
free state in the presence of a highly antigenic environment (commensal 
microbiota and food antigens). However, the intestinal immune system also has 
the capacity to respond appropriately to pathological organisms. Any defects in 
this delicate balance could lead to an overly aggressive immune response to 
normal gut flora or food antigen, resulting in inflammation and tissue damage. At 
the other end of the spectrum, a lack of or absent immune response to 
pathological organisms in the gut lumen could lead to unimpaired infection. In 
order to achieve this balance between ‘tolerogenic’ and ‘immunogenic’ responses, 
there is a tightly regulated state of restrained immune activity termed 
‘physiological inflammation’.  
 
In view of their ability to shape an immune response on the basis of signals 
received from the local environment, DCs are critical in ensuring that active 
inflammatory processes are not triggered by harmless or commensal antigenic 
material within the gut lumen. This tolerogenic function is performed by 
migration of DCs within the LP to MLNs where they perform antigen 
presentation to T-cells under the influence of CCR7 expression. This migration 
increases in the presence of inflammatory stimuli, but has also been shown to 
occur in the absence of such a stimulus (Turnbull, Yrlid et al. 2005). Furthermore, 
impaired migration of DCs from the LP to MLN in a CCR7-/- murine model leads 
to defective tolerance to luminal antigens (Worbs, Bode et al. 2006). There are 
several mechanisms in the literature pertaining to induction of tolerance by DCs:   
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 The level of DC maturity at the time of antigen presentation is likely to 
play a role in the development of tolerance. Repetitive stimulation with 
allogeneic immature human DCs results in induction of IL-10-producing, 
non-proliferating CD4+ T-cells with regulatory properties (Jonuleit, 
Schmitt et al. 2000). 
 
 Down-regulation of CD80 and CD86 (Steinman, Hawiger et al. 2003). The 
reduction in CD80 and CD86 molecules also causes suppression of the 
production of indoleamine-2,3-deoxygenase (IDO). IDO is an enzyme 
which functions as the rate-limiting step in the production of tryptophan 
(an amino acid, essential for T-cell proliferation).  
 
 Signalling through novel receptor-ligand interactions, such as serrate 1-
induced notch signalling. This may regulate the decision between 
immunity and tolerance (Hoyne, Dallman et al. 2000). 
 
 Production of a ‘tolerogenic’ cytokine profile by DCs (IL-10, TGFβ or 
IFNα) may also play a role in polarising T-cells towards a regulatory 
phenotype (Levings, Sangregorio et al. 2001; Yamagiwa, Gray et al. 2001). 
Furthermore, production of TGFβ by epithelial cells also results in 
downregulation of IL-12/23 production by DCs (Ng, Kamm et al. 2010).  
 
 
1.2.13  Role of DC in intestinal inflammation  
 
Intestinal inflammation in IBD occurs when there is dysregulation of the immune 
system to intestinal flora. In a murine model of CD4+ T-cell-induced colitis, 
Krajina et al. demonstrated lamina propria DCs had an activated phenotype, with 
up-regulation of CD40, CD80 and CD86 and increased IL-12 expression, 
compared with non-colitic mice (Krajina, Leithauser et al. 2003). In this model of 
colitis, this suggests that DCs are driving a pro-inflammatory Th1 response.  
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Hart et al. demonstrated DCs from inflamed CD tissue express higher levels of 
CD40 than DCs from non-inflamed CD tissue or healthy tissue (Hart, Al-Hassi et 
al. 2005). These elevated levels of CD40 returned to normal after successful 
treatment with anti-TNF alpha therapy. The finding of elevated co-stimulatory 
molecules on DC in patients with active IBD is supported by other 
immunohistological studies which have shown increased numbers of DCs 
expressing CD40, CD86 in active IBD (Ikeda, Akbar et al. 2001; Vuckovic, Florin 
et al. 2001).  
 
DCs appear in the colon early in the process of intestinal inflammation, before 
the development of epithelial lesions and tissue degradation (Karlis, Penttila et al. 
2004). In another animal model of colitis, a 15-36 fold increase in the number of 
activated DC were observed in the MLN compared with normal mice or mice that 
had been administered regulatory T-cells to prevent the development of disease 
(Malmstrom, Shipton et al. 2001). All together, these observations highlight the 
role of intestinal DC in controlling the dysregulated immune response in CD.  
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endothelium and to concentrate within T cell-rich
areas. DC located within these areas amplify this
chemotatic signal since they also express CCL21
and CCL19 [60]. 
The maturing DC is also characterised by tight
control over the formation of MHC/peptide com-
plexes and their expression on the cell surface along
with costimulatory molecules. Internalised protein
antigen can accumulate in MIIC for up to 60hr in
immature DC [55]. However, within 3 4hr after
induction of maturation of DC, antigen rapidly
begins to complex with MHC-II within MIIC. This
process involves downregulation of cystatin C, an
inhibitor of cathepsin S. Cathepsin S degrades the
invariant chain, leaving its MHC-II-associated
invariant chain peptide fragment (CLIP) in the pep-
tide binding groove of MHC-II [63]. MHC-II are
then released from the endosomal sorting motifs of
the invariant chain and CLIP is thought to be
replaced with antigen peptide by the action of the
resident catalyst H-2M [64, 65]. MHC-II/peptide
complexes then separate from the bulk of unpro-
cessed antigen and accumulate in LAMP-H-2M-
compartments designated Class-II vesicles (CIIV),
which are located in the periphery of the cell [55].
CIIV appear to emanate from MIIC as extensive
tubules that separate off and move towards the cell
periphery in a microtubule-dependent manner upon
DC maturation [66, 67]. Maturation of DC also trig-
gers neo-biosynthesis of MHC-I [53]. MHC-I,
along with CD86 molecules, appear to accumulate
in CIIV directly from the ER/trans-Golgi network
[55, 67]. CIIV can fuse with the PM resulting in
expression of MHC-II, CD86 and MHC-I at the cell
surface [55, 67]. Concomitantly, maturing DC
downregulate their endocytic capacity, thereby pre-
venting reabsorption and degradation of MHC-
II/peptide complexes and promoting their stable
expression at the cell surface [68].
Functional maturation culminates with DC
residing in T cell-rich areas of lymphoid tissues
presenting peptide antigens acquired in the periph-
ery in the context of MHC to passing T cells. MHC
molecules are expressed 10 100 fold higher on
mature DC than on B cells and monocytes [69].
Mature DC also upregulate expression of several
costimulatory molecules including CD80, CD86
and CD40 [70] and also begin expression of a
novel chemokine, DC-CK1, that preferentially
attracts naïve (CD45RA+) T cells [71]. They also
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Fig. 1 A dual role for DC in immunity and tolerance.
Hemopoietic stem cells (HSC) in bone marrow seed DC
precursors in blood, which supply peripheral tissues
with immature DC. Immature DC constitutively take up
surrounding antigens, both self and foreign. In the
immune steady-state, DC would commonly take up self
antigens, mature and follow a tolerogenic pathway of
development. They migrate with self antigens to T cell
areas of lymphoid tissues where they present self anti-
gen in the context of MHC and promote unresponsive-
ness in T cells specific for self antigens. Upon exposure
to 'danger' signals, immature DC undergo activation
during their maturation leading acquisition of immuno-
genic characteristics. They migrate to lymph nodes
(LN) and present foreign antigen in the context of MHC
and costimulatory molecules to T cells which are driven
to differentiate into effector cells. The type of effector T
cells generated, either TH-1 or TH-2, is influenced by the
DC, and is dependent on the activating antigen. It is cur-
rently not known what signals lead to maturation of DC
for T cell tolerance or how activationwith 'danger' sig-
nals  leads to maturation and T cell immunity.
 
 
Figure 8. Homeostatic and immunogenic properties of human dendritic cells. 
Immature DCs in the peripheral tissues develop from these DC precursors. In the 
steady state, they take up self-antigens, mature and follow a tolerogenic pathway 
of development. Upon exposure to infectious/inflammatory antigens, immature DCs 
mature and migrate to lymph nodes when antigen presentation leads to T-cell 
expansion and differ ntiatio  (Quah and O'Neill 2005).  
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1.3  Anti tumour necrosis factor alpha therapies for Crohn’s 
disease 
 
1.3.1   Biology of the TNF alpha cytokine 
 
TNF alpha was first described by Carswell et al. in 1975 as an endotoxin-induced 
glycoprotein, which caused haemorrhagic necrosis of solid tumors (Carswell, Old 
et al. 1975). At low concentrations, TNFα has beneficial effects in the human 
body, initiating defense responses to local injuries and playing a central role in 
host defense against infections (Chowers and Allez 2010). At high concentrations, 
TNFα contributes to excessive inflammation, resulting in tissue damage (Kollias 
2005). In patients with CD, there are elevated concentrations of TNFα in 
inflamed tissue (Braegger, Nicholls et al. 1992), and hence it is considered a pro-
inflammatory cytokine.  
 
TNFα is predominantly synthesised by lymphocytes and activated macrophages 
(Vassalli 1992) but also by other immune cells (dendritic cells, eosinophils, 
neutrophils, and mast cells), non-immune cells (glial cells, astrocytes, fibroblasts, 
granuloma cells and keratinocytes) and many kinds of tumour cells (Bazzoni and 
Beutler 1996).    
 
TNFα is generated as a 26-kDa transmembrane type II polypeptide precursor 
(tmTNF). The 17-kDa soluble TNFα (sTNF) is released from tmTNF by the action 
of TNFα converting enzyme (TACE) (Black, Rauch et al. 1997). Both sTNF and 
tmTNF are biologically active by binding to one of two structurally distinct 
receptors: TNF receptor type I (TNFR1, subsequently referred to as the p55 TNF 
receptor) and TNF receptor type II (TNFR2 or p75 TNF receptor) (Vandenabeele, 
Declercq et al. 1995). TNFR1 and TNFR2 are found on all cell types with the 
exception of erythrocytes. The receptors share the same extracellular TNF-
binding domain structure, but induce different cytoplasmic signaling pathways 
(Wallach, Varfolomeev et al. 1999). sTNF binds to TNFR1 with a high affinity. 
TNFR1 contains a death domain which mediates the induction of apoptosis. 
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Historically this action was considered to be the principal mechanism through 
which TNFα induces its pro-inflammatory mechanism. However, the role of 
tmTNF and subsequent TNFR2 signaling is becoming increasingly relevant. 
Indeed, tmTNF induces colitis in the absence of sTNF (Corazza, Brunner et al. 
2004).   
 
In addition to its action on effector cells (‘forward signaling’), tmTNF also 
functions as a cellular receptor on TNFα-producing cells, resulting in ‘reverse 
signaling’. By this process, the membrane-integrated ligands can receive signals, 
acting as receptors that can transmit positive and negative feedback signals into 
the ligand-bearing cell. Eissner et al. demonstrated that reverse signaling 
through tmTNF in human monocytes and macrophages confers resistance to LPS 
(Eissner, Kirchner et al. 2000). Reverse signaling by tmTNF also induces E-
selectin expression in activated human CD4+ T cells (Harashima, Horiuchi et al. 
2001). Therefore, current evidence suggests that drugs can target tmTNF in 
different ways: by acting as an antagonist (blocking tmTNF interaction with 
TNFR1/2), or as an agonist by initiating reverse signaling, leading to apoptosis, 
cell activation or cytokine suppression. Reverse signaling is an emerging area of 
interest regarding the mechanisms of action of anti-TNFα antagonists.  
 
 
 
Figure 9. The synthesis, biology, cellular receptors and effector functions of the 
TNFα cytokine.  
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1.3.2   Anti-TNFα therapies for CD 
         
The era of biological therapy for IBD began in 1998 with the approval of the anti 
TNFα agent, infliximab, for the treatment of luminal CD. Later, it was approved 
for the treatment of fistulising CD and for patients with acute severe UC. 
Adalimumab was subsequently approved in 2007 and certolizumab pegol in 
2008 for luminal CD. To date, certolizumab pegol has not received approval for 
use by the European Medicines Agency and therefore it is only available for use 
in the United States and Switzerland.  
 
Biological therapies have offered a powerful new weapon in the treatment of IBD 
thanks to their ability to induce and maintain remission, heal mucosa, reduce 
admissions to hospital, prevent surgical operations and restore quality of life (Di 
Sabatino, Liberato et al. 2011). The use of biological therapy in CD is currently 
reserved for patients with disease not responding to conventional therapy 
(corticosteroids and/or immunosuppressants).  
 
Infliximab 
Infliximab (IFX) is a mouse chimeric monoclonal antibody that targets the 
human TNFα cytokine. It is composed of a human constant region IgG1k light 
chain that accounts for approximately 75% of the antibody, and a mouse variable 
region (25%). It is administered intravenously (usually 5mg/kg body weight) 
typically at 6-8 week intervals (following an accelerated induction course).  
 
IFX has a rapid onset of action, and disease response can be evaluated after only 
3 doses. Week 4 response rates after a single dose of IFX was 66% and remission 
rate was 33%, both being superior to placebo (Targan, Hanauer et al. 1997).  
 
This early response rate to IFX was further demonstrated in the large ACCENT I 
trial (A Crohn's disease Clinical study Evaluating infliximab in a New long term 
Treatment regimen), which demonstrated that patients who responded to a 
single dose of IFX were more likely to stay in remission up to week 54 if they 
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continued with maintenance IFX treatment compared to placebo (Hanauer, 
Feagan et al. 2002).  
 
A Cochrane Database System Review in 2008 examined three randomized 
control trials examining maintenance of remission of CD with IFX treatment 
(Behm and Bickston 2008). IFX was better than placebo for maintenance of 
remission (relative risk, RR, = 2.50), clinical response (RR = 2.19), steroid-
sparing effects (RR = 3.13) and complete fistula healing (RR = 1.87) to week 54.  
 
Adalimumab 
Adalimumab (ADA) is a fully human IgG1 monoclonal antibody to TNFα. It is 
administered subcutaneously, usually every 2 weeks at a dose of 40mg 
(following an induction course).  
 
The CHARM trial (Crohn’s Trial of the Fully Human Antibody Adalimumab for 
Remission Maintenance) (Colombel, Sandborn et al. 2007) showed ADA to be 
superior to placebo in maintenance of remission of moderate to severe CD at 
week 26 (40% versus 17% respectively) and week 56 (36% versus 12% 
respectively). There was no significant difference in clinical efficacy when 
comparing ADA 40mg every other week to 40mg weekly dosing.  
 
There are no clinical trials directly comparing efficacy of IFX to ADA, but clinical 
remission rates appear comparable. Remission rates with ADA were 40% at 
week 26 in the CHARM trial, compared to IFX which achieved 41.8% remission at 
week 30 in the ACCENT I trial. The two therapies also have similar rates of 
complete fistula closure; 36% for IFX (Sands, Anderson et al. 2004) and 33% for 
ADA in subgroup analysis of the CHARM trial at week 54, although there is no 
trial involving ADA looking at fistula closure as the primary outcome.   
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Certolizumab 
Certolizumab (CZP) is a humanised TNFα Fab’ monoclonal antibody fragment 
linked to polyethylene glycol. The PEGylation increases its plasma half-life and 
reduces the requirement for frequent dosing, possibly reducing immunogenicity 
as well. CZP is administered subcutaneously, usually every 4 weeks at a dose of 
400mg (following an induction course). 
 
The Pegylated Antibody Fragment Evaluation in Crohn’s Disease: Safety and 
Efficacy 1 (PRECISE I) study (Sandborn, Feagan et al. 2007) examined the 
efficacy of CZP in 662 patients with moderate to severely active CD, and 
concluded that induction and maintenance therapy with CZP was associated with 
a modest improvement in response rates compared with placebo, but with no 
significant improvement in remission rates.  
 
The PRECISE 2 study was designed differently by giving all patients an induction 
course of CZP and those with a defined clinical response at week 6 were 
randomly assigned to receive either CZP maintenance therapy or placebo and 
followed up to week 26 (Schreiber, Khaliq-Kareemi et al. 2007). The study 
showed that patients with moderate to severe Crohn's disease who had a 
response to CZP induction therapy were more likely to have a maintained 
response and be in remission at 26 weeks with maintenance CZP treatment than 
with a switch to placebo. 
 
Etanercept 
Etanercept is a genetically engineered fusion protein consisting of two 
recombinant human TNF p75 receptors linked to an Fc portion of human IgG1 
fragment. It is administered subcutaneously at a dose of 25mg twice weekly. 
 
Etanercept is effective in the treatment of rheumatoid arthritis, but is ineffective 
in the treatment of CD (Sandborn, Hanauer et al. 2001), although this may be the 
result of insufficient dosing of etanercept in the study as opposed to fundamental 
differences in the mechanism of action of the drug.  
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1.3.3  Mechanisms of action of anti-TNFα therapies in Crohn’s 
disease 
 
Studies in CD have shown an increased number of lamina propria sTNF-
producing cells and high concentrations of sTNF can be detected in the stool of 
patients with active inflammatory responses (Braegger, Nicholls et al. 1992; 
Breese and MacDonald 1995). All the available anti TNF antibodies effectively 
neutralise the bioactivity of sTNF (ten Hove, van Montfrans et al. 2002). However, 
the apparent failure of etanercept in phase II clinical trials in the treatment of CD 
means that neutralisation of sTNF in isolation is unlikely to represent the only 
mechanism of action of anti-TNFα antibodies, with the proviso that inadequate 
dosing of etanercept was not responsible for the lack in clinical benefit observed. 
 
Binding of anti-TNFα antibodies to tmTNF also occurs and suppresses pro-
inflammatory cytokines, cell activation and upregulation of adhesion molecules 
in different tmTNF transfected cell lines (Tracey, Klareskog et al. 2008), resulting 
in a down-regulation of inflammation. IFX, ADA and CZP are comparable with 
regards their tmTNF-antagonist activity when compared directly in vitro 
(Gramlick, Fossati et al. 2006). 
 
Although all anti-TNFα antibodies bind to tmTNF, there is evidence for 
differential induction of cytokine suppression through reverse signaling (Scallon, 
Cai et al. 2002; Mitoma, Horiuchi et al. 2004; Mitoma, Horiuchi et al. 2005). This 
may be, in part, the result the phenomenon of ‘crosslinking’. IFX and ADA are 
bivalent antibodies that recognize each monomeric component of trimeric TNF 
(Scallon, Cai et al. 2002). Therefore, a single sTNF or tmTNF is capable of being 
bound by three different molecules of IFX or ADA. As each IFX or ADA molecule 
has two antigen-binding sites, a single antibody might bind different soluble 
and/or transmembrane TNF molecules (crosslinking). These qualities enable IFX 
and ADA to bind to tmTNF at much higher levels than etanercept (Scallon, Cai et 
al. 2002) or CZP.        
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Neutralisation of TNFα is clearly important in the clinical effect of anti-TNFα 
therapies in the treatment of CD. However, the different degrees of efficacy of 
different anti-TNFα drugs mean that this is not the only mechanism of action of 
anti-TNFα agents. Other biological effects on barrier function, lymphocyte 
apoptosis, mucosal angiogenesis and immunological mechanisms have also been 
demonstrated, as outlined below. 
 
1.3.3.1  Barrier function 
 
The gastrointestinal epithelial lining consists of a monolayer of columnar cells 
held together by circumferential intercellular junctions. It forms a selectively 
permeable barrier between the luminal contents and the body, preventing 
potentially harmful macromolecules and microorganisms exiting the intestinal 
lumen. The structural and functional properties of the epithelium regulate the 
quantity of antigenic material that reaches the epithelial surface (mucus 
secretion) and also control the antigenic exposure to M-cells and DC that sample 
antigenic material and provide signals to the mucosal immune system, thereby 
guaranteeing permanent immunosurveillence. 
 
Tight junctions (TJs) are located at the apical end of the intercellular space and 
play a vital role in regulating paracellular movement of fluid and solutes (Turner, 
Rill et al. 1997). TJs are made up of many different proteins, including ZO-1, 
occludins and the claudins. Increased permeability of TJs is associated with the 
pathogenesis of CD (Gassler, Rohr et al. 2001). Patients with CD have increased 
intestinal permeability and reduced amounts of occludin in the diseased 
intestine (Poritz, Lynch et al. 1997). Therefore, in active disease, there is 
increased exposure of the mucosal innate and acquired immune system to pro-
inflammatory molecules, and is a major factor in the development of mucosal 
inflammation.  
 
TNFα and the intestinal epithelial barrier function are intimately related. In vitro 
models have demonstrated that TNFα influences barrier function by inducing 
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disassembly of TJs in epithelial cells (Bruewer, Luegering et al. 2003; Wang, 
Graham et al. 2005). TNFα may also act to increase barrier permeability by 
induction of epithelial apoptosis (Zeissig, Bojarski et al. 2004).  
 
More recent work in murine models of colitis found that TNFα is involved in 
early TJ rearrangement and its effects are mediated through TNFR1. The study 
investigated the effects of both IFX and etanercept in this model and found them 
to be equally effective despite their clinical differences in efficacy in CD (Fries, 
Muja et al. 2008).  
 
A study by Suenaert et al. examined intestinal permeability (by measurement of 
urinary 51Cr-EDTA excretion after oral intake) in refractory CD before and 4 
weeks after a single infusion of IFX (5mg/kg). The authors found that following 
IFX infusion, there was a significant reduction in gut inflammation and a largely 
restored gut barrier (Suenaert, Bulteel et al. 2002). It remains unclear whether 
this observation simply reflects healing of the injured mucosa independently of 
the mechanism by which it was achieved. 
 
Furthermore, epithelial apoptosis was up regulated in the colon of patients with 
active CD and was restored to normal in 10 of 11 patients, 2 weeks following IFX 
treatment (5mg/kg). Interestingly, the expression of TJs (occludin, claudin 1 and 
claudin 4) did not alter following IFX therapy and therefore did not contribute to 
this therapeutic effect (Zeissig, Bojarski et al. 2004).  
 
Restoration of epithelial barrier integrity in CD by anti-TNFα drug treatment is 
likely to play a major role in the long-term anti-inflammatory therapy effect, and 
indeed such ‘barrier healing’ may represent the first step towards ‘mucosal 
healing’ that is seen in some patients receiving anti-TNFα therapy.   
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1.3.3.2  Apoptosis 
 
Apoptosis is a distinct mode of cell death and represents a crucial regulatory 
mechanism to remove redundant cells in many physiological events. CD is 
characterised by mucosal T-cell proliferation that exceeds T-cell apoptosis (Ina, 
Itoh et al. 1999), resulting in an accumulation of activated lamina propria T 
lymphocytes.  
 
Apoptosis is regulated by trimerisation of specific death receptors, including 
TNF-R1, Fas/APO-1, TRAIL-R1 and TRAIL-RII (Arnold, Brenner et al. 2006). This 
leads to the formation of a death-inducing signaling complex and proteolytic 
cleavage of procaspases, ultimately activating caspse-3, a key effector of 
apoptosis. An alternative pathway of apoptosis involves molecules released from 
the mitochondria. Two such proteins are Bax (pro-apoptotic) (Brady, Gil-Gomez 
et al. 1996) and Bcl-2 (anti-apoptotic) (Kroemer 1997). The intracellular ratio of 
Bax:Bcl-2 determines whether the cell will respond to apoptotic signals (Adams 
and Cory 1998). A reduced intracellaular ratio of Bax:Bcl-2 correlates with 
resistance of lamina propria lymphocytes to Fas mediated apoptosis in CD in 
several studies (Boirivant, Marini et al. 1999; Ina, Itoh et al. 1999).  
 
Lugering et al. used Annexin V staining by flow cytometry to demonstrate 
increased apoptosis of peripheral blood monocytes in patients with chronic 
active CD, 4 hours after being administered IFX (5mg/kg). IFX-induced apoptosis 
in monocytes was dependent on proteolytic activation of different members of 
the caspase family, such as the initiator caspase-8 and caspase-9, as well as the 
effector caspase-3 (Lugering, Schmidt et al. 2001). T-lymphocyte apoptosis 
results from a caspase-dependent phenomenon following IFX treatment (Di 
Sabatino, Ciccocioppo et al. 2004).  
 
Ten Hove et al. demonstrated that IFX restores the inappropriate T-cell 
accumulation present in CD by induction of T-cell apoptosis in vivo (ten Hove, 
van Montfrans et al. 2002). Ten patients with steroid-refractory Crohn’s disease 
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were treated with IFX (5mg/kg) and a clinical response was achieved in 9/10 
patients. The expression of activation markers, homing receptors, memory cells, 
Fas expression or Bax:Bcl-2 expression on peripheral blood T-lymphocytes did 
not change. However, there was a significant increase in CD3 and terminal dUTB 
nick end labeling (TUNEL) positive cells in colonic biopsies 24 hours following 
IFX administration. IFX-induced apoptosis, and an increase in the Bax:Bcl-2 ratio, 
of CD3/CD28 stimulated Jurkat cells, but not in unstimulated Jurkat cells. This 
suggests that IFX stimulates a rapid and specific increase in apoptosis of T 
lymphocytes in the gut mucosa.  
 
A recent study isolated CD14+ macrophages and CD4+ T-cells from peripheral 
blood and lamina propria mononuclear cells in patients with IBD and healthy 
control subjects (Atreya, Zimmer et al. 2011). Immunohistochemistry and 
fluorescence-activated cell sorting techniques were used to assess cell surface 
markers and apoptosis. All the clinically effective anti-TNFα antibodies studied 
(IFX, ADA and CZP) resulted in a significant induction of T-cell apoptosis in IBD 
when lamina propria CD4+ T-cells expressing TNFR2 were cultured with mTNF+ 
CD14+ intestinal macrophages. In contrast, the anti-TNFα antibodies did not 
induce significant apoptosis in mono-cultured or co-cultured CD14+ and CD4+ 
cells from healthy control subjects. T-cell apoptosis was critically dependent on 
TNFR2 signaling and could be prevented by IL-6 signal transduction. The 
findings highlight the important role of the mTNF/TNFR2 pathway in anti-TNFα-
induced apoptosis.  
 
The clinical relevance of anti-TNFα-induced apoptosis of activated lamina 
propria T-lymphocytes in patients with active CD has been shown in a study by 
Van den Brande et al (Van den Brande, Koehler et al. 2007). This study used 
99mTechnetium-annexin V single photon emission computer tomography 
(SPECT) to study the effect of anti-TNFα treatment on apoptosis in the intestine 
in patients receiving IFX therapy. They found that colonic uptake of 99mTc-
annexin V correlated with the clinical benefit of anti-TNFα therapy in vivo, and 
therefore may be predictive of therapeutic success.  
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While these studies support the ‘apoptosis theory’ as a mechanism of action of 
anti-TNFα antibodies, there is conflicting data. Induction of apoptosis in 
monocytes and/or T-lymphocytes by IFX has been demonstrated in multiple in 
vitro and in vivo studies. ADA is also effective in inducing apoptosis of human 
monocytes (Shen, Assche et al. 2005), and both of these anti-TNFα therapies are 
effective in CD. However CZP, despite its clinical efficacy in CD, does not induce 
apoptosis (Nesbitt, Fossati et al. 2007). Etanercept does not induce apoptosis 
and is not effective in the treatment of CD (Van den Brande, Koehler et al. 2007); 
however Onercept (a soluble p55 TNF receptor) does induce apoptosis but, again, 
is not effective in the treatment of CD (Lugering, Lebiedz et al. 2006). It is 
therefore likely that apoptosis, although an important mechanism of action of 
anti-TNFα antibodies, is not the only mechanism by which these treatments 
exert their effect in CD.  
 
1.3.3.3  Mucosal angiogenesis 
 
Angiogenesis is the formation of new capillaries from pre-existing blood vessels, 
and is a fundamental component of complex biological processes such as chronic 
inflammation (Szekanecz, Besenyei et al. 2010), including contributing to the 
pathogenesis of IBD (Danese, Sans et al. 2006). Vascular endothelial growth 
factor-A (VEGF-A) is the predominant cytokine regulating angiogenesis in IBD 
(and other chronic inflammatory disorders). Overexpression of VEGF-A occurs in 
patients with IBD, and neutralisation of VEGF-A correlates with the inhibition of 
angiogenesis (Scaldaferri, Vetrano et al. 2009).  
 
A recent study by Rutella et al. examined mucosal angiogenesis by staining 
endoscopic biopsies with CD31 and Ki-67 in CD patients prior to IFX treatment 
and again, following 54 weeks of IFX therapy (Rutella, Fiorino et al. 2011). VEGF-
A release was also studied by enzyme-linked immunosorbant assay (ELISA). In 
vitro studies were performed in cultures of human intestinal fibroblasts 
stimulated with TNFα in the presence or absence of IFX. The authors found that 
the administration of IFX down regulates mucosal angiogenesis in patients with 
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CD and restrains the production of VEGF-A by mucosal fibroblasts. These 
phenomena did not occur in patients who showed no clinical response to IFX 
treatment. The results of this study indicate that IFX ameliorates inflammation-
driven angiogenesis in the gut mucosa in patients with CD.  
 
1.3.3.4  Cytokine production 
 
Cells of the innate immune system, such as macrophages, monocytes and DC, 
secrete several pro-inflammatory cytokines in response to a danger signal, for 
example an infectious agent. The resulting cytokine milieu directs the 
development of adaptive immunity mediated by T- and B- lymphocytes 
(Papadakis and Targan 2000). As previously discussed, the immune response in 
CD is a Th1/Th17 response, with the production of the stimulatory cytokines 
IFNγ, IL-2, IL-12, IL-17 and TNFα.  
 
IFX acts on multiple constituents of the cytokine network in order to exert its 
action. To examine the effect of IFX on cytokine production, Ringheanu et al. 
isolated monocytes from healthy individuals and pre-treated the cells in vitro 
with IFX before stimulation with LPS or staphylococcal enterotoxin A (SEA) to 
assess gene expression for pro-inflammatory cytokines (TNF-alpha, IL-1β, IL-6, 
and IL-8) by reverse transcription polymerase chain reaction (Ringheanu, Daum 
et al. 2004). The effect of in vivo IFX treatment of monocytes was similarly 
determined by comparing the responses of monocytes from CD patients before 
and immediately after IFX infusion. The authors found that, following pre-
treatment with IFX in vitro, monocytes produced significantly less TNFα after 
stimulation with the bacterial products LPS and SEA. Peripheral blood 
mononuclear cells isolated from patients 1 hour following IFX infusion had fewer 
copies of IL-1β, IL-6, IL-8 and TNFα following stimulation with LPS and SEA than 
prior to the IFX infusion. 
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Other in vitro studies have supported these findings by showing complete 
suppression of TNFα and IL-1β production by monocytes by IFX, ADA and CZP, 
but only partial suppression with etanercept (Nesbitt, Fossati et al. 2006). 
 
Agnholt et al. cultured in vitro colonic T-cells from 25 patients with Crohn’s 
disease and 10 healthy controls, using medium supplemented with IL-2 and IL-4 
(Agnholt and Kaltoft 2001). T-cells from CD patients produced significantly 
higher levels of IFNγ and TNFα than T-cells from healthy controls. When 
cultured in the presence of IFX, colonic T-cells from CD patients decrease their 
expression of IFNγ, demonstrating the effect of IFX on the secretion of pro-
inflammatory cytokines by intestinal T-cells. 
 
Mizutani et al. have further demonstrated the effect of IFX on cytokine levels in 
patients with CD in vivo. In this study, 37 patients with active CD were enrolled 
and administered IFX 5mg/kg intravenously. A Bio-Plex suspension array system 
was used before treatment and 4 and 8 weeks after IFX treatment to quantify 
serum levels of 17 cytokines. They found serum levels of IL-6, IL-7, IL-8 and MIP-
1β were statistically significantly decreased in CD patients following IFX 
treatment compared to before treatment (Mizutani, Akasaka et al. 2011).  
 
The evidence above suggests that therapeutic blockade of TNFα may lead to an 
interruption in the cascade of inflammatory cytokines and ultimately reduce the 
inflammatory response.  
 
1.3.3.5  CD40/CD40L  
 
Naïve T-cells require contact with activated dendritic cells in order to be primed 
and cause an inflammatory response. Intestinal DCs act as professional antigen 
presenting cells (APCs) by sampling antigenic material within the gut lumen, DCs 
sense microbes by a series of surface receptors (including TLRs), which 
recognise structural elements displayed on the surface of microbes (Kadowaki, 
Ho et al. 2001). After interaction with the antigenic material (or other 
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maturation stimuli such as cytokines), immature DCs migrate to the draining 
lymphoid tissue under the influence of alterations in surface expression of 
chemokine receptors (Banchereau and Steinman 1998). During this process, DCs 
down-regulate their antigen-acquisition machinery and up-regulate cell surface 
expression of molecules required for the activation of naïve T-cells. At the time of 
antigen presentation, DCs deliver 3 signals to the T-cell. The first signal is the 
antigen itself, expressed on the surface of the DC by MHC class II molecules (such 
as HLA DR). The second signal is provided by surface expression of co-
stimulatory molecules, such as CD40, CD80 and CD86, which are recognised by 
CD40L and CD28 respectively on T-cells. The third signal refers to the cytokine 
milieu (produced by DCs) in which antigen presentation takes place. The 
quantity and quality of the 3 signals determines the ultimate T-cell response in 
terms of immune response or immune tolerance.   
 
The CD40-CD40L interaction is one of the most effective APC-activating signals. 
In patients with active CD, CD40 is up regulated in several cell types including 
microvascular endothelial cells resulting in vascular inflammation. In the same 
patients, CD40L expression is up regulated by lamina propria T-cells and 
platelets, with the soluble form (sCD40L) being increased in the circulation of 
IBD patients (Tilg, Moschen et al. 2007). These observations indicate that the 
CD40/CD40L pathway plays a key pathogenic role in intestinal inflammation 
(Danese, Sans et al. 2004).  
 
Danese et al. evaluated 18 patients with CD and found that IFX treatment 
decreases serum levels of sCD40L and CD40L expression on peripheral T-cells 
and platelets (Danese, Sans et al. 2006). They also demonstrated that following 
IFX treatment, there was reduced colonic tissue expression of CD40 and vascular 
cell adhesion molecule-1 (VCAM-1). In vitro IFX prevented TNFα-induced CD40 
and VCAM-1 expression by human intestinal microvascular endothelial cells 
(HIMEC) and reduced T-cell surface CD40L expression and sCD40L release. In 
addition, IFX decreased T-cell-induced VCAM-1 expression in HIMEC by down-
regulating CD40L in T-cells and promoting T-cell apoptosis. 
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These findings have been mirrored when examining CD40 expression on DCs in 
CD. Hart et al. demonstrated significantly higher levels of CD40 expression on 
intestinal DCs taken from inflamed mucosa in CD patients when compared to 
non-inflamed CD tissue or healthy controls. In 7 patients with CD receiving 
treatment with IFX, levels of CD40 expression on colonic DCs was evaluated 
before and after infusion. There was a significant reduction in CD40 expression 
on DCs after treatment with IFX, which was irrespective of resolution of 
inflammation (Hart, Al-Hassi et al. 2005).  
 
1.3.3.6  Cell-mediated and complement-dependent cytotoxicity  
 
TNFα antagonists also bind to tmTNF-bearing cells and therefore have the 
potential to induce cell cytotoxicity by Fc-dependent mechanisms including; i) 
antibody-dependent cell-mediated cytotoxicity (ADCC) and/or ii) complement-
dependent cytotoxicity (CDC).  
 
ADCC is a mechanism of cell-mediated immune defense whereby an effector cell 
actively lyses a target cell that has been bound by specific antibodies. In CDC, the 
pathway is initiated by binding of C1q to the CH2 domain of the Fc region of cell-
bound antibodies or Fc-fusion proteins. Cross-linking of these molecules can 
result in activation of the complement cascade and the formation of the 
membrane attack complex, pore formation and cell lysis.  
 
Only a few in vitro studies exist to show the effects of anti-TNFα agents on CDC 
and ADCC potential. The Fc regions of IFX, ADA and Etanercept are all of the IgG1 
isotype and therefore capable of mediating CDC and ADCC. Although IFX, ADA, 
CZP and Etanercept all bound to a tmTNF transfected cell line, IFX and ADA were 
more active than Etanercept in mediating ADCC and CDC. CZP was inactive, as 
would be expected in a molecule that lacks an Fc region (Scallon, Cai et al. 2002; 
Gramlick, Fossati et al. 2006).  
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However, there are no in vivo studies to show the effect of these agents on ADCC 
and CDC, and therefore whether anti-TNFα therapies mediate these effects in 
patients is unknown.  
 
1.3.3.7  Regulatory T-cells  
 
Several studies have demonstrated data on the interaction of IFX and putative 
Tregs in rheumatoid arthritis. TNFα inhibits the suppressor function of Treg cells 
through the TNFR2 receptor. Treatment with IFX restored the capacity of Tregs 
to inhibit cytokine production and to convey a suppressive phenotype to 
‘conventional’ T-cells. Furthermore, IFX treatment led to a significant rise in the 
number of T-cells with a regulatory phenotype in patients with rheumatoid 
arthritis responding to treatment, correlating with a fall in C-reactive protein 
(Ehrenstein, Evans et al. 2004).  
 
Nadkarni et al. demonstrated that IFX therapy leads to the generation of a 
specific population of regulatory T cells (Nadkarni, Mauri et al. 2007). This 
population of T-cell exerts its suppressor function through the anti-inflammatory 
cytokines TGFβ and IL-10. These cells lack expression of CD62L, thereby 
distinguishing them from natural Treg cells present in healthy individuals and 
patients with active rheumatoid arthritis. 
 
A recent study examined the immunosuppressive effects of different anti-TNFα 
therapies on activated T-cells in vitro (Vos, Wildenberg et al. 2012). The authors 
found that for an anti-TNFα therapy to inhibit T-cell proliferation, the compound 
needed to bind to tmTNF on activated T-cells. They demonstrated that IFX and 
ADA bind efficiently to tmTNF, with intermediate binding of CZP and low binding 
of etanercept and IgG control. Furthermore, the compound must possess an Fc 
region to interact with the Fc receptor on APC. The result of this binding induces 
formation of a distinct macrophage subset with an immunosuppressive 
phenotype. These macrophages inhibit the proliferation of activated T-cells, 
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produce anti-inflammatory cytokines and express the regulatory macrophage 
marker CD206.     
 
 
 
 
 
Figure 10. The mechanisms of action of anti-TNFα therapies in Crohn’s disease.  
A) General mechanisms of action of anti-TNFα therapy, including; 1 
neutralisation of soluble and transmembrane TNFα; 2 restoration of 
epithelial tight junction integrity; 3 inhibition of mucosal angiogenesis in 
gut mucosa; 4 induction of T-cell apoptosis.  
B) Immunologically-mediated mechanisms of action of anti-TNFα therapy, 
including; 5 apoptosis of tmTNF-expressing cells (cell and/or complement-
mediated); 6 down regulation of co-stimulatory molecules on DCs (CD40); 7 
reduced production of pro-inflammatory cytokines; 8 induction of Treg 
population.  
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1.3.4   Anti-TNFα therapy-induced paradoxical inflammation 
 
Although proven to be clinically efficacious in the treatment of IBD, anti-TNFα 
agents are associated with rare side effects, including opportunistic infections 
(Toruner, Loftus et al. 2008) and lymphoproliferative diseases (Siegel, Marden et 
al. 2009). The phenomenon of paradoxical inflammation (PI) has recently been 
described in patients with various chronic inflammatory diseases, following 
treatment with an anti-TNFα agent. It is defined as the development of 
inflammatory lesions in patients with immune mediated inflammatory disease 
after initiation of treatment with anti-TNFα agents, normally used to treat them 
(Chowers, Sturm et al. 2010). For example, a patient with CD can paradoxically 
experience the onset of another immune mediated inflammatory process (eg 
psoriasis), suggesting the ability of anti-TNFα agents to promote inflammation at 
remote sites in some patients. 
 
The development of inflammatory skin disorders following anti-TNFα therapy 
for IBD is an emerging problem. A recent prospective study was performed from 
January 2006 to January 2010 of all patients treated with an anti-TNFα therapy 
and presenting with eczematiform or psoriasiform lesions to a centre in Lille, 
France (Rahier, Buche et al. 2010). Over the study period, 562 patients were 
initiated on anti-TNFα treatment (341 IFX, 221 ADA) and 28 patients (5%) 
developed an inflammatory skin lesion (3% eczematiform and 2% 
psoriasaiform). Other studies have found the incidence rate of paradoxical skin 
lesions to be higher; Fidder et al. 9% of 743 patients with IBD treated with IFX 
(Fidder, Schnitzler et al. 2009); Esmailzadeh et al. 16% patients receiving IFX for 
various inflammatory disorders including 59 patients with IBD (Esmailzadeh, 
Yousefi et al. 2009).   
 
There is also evidence of new onset IBD in patients with other immune mediated 
inflammatory diseases receiving anti-TNFα therapy. Toussirot et al. published a 
French nationwide series in patients with inflammatory rheumatic disease who 
have developed IBD following anti-TNFα therapy (Toussirot, Houvenagel et al. 
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2011). During the two-year study period, 16 rheumatology patients developed 
IBD with a mean onset of 29.3 ± 20.1 months. Fourteen of these patients had 
received etanercept and 2 had received IFX. According to endoscopic and 
histological findings, the IBD was classified as CD in 8 cases, Crohn’s-like disease 
in 6, indeterminate in one case and definite ulcerative colitis in one case. In all 
cases, the anti-TNFα agent was discontinued and replaced by another 
monoclonal anti-TNFα agent without any evidence of recurrent IBD.  
 
The mechanism(s) responsible for PI in patients treated with anti-TNFα therapy 
are unknown. Evidence suggests that all the anti-TNFα agents have the potential 
to induce PI, thereby indicating that a class effect may be responsible.  
 
One hypothesis is that some patients have a genetic predisposition to developing 
PI (such as NOD2/CARD15 gene variants), and the introduction of the anti-TNFα 
agent may modify the cytokine balance leading to circumstances where PI can 
develop (Toussirot, Houvenagel et al. 2011).   
 
Another possibility is that some inflammatory pathways in CD may be TNFα-
independent, and subsequently are up regulated during TNFα blockade. For 
example, IFNα production by pDCs is down regulated by the presence of TNFα, 
and vice versa (Palucka, Blanck et al. 2005). pDCs infiltrate the skin of psoriatic 
patients and become activated to produce IFNα early in the disease process 
(Nestle, Conrad et al. 2005). Hence, the administration of anti-TNFα agents has 
the effect of increasing the production of IFNα (Schmitt, Zhang et al. 2008). This 
has been shown by De Gannes et al. who found increased levels of IFNα in the 
dermal vasculature and perivascular lymphocytic infiltrate of lesional skin of 
patients with TNFα antagonist therapy (de Gannes, Ghoreishi et al. 2007).  
 
Murine models of joint disease have shown TNFα blockade to increase the 
populations of Th1 and Th17 cells in the periphery, while inhibiting their 
accumulation in the joints (Notley, Inglis et al. 2008). This finding of increased 
Th1 and Th17 cells in organs other than those that are inflamed further supports 
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the suggestion that TNFα blockade is up-regulating other pro-inflammatory 
cytokines, and this may be partly responsible for the phenomenon of PI.  
 
Altered lymphocyte homing profiles may also play a role in PI, with some 
evidence suggesting this may occur through the expression of chemokine 
receptor CXCR3 ligands (Seneschal, Milpied et al. 2009). Other homing markers 
on DCs and/or T-cells may also be implicated, as indicated by work described in 
this thesis.  
 
PI remains a relatively rare phenomenon but is now a recognised adverse event 
of anti-TNFα therapy, and it appears that the broad impact on the immune 
system of anti-TNFα agents exceeds the blockade of TNFα itself (Chowers, Sturm 
et al. 2010). The mechanism of PI is not fully understood, but it seems likely that 
a number of TNFα-independent inflammatory pathways may be responsible.     
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1.4  Hypothesis and Aims 
 
Hypothesis 
We hypothesise that aberrant expression of homing markers on DCs drives 
inflammation in CD, and that these homing markers give rise to different clinical 
phenotypes of CD and are altered by the presence of a clinically efficacious anti-
TNFα therapy in vitro. 
 
Specific aims 
 
Chapter 3 
To characterise the phenotype of circulating DCs in patients with CD in whom 
inflammation is confined to specific anatomical locations. Study groups include: 
 Active small bowel CD  
 Active colonic CD  
 Extra-intestinal manifestations of CD, ie skin manifestations  
 Inactive ileocolonic CD  
 Healthy controls 
 
Chapter 4 
To examine the in vitro effects of anti-TNFα therapy on homing marker 
expression of peripheral blood mononuclear cell (PBMCs). 
 
Chapter 5 
To examine the in vitro effects of anti-TNFα therapy on blood-enriched DCs or 
low density cells (LDCs). The following parameters will be investigated:  
 LDC homing marker expression 
 LDC activation and maturation marker expression 
 Ongoing LDC intracellular cytokine production 
 Cell-free supernatant cytokine profile 
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Chapter 6 
To examine the effects of anti-TNFα-treated LDCs on subsequent T-cell 
responses in both patients with active CD and healthy controls, characterising 
the phenotype of stimulated T-cells through: 
 T-cell homing marker expression 
 T-cell primed cytokine profiles 
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Chapter 2  
 
 
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
2.1  Ethical Approval 
 
Ethical approval has been obtained under the title ‘Prospective study of 
immunological and microbiological factors in inflammatory bowel disease’ by 
Brent Research and Ethics Committee, for the use of human blood.  
 
REC reference:  08/H0717/24 
Protocol number:  cro1043.  
 
All patients and healthy volunteers recruited for research were given 
information sheets and provided written consent for samples to be taken.  
  
Local NHS Research and Development approval and sponsorship to conduct the 
study was secured from Imperial College London and the North West London 
Hospitals NHS Trust.  
 
 
2.2  Materials 
 
2.2.1   Human blood samples 
 
Venesection was performed on patients and healthy volunteers according to the 
study protocol. Volumes of blood taken ranged between 20ml and 50ml per 
venesection, depending on the experiment design. Blood samples were collected 
in 10ml lithium heparin vacutainer tubes (BD Biosciences) and processed within 
30 minutes of venesection in the Antigen Presentation Research Group (APRG) 
laboratory at Imperial College London.  
 
The diagnosis of patients with CD was made using clinical parameters, 
radiological, endoscopic and histological criteria. Demographical information 
was obtained and full medication histories recorded. Disease activity was 
assessed using the Harvey Bradshaw Index for CD (see section 3.3.1).  
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2.2.2   Patient inclusion and exclusion criteria 
 
Strict inclusion and exclusion criteria were used during all patient recruitment 
throughout the research project, to ensure the accuracy of data obtained. The 
following criteria were applied to patient recruitment:  
 
Inclusion criteria: 
 Age ≥ 18 years 
 Able to provide informed, written consent 
 Histology compatible with a diagnosis of CD 
 Endoscopic and radiological study within 6 months of recruitment 
 No medication or dose change within last 3 months 
 
Exclusion criteria: 
 Local or systemic sepsis 
 Co-existing inflammatory condition (eg tuberculosis, sarcoid, 
diverticulitis) 
 Perianal CD 
 Previous intestinal resection surgery 
 Polyposis syndrome 
 Current or any past history of cancer 
 Biological, corticosteroid or methotrexate therapy within 3 months 
 
 
2.2.3   Culture medium 
 
Dutch modification RPMI-1640 medium (Sigma Aldrich, UK) was used for cell 
dilution and suspension during whole blood processing. Dutch modified RPMI 
1640 medium incorporates both HEPES buffer for partial pH control and 
bicarbonate for gas exchange. 
 
 
78 
 
2.2.4   Complete medium 
 
For washing and culture of both peripheral blood mononuclear cells (PBMCs) 
and DC-enriched low density cells (LDCs), cells were suspended in RPMI 1640 
Dutch modification, supplemented with 2mM L-glutamine, 100μg/ml 
streptomycin, 100units/ml penicillin, 50μg/ml gentamicin and 10% foetal calf 
serum (FCS, Harlan Laboratories).  
 
 
2.2.5   Buffers  
 
2.2.5.1  FACS Buffer 
 
Cells were washed and re-suspended in FACS buffer in preparation for antibody 
labeling and analysis by flow cytometry. FACS buffer was prepared from 
phosphate buffered saline (PBS), supplemented with FCS (2%), sodium azide 
(0.02%, Sigma, UK) and EDTA (1mM, Sigma, UK).  
 
2.2.5.2  MiniMACs buffer 
 
Sterile PBS supplemented with 0.5% bovine serum albumin (BSA) and 2mM 
EDTA was used for T-cell separation using negative magnetic cell separation 
columns (see section 2.3.4). 
 
 
2.2.6   Reagents 
 
2.2.6.1  5-carboxyfluorescein-diacetate-succinimidyl ester (CFSE) 
 
CFSE (Invitrogen Ltd, UK) is a fluorescent cell staining dye and was used to 
fluorescently label human T-cells prior to co-culture with allogeneic DC. CFSE is 
incorporated into cells and is used to identify cell proliferation assays due to 
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progressive halving of CFSE fluorescence within daughter cells following cell 
division.  
 
2.2.6.2  Ficoll-Plaque 
 
Ficoll-Plaque (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) is a 
polysaccharide dissolved in an aqueous solution and creates a density gradient 
at centrifugation. This gradient was used to isolate PBMCs from fresh venous 
blood samples. 
 
2.2.6.3  Flow-countTM fluorospheres 
 
Flow-countTM fluorospheres (Beckman Coulter, Buckinghamshire, UK) with a 
known density (depending on the batch) were used as a reference during flow 
cytometry analysis of human cells for calculation of absolute cell numbers. 
 
2.2.6.4  Foetal calf serum (FCS) 
 
FCS (TCS Cellworks, Buckingham, UK) was added to cell culture media to provide 
positive growth factors for cells. FCS also was also used during monoclonal 
antibody labeling to block non-specific binding.  
 
2.2.6.5  Leucoperm A  
 
Leucoperm A (Serotec, UK) was used as a fixative reagent and is used for 
intracellular cytokine staining of LDCs. It contains paraformaldehyde.  
 
2.2.6.6  Leucoperm B 
 
Leucoperm B (Serotec, UK) is a cell permeabilisation reagent used to assess the 
intracellular cytokine staining of LDCs by flow cytometry. 
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2.2.6.7  Monensin 
 
Monensin (Sigma, UK) was prepared in ethanol at a stock concentration of 3mM 
and stored at -70°c. Monensin was further diluted and added to cell cultures to 
give a final concentration of 3μM. Monensin is an ionophore originating from 
Streptomyces cinnamonensis that disrupts protein transportation from the Golgi 
apparatus leading to the trapping of newly synthesised protein within the cell 
cytoplasm (Mollenhauer, Morre et al. 1990).  
 
2.2.6.8  Nycoprep 
 
Nycoprep (Axis-Shield, Oslo, Norway) was used to create a density gradient to 
separate LDCs from the non-adherent fraction of PBMCs. 
 
2.2.6.9  Paraformaldehyde (PFA) 
 
Paraformaldehyde (BDH chemicals, UK) was dissolved in saline (0.85%) through 
slow heating at 60°c at pH 7.0-7.4 to make a 1% stock solution which was added 
directly to antibody-labelled cells as a fixative reagent.  
 
2.2.6.10  Trypan blue 
 
Trypan blue (Sigma, Poole, UK) is a diazo dye used to selectively colour dead 
cells and tissue, visible by optic microscopy. Live cells with intact membranes are 
not coloured by the dye and therefore this allowed counting of live cells. Trypan 
blue was used at a working concentration of 0.4%.  
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2.2.7   Infliximab  
 
Infliximab (MSD Pharmaceuticals, Hertfordshire, UK) was used in all relevant 
experiments as the study anti-TNFα drug. The drug was stored in powder form 
at 4°c. When required, it was re-constituted from powder with sterile water to a 
concentration of 10mg/ml (10ml total volume) as per manufacturer’s 
instructions.  
 
Stock was stored at 4°c and used within eight hours of reconstitution. The stock 
was further diluted with complete medium to create the study concentrations 
(1μg/ml, 10μg/ml and 100μg/ml).  
 
 
2.2.8   Antibodies 
 
Antibodies with specificities and fluorochrome-conjugated labels were used. 
Matched isotype-controls were derived from the same manufacturer. Table 4 
lists the antibodies and isotype-controls used. 
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Abs specificity Clone Conjugated 
fluorochrome 
Isotype  
control 
Manufacturer 
 
CLA HECA-452 FITC Rat IgM BD Biosciences 
CDllc KB90 FITC/PE Mse IgG1 Dako Cytomation 
HLA DR G46-6 FITC/APC/PeCy5 Mse IgG1 BD Biosciences 
CD8 SK1 FITC Mse IgG1 BD Biosciences 
CCR5 2D7 FITC Mse IgG2a BD Biosciences 
TLR 2 TLR2.3 FITC Mse IgG2a Serotec 
TLR 4 HTA125 FITC Mse IgG2a Serotec 
β7 integrin FIB504 PE/PeCy5 Rat IgG2a BD Biosciences 
CCR7 150503 PE Mse IgG2a R&D Systems 
CD8 B9.11 PE Mse IgG1 BD Biosciences 
CD40 LOB7/6 PE Mse IgG2a Serotec 
CD86 24F PE Mse IgG2a BD Biosciences 
CCR9 112509 PE Mse IgG2a R&D Systems 
CD3 SK7 PeCy5 Mse IgG1 BD Biosciences 
CD14 RMO52 PeCy5 Mse IgG2a Beckman Coulter 
CD16 3G8 PeCy5 Mse IgG1 Beckman Coulter 
CD19 J4.119 PeCy5 Mse IgG1 Beckman Coulter 
CD34 581 PeCy5 Mse IgG1 Beckman Coulter 
CCR4 205410 APC Mse IgG2b R&D Systems 
CCR8 191704 APC Rat IgG2b R&D Systems 
CCR10 314315 APC Rat IgG2a R&D Systems 
CD8 SK1 APC Mse IgG1 BD Biosciences 
TNFα MP9-20A4 FITC Mse IgG1 Serotec 
IL-6 1936 FITC Mse IgG2b R&D Systems 
IL-15 151303 PE Mse IgG2b R&D Systems 
TGFβ 35409 PE Mse IgG1 R&D Systems 
IL-10 JES3-19F1 APC Rat IgG1 BD Biosciences  
IL-12 C11.5 APC Mse IgG1 BD Biosciences 
 
Table 4. Fluorochrome-conjugated antibodies including isotype, clone, conjugated 
fluorochrome and manufacturer  
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2.2.9   Immunomagnetic beads and cell separation columns 
 
Anti-CD14, anti-CD19 and anti-HLA DR immunomagnetic beads (Miltenyi 
Biotech, Bisley, UK) were used in conjunction with LD magnetic columns and 
MidiMACs apparatus (Miltenyi Biotech, Bisley, UK) for T-cell separation prior to 
mixed leukocyte reaction, as described in section 2.3.4.  
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2.3  Methods 
 
2.3.1   Isolation of PBMCs 
 
PBMCs were obtained by centrifugation of human peripheral venous blood over 
Ficoll Plaque at 650g for 30min at room temperature and harvesting the buffy 
coat layer from the interface. As previously described, Ficoll Plaque separates 
whole blood into a top layer of plasma, followed by a layer of PBMCs and a 
bottom fraction of polymorphonulcear cells (eg neutrophils and eosinophils) and 
erythrocytes. PBMCs were washed twice in culture medium by centrifugation at 
650g for 5min.  
 
PBMCs were used for direct phenotypic analysis, culture in the presence of IFX, 
dendritic cell enrichment or for T-cell enrichment.  
    
 
2.3.2   Enrichment of dendritic cells 
 
To obtain blood-enriched DCs or low density cells (LDCs), PBMCs were 
suspended in complete medium and incubated for 24 hours at 37°c, 5% CO2 and 
high humidity in T75 tissue culture flasks (35-50 million PBMCs/flask). Non-
adherent cells from overnight cultures were centrifuged at 600g for 15min over 
Nycoprep to obtain a density gradient. LDCs were recovered from the interface 
and washed twice in complete medium. 
 
 
2.3.3   Viable cell counts 
 
Viable cell counts were performed by adding known volumes of cells, medium 
and trypan blue dye to a mixing well at the ratio 1:3:1 (cells:medium:dye). Viable 
cells exclude the blue dye from their cytoplasm and are therefore easily 
recognisable at light microscopy. The solution was pipetted onto a counting slide 
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and cell count was performed under a light microscope. The numbers of cells/ml 
solution was calculated (number of viable cells) counted x 104 (number of 
cells/ml) x 5 (corrects dilution of mixing cell) x total volume of cell suspension 
(ml).  
 
 
2.3.4   Mixed leucocyte reaction  
 
The stimulatory capacity of blood LDCs was assessed in an allogeneic mixed 
leukocyte reaction (MLR). The following steps were performed to carry out an 
MLR: 
 
Step 1. T-cell enrichment 
PBMCs from healthy volunteers were washed twice in miniMACs buffer before 
being incubated with anti-CD14, anti-HLA DR and anti-CD19 immunomagnetic 
beads (30μl each) on ice for 20 minutes following manufacturer’s instructions. 
Cells were then washed twice with miniMACs buffer. During this time, the 
magnetic cell sorting system (VarioMACSTM Separation System, Miltenyi Biotech, 
Bisley, UK) was setup and the columns washed through twice with MiniMACS 
buffer. Cells were kept at 4°c throughout the entire T-cell enrichment process by 
use of ice and pre-cooled centrifuges.    
 
Cells that had been incubated with the immunomagnetic beads were added 
directly into the column, followed by 4ml of miniMACS buffer at 4°c. The 
resultant solution is depleted of CD19+, CD14+ and HLA DR+ cells. In order to 
increase T-cell purity, a new depletion column was setup and the T-cell solution 
was run through the column again.  
 
The final solution has a CD3+ T-cell purity of >98% (Bernardo, Al-Hassi et al. 
2012). The cells were washed twice in cold PBS and re-suspended in 3ml PBS.   
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Step 2. T-cell CFSE labeling  
CFSE (5μL) was suspended in 10ml PBS (tube CFSE1). 3ml of solution from 
CFSE1 was then diluted in a further 3ml PBS (tube CFSE2). This was then added 
to the enriched T-cell suspension and gently mixed. The solution was then left for 
exactly 3 minutes, with one further gentle mix performed at 1½mins. The 
reaction was quenched by addition of 6ml of sterile FCS. The CFSE-labeled T-
cells were then washed twice by adding complete medium and centrifuging 
(600g, 5min). The supernatant was discarded and the pellet re-suspended in 1ml 
of complete medium. A trypan blue cell count was then performed to determine 
the T-cell concentration. Once the cell count was known, the solution was further 
diluted with complete medium, to give a final concentration of 4 million T-
cells/ml.  
 
Step 3. MLR and proliferation assays 
LDCs obtained from the blood were cultured with various concentrations of IFX 
in 5ml polystyrene round-bottom (FACS) tubes (BD Falcon) in 1ml complete 
medium at a concentration of 0.5 million cells/ml. Three different IFX 
concentrations were used (as previously described) and LDCs in basal conditions 
served as an internal control. Cells were washed twice in complete medium 
(600g, 5 mins) to ensure any remnants of the active drug had been removed 
prior to addition of T-cells.  
 
CFSE-labelled T-cell solution (100μl, 4x105 cells) were placed in separate 
chambers in a 96-well round bottom plate. The pre-treated LDCs were then 
added to each T-cell aliquot at known concentrations (0% or no LDCs, 1% or 
4000 LDCs, 2% or 8000 LDCs and 3% or 12,000 LDCs). These test conditions 
were performed for each concentration of IFX being studied.  
 
Cells were then incubated for 5 days at 37°c, 5% CO2 and high humidity. Cells 
were recovered at the end of this time and T-cell proliferation was quantified by 
way of CFSE dilution. Homing marker expression and intracellular cytokine 
profile was measured by antibody staining and flow cytometry.       
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2.3.5   Antibody labeling 
 
For phenotypic analysis, cells were washed twice in FACS buffer and divided into 
100µL aliquots in FACS tubes (minimum of 5x104 cells per FACS tube). 15μL of 
FCS was added to each tube to reduce non-specific antibody binding. Cells were 
labeled with antibodies (5 or 10μL of antibody as per manufacturer instructions) 
on ice and left in the dark for 20min (a method pre-determined in the laboratory 
to optimise cell antibody labeling).  
 
After 20 minutes, cells were washed twice in FACS buffer to remove excess 
fluorochrome. Flow count fluorospheres (20µL) were added to appropriate 
tubes. Finally, cells were fixed in 1% PFA, and stored at 4°c prior to acquisition 
on the flow cytometer. Acquisition was performed within 48 hours of cell 
fixation. 
 
 
2.3.6   Conjugated antibody labeling  
 
In the absence of a directly conjugated antibody, secondary labeling was 
performed. To study the expression of the skin-homing marker, CLA, on T-cells, 
the cells were incubated with a monoclonal antibody, anti-CLA, conjugated with 
Biotin (CLA-biotin). Cells were then washed and re-incubated with the APC 
fluorochrome conjugated to Strepavidin (Strepavidin-APC). Finally, cells were 
washed twice in FACS buffer and fixed in 1% PFA as described in the previous 
section prior to acquisition. 
 
 
2.3.7   Intracellular cytokine staining 
 
LDCs (0.5x106 cells/ml) were cultured in complete medium with 7.5µL of 
monensin or an additional 7.5µL of complete medium (controls) for 4 hours at 
37°c, 5% CO2, high humidity. Cells were then washed in FACS buffer and the cell 
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pellet re-suspended in 100μL Leucoperm A fixative reagent and incubated at 
room temperature for 30min. The fixed cells were then washed in FACS buffer 
and re-suspended in 100μL Leucoperm B reagent which permeabalises the cells. 
The cell suspension was then incubated with 5μL anti-cytokine antibody for 30 
minutes at room temperature in the dark. The labeled cells were then washed 
twice in FACS buffer and fixed in 300μL 1% PFA prior to acquisition. 
   
 
2.3.8   Multiplex  
 
BD Cytometric Bead Array (CBA). Human Th1/Th2/Th17 Cytokine Kit.  
Catalogue no 560484 
Includes: IL-2, IL-4, IL-6, IL-10, TNFα, IFNγ, IL-17A 
 
The BD CBA Human Th1/Th2/Th17 Cytokine Kit uses bead array technology to 
simultaneously detect multiple cytokine proteins in research samples. Seven 
bead populations with distinct fluorescence intensities had been coated with 
capture antibodies specific for their specific cytokine (IL-2, IL-4, IL-6, IL-10, 
TNFα, IFNγ and IL-17a). The seven bead populations are then mixed together to 
form a bead array, which is analysed in the APC channel of the flow cytometer.  
 
During the assay procedure, the cytokine capture beads were mixed with the 
recombinant standards and research samples and incubated with PE-conjugated 
detection antibodies to form sandwich complexes. The intensity of PE 
fluorescence of each sandwich complex reveals the concentration of that 
cytokine (figure 11).  
 
Detection limits were calculated by taking the mean + 2 standard deviations of 
the blank (control) and plotting this onto the standard curve for each cytokine. 
Results falling below this value were given the detection limit as their result.    
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Figure 11. CBA Human Th1/Th2/Th17 Cytokine Kit. Graph showing the different 
cytokine peaks taken directly from the flow cytometer. The Y axis identifies the 
different cytokines and the X axis quantifies their relative concentration. 
 
 
2.3.9   Flow cytometry 
 
Flow cytometry allows simultaneous multiparametric analysis of the physical 
characteristics of cells, as they pass through one or more focused light and laser 
beams in suspension. As the cells pass through the light and laser beams, they 
disrupt and scatter light in two different planes. This degree of scatter correlates 
with the cell’s morphology with forward scatter (FSC) giving a representation of 
the cell’s size, and side scatter (SSC) correlating with granularity. This allows cell 
populations to be identified based on their physical characteristics (figure 12). 
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Figure 12. Identification of cell populations by flow cytometry. Histogram to 
identify cell populations by way of physical characteristics of cell granularity (SSC) 
and cell size (FSC).    
 
 
Monoclonal antibodies conjugated to fluorescent dyes, which are conjugated to 
cells, can be detected by colour-specific detectors (channels) of the flow 
cytometer. Each fluorochrome emits light at a different wavelength when excited 
by the laser beam (table 5). The machine registers the fluorescence generated as 
cells pass through it, enabling analysis of the phenotypic properties of cells. This 
method of analysis is widely used for: 
 
 Analysing expression of cell surface and intracellular molecules 
 Defining different cell types in heterogenous cell populations 
 Assessing purity of isolated subpopulations 
 Analysing cell volume, size and granularity 
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Channel Name Excitation laser 
line (nm) 
Emission 
wavelength (nm) 
Colour 
FL1 FITC 488 519 Green 
FL2 PE 488 578 Yellow 
FL3 PE-Cy5 488 667 Red 
FL4 APC 635 660 Red 
 
Table 5. Fluorochromes used in flow cytometry in this study. Monoclonal antibodies 
are conjugated to fluorochromes to allow for detection at flow cytometry. When 
the cytometer laser is shone at the fluorochrome, a specific wavelength of light is 
emitted which is recorded by the machine.  
 
 
Two flow cytometry machines were used during this project. Data contained in 
results chapters 3 and 4 of this thesis were analysed using a 4-colour 
FACSCalibur flow cytometer (BD Biosciences). The cytometer is capable of 
detecting the fluorochrome dyes Fluorescein (FITC), Phycoerythrin (PE), PE-Cy5 
and Allophycocyanin (APC), corresponding to wavelengths FL1, FL2, FL3 and 
FL4 respectively (table 5).  
 
Data contained in results chapters 5 and 6 of this thesis were analysed using a 6-
colour FACSCantoII flow cytometer (BDBiosciences), which has two further 
channels (PE-Cy7 and APC-Cy7) in addition to the four channels above. These 
additional two channels were not used to obtain data during this project.  
 
2.3.9.1  Compensation 
 
DCs only constitute a small proportion of total leucocytes from peripheral blood 
and cells from different samples emit different levels of innate/background 
autofluorescence. Therefore, compensation was carried out separately of each 
individual experiment.  
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CellQuest software (BD Biosceinces) was used for partial online compensation 
prior to cell acquisition, and generation of listmode data files. Compensation was 
completed and listmode data files analysed offline using WinListTM software 
(Verity Software House, Maine, US).   
 
In order to perform partial online compensation, 5 compensation tubes are made, 
each containing PBMCs in FACS buffer suspension. One tube is left unlabelled 
and the remaining 4 are labelled with a fluorochrome conjugated antibody to 
either CD3+ or CD8+ (one tube for each fluorochrome; FITC, PE, PECy5 and APC). 
The unlabelled PBMC compensation tube was initially used to set the amperes 
and voltages on the machine, based on the cell’s background or autofluoresence. 
The FSC:SSC plot was adjusted using the FSC gain and range and the SSC voltage 
to place the cell population of interest in the centre of the FSC:SSC plot and 
therefore eliminate most of the fine subcellular debris. The cell suspensions, 
labelled with each fluorochrome were then analysed and compensation adjusted 
accordingly. Samples were then acquired and saved as listmode data files.  
 
Compensation was completed offline using the compensation toolbox on the 
WinListTM software program by identifying lymphocyte populations labelled 
with antibodies specific for T-cells. Each individual experiment has its own 
unique compensation settings, saved as compensation files.  
 
2.3.9.2  Identification of cell populations 
 
PBMCs are defined as any blood cell containing a round nucleus and includes 
several cell types, including lymphocytes, monocytes, DC, macrophages etc.  
 
Cell populations were identified by expression of their specific antibody within a 
gated leukocyte population (T-cells CD3+ve; B-cells CD19+ve and monocytes 
CD14+ve). The example below demonstrates this method to identify T-cells 
(figure 13). 
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Figure 13. Identification of T-cell population in PBMCs. A) Light scatter plot 
showing region R1 which contains all lymphocytes. B) One-parameter histogram 
identifying cells in region R1 with positive staining for CD3, gated in region R2.  
 
 
Unlike most other cell types, there is not a single marker for DCs that easily 
allows for their identification. Our laboratory identifies DCs by a double gating 
strategy. Initially a light scatter plot is performed of all PBMCs and a gate is 
drawn around all living cells, thereby excluding erythrocytes, platelets and cell 
debris (figure 14A). A second two-way histogram is then created, including 
events from within the viable cell gate, to identify cells positive for HLA DR 
expression, but negative for lineage cocktail (a cocktail of other non-DC cell 
lineage markers, including CD3, CD14, CD16, CD19 and CD34), as shown in figure 
14B.  
 
 
 
Figure 14. Identification of DC population from peripheral blood by flow cytometry. 
A) Light scatter plot showing all viable cells within the gated region. B) Two 
parameter histogram of HLA DR (x axis) and Lineage cocktail (y axis) gated on all 
viable cells. Region 2 (R2) contains the DC population to be studied.  
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2.3.9.3  Region gating 
 
One method for determining the surface marker expression on cells is to 
calculate the proportion of antibody stained cells falling beyond the distribution 
of staining from an isotype matched control antibody. For example, a region is 
drawn that excludes irrelevant, isotype matched control antibodies or non-
specific staining. All events that fall within this region exceed isotype control 
staining intensity and are therefore regarded as positively labelled cells (figure 
15). The proportion of positive cells amongst the total cell population can then 
be calculated by WinList software. 
 
 
Figure 15. Cell surface labelling by region gating. A) A region (R3) is drawn on the 
isotype-matched control monoclonal antibody staining that excludes non-specific 
staining. B) The same region is then applied to the phenotype staining histogram 
(R4). The result gives the total percentage positive cells for that marker (71.4% of 
cells expressing CCR8 in the example above).    
 
 
2.3.9.4  Enhanced normalised subtraction method 
 
Region gating, described above, is the widely accepted method for identifying 
cell types. However, it can be inaccurate when assessing quantitative markers 
due to overlapping between marker expression and the isotype. In this situation, 
different operators performing analysis may obtain different results, depending 
on where the region is placed. An alternative strategy, which avoids this 
potential issue, is the use of super-enhanced Dmax (SED) normalised subtraction.   
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In this method, single parameter histograms are created for both the antibody-
specific staining and the negative (isotype) control staining. The isotype control 
is then subtracted from the antibody staining using the super-enhanced Dmax 
(SED) normalised subtraction facility in WinList, as shown in figure 16.  
 
This method provides values for total percentage expression of the antibody and 
the intensity ratio (IR) of staining (ie the amount of marker that is being 
expressed on positive cells), irrespective of the operator. The Dmax is given as a 
percentage following subtraction of the test and control histograms. If the two 
histograms are identical and overlap perfectly, a Dmax of 0% is the result. If the 
test histogram has a higher fluorescent intensity than the control and there is no 
overlap, then the Dmax is 100%. An example of such subtraction is shown in 
figure 16.  
 
 
Figure 16. Enhanced normalised subtraction method. A) FACS histograms 
demonstrating marker expression (β7 in this example) and matched isotype 
control (Rat IgG 2a). B) Subtraction histogram, values indicating total percentage 
β7 expression on cells (88.1% in this example) and intensity ratio (IR) of β7 
expression on positive cells (22.4 in this example). 
 
In order to calculate the proportion of ongoing cytokine production in cells, the 
staining of cells cultured in the absence of monensin was subtracted from 
staining of cells cultured in the presence of monensin, again using SED 
normalised subtraction. The result is representative ongoing cytokine 
production in the absence of exogenous stimulation over the 4-hour assay period. 
The same antibody is used to label cells from both monensin-treated and 
untreated cultures, therefore giving the technique a high degree of sensitivity for 
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identifying small changes in antibody binding (Hart, Al-Hassi et al. 2005). This 
process determines natural or spontaneous cytokine production, within a 4 hour 
time period, in the absence of external stimulatory factors. An example of 
cytokine labelling and subtraction is shown in figure 17. 
 
 
 
Figure 17. Intracellular cytokine staining by subtraction. A) Staining of 
intracellular TNFα with (red) and without (blue) monensin. B) Subtraction 
histogram created by subtracted total staining of TNFα without monensin from the 
staining of TNFα with monensin. Result shown as percentage of cells producing 
TNFα and intensity ratio.  
 
 
2.3.9.5  WinList statistics  
 
In order to determine if two histograms in a pair were significantly different, 
Kolmogorov-Smirnov (K-S) statistics were used to calculate the critical D value 
(Dcrit), using the following equation: 
 
Dcrit   = 
 
Dmax 
{ (n1 + n2) / (n1 x n2) }  
 
Dmax  The value calculated by WinList when subtracting the control histogram 
from the test histogram 
n1 The number of events in the region on which the test histogram is gated 
n2 The number of events in the region on which the control histogram is 
gated 
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2.3.9.6  Absolute cell counts 
 
Absolute cell counts were obtained by simultaneous acquisition of Flow-Count 
fluorospheres. Fluorescent counting beads were identified and gated on a 
FL1:SSC histogram plot. The absolute cell count is calculated by taking the 
number of events in the gated region of interest, the number of events in the 
bead gate and a known concentration of beads used at a 1:5 ratio during cell 
acquisition. The figures are entered into the equation below and the final cell 
count is expressed as number of cells per µL of blood: 
 
 
 
 
2.3.10  Statistical analysis 
 
Statistical analysis was carried out using Prism software (Graphpad Software Inc, 
San Diego, USA).  
 
Statistical analysis was performed with either paired t-test, unpaired t-test, one-
way and two-way repeat measures analysis of variance (ANOVA). In the case of 
multiple comparisons, subsequent ad-hoc Dunnett’s multiple comparison test 
was applied. Studies correlating patient demographical data with laboratory data 
were performed with Pearson’s rank correlation coefficient test.   
 
P values of <0.05 were considered significant in all cases.  
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Chapter 3 
 
 
Circulating dendritic cell phenotype in patients with 
Crohn’s disease 
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3.1  Abstract 
 
Background 
CD is a chronic transmural inflammatory disease of the gut, which can occur 
anywhere from mouth to anus. Although the precise aetiology of CD is unknown, 
a dysregulated immune response to gut microbiota and aberrant immune cell 
trafficking play a central role in the disease pathogenesis.   
 
DCs play a key role in discriminating between commensal microorganisms and 
potentially harmful pathogens, thereby creating a balance between immune 
tolerance and active immunity. DCs also direct T-cell differentiation and imprint 
specific homing properties on stimulated T-cells, sending them to the effector 
site (eg, gut, skin). Despite this, information about homing marker expression on 
human DCs is scarce. We set out to investigate homing molecule expression on 
blood DCs in different phenotypes of active CD. 
 
Methods 
Blood from patients with active isolated small bowel (SB) CD (Harvey Bradshaw 
Index, HBI ≥ 7), isolated colonic (LB) CD (HBI ≥ 7) and active extra-intestinal 
manifestations of CD was obtained. Control groups included patients with 
inactive (IA) ileocolonic CD (HBI ≤ 3) and healthy subjects (HC). 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from fresh blood 
following Ficoll gradient separation. DCs were identified as HLA DR +ve, Lineage 
(CD3, CD14, CD16, CD19, CD34) -ve. Expression of gut (β7, CCR9), skin (CLA, 
CCR4, CCR10) and lymph node (CCR7) markers on DC were quantified. Unpaired 
t-test was applied. 
 
Results 
CCR9 (small bowel homing marker) was up regulated on DC from patients with 
SB CD compared with HC (p=0.03), IA CD (p=0.04) and LB CD (p=0.013), while 
CLA expression was down regulated compared with expression in HC (p=0.002), 
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IA (p=0.03) and LB (p=0.021). CCR9 expression was also down regulated on DC 
isolated from patients with active colonic CD compared to HC (p=0.016).   
 
Beta7, a gut-homing integrin, was up regulated on DC from LB CD compared with 
IA (p<0.0001) and HC (p<0.05). 
 
CCR10, a skin-homing marker, was up regulated on DC from patients with EIMs 
compared to HC (p=0.01) and IA (p=0.03). CCR4 (another skin-homing marker) 
was down regulated on patients with EIMs compared to IA CD (p=0.0002) and 
patients with isolated active SB CD (p=0.0005). 
 
Conclusion 
We demonstrate dysregulation of human DC phenotype in CD. Furthermore, DC 
obtained from patients with CD isolated to particular anatomical locations 
express specific homing marker phenotypes, which are likely to correlate with 
infiltrates of effector cells at those sites. 
 
 
This abstract was presented at BSG conference 2012 and subsequently published in Gut journal with 
the following reference. Permission to reprint in Appendix, section 10.2.  
 
Altered homing molecule expression on blood dendritic cells in different phenotypes of Crohn’s 
disease 
Peake ST, Bernardo D, Mann ER, Al-Hassi HO, Landy J, Knight SC, Hart AL 
Gut 2012; 61(S3): A390 
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3.2  Introduction 
 
3.2.1  Anatomical location of inflammation in Crohn’s disease 
 
Crohn’s disease represents a heterogonous entity. Wide variations are seen 
between disease patient demographics, disease behaviour and anatomical 
location of inflammatory lesions. This diversity of disease phenotype contributes 
towards the difficulty in developing efficacious and safe therapies.  
 
Classification systems have been developed to incorporate the phenotypical 
characteristics of Crohn’s disease, and therefore allow for the identification of 
patient subgroups and guide therapeutic interventions. Such classification 
systems include the Montreal classification system (see table 1, section 1.1.3) 
and the Vienna classification, proposed at the 1998 world gastroenterology 
meeting in Vienna (Gasche, Scholmerich et al. 2000).  As well as helping to guide 
treatment, these standardised classification systems aid the ability to correlate 
putative aetiological factors (genetic and environmental) with particular disease 
phenotypic characteristics (Lichtenstein, Hanauer et al. 2004).  
 
Disease location is a major determinant of symptoms, clinical course and 
prognosis of disease. Studies have shown that most patients with CD will develop 
complications of stricturing or penetrating disease and that the initial location of 
disease will determine the time and type of these complications (Cosnes, Cattan 
et al. 2002). In a historic study of 615 CD patients, Farmer et al. found that 
complications such as perianal fistulas, internal fistulas and intestinal 
obstruction were associated with ileocolonic disease. Patients with colonic 
disease had complications such as rectal bleeding, perianal fistulas, toxic 
megacolon and arthritis. In addition, 73% of patients with ileocolonic CD 
required surgery, compared with 51% of patients with isolated colonic disease. 
Patients who had disease confined to the small bowel only had the best 
prognosis with lower rates of surgery (Farmer, Hawk et al. 1975). 
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The anatomical location of CD remains broadly stable over time (Peyrin-Biroulet, 
Loftus et al. 2010). One study found that over a 10 year period, 85% of patients 
did not show any change in the anatomical location of CD (Louis, Collard et al. 
2001). During the course of CD, extension or regression within the same region 
may occur, but only rarely does the disease change in classification, as defined by 
Montreal or Vienna classification. When it does occur, the main change appears 
to be from ileal (L1) or colonic (L2) to ileocolonic (L3) disease. The incidence of 
CD affecting the upper gastrointestinal tract (L4) at diagnosis is rare and very 
few patients develop this over the course of their disease (Louis, Collard et al. 
2001). 
 
Genetics 
The factors determining disease location in individual patients with CD remains 
unclear, however there is likely to a significant genetic component. A study by 
Bayless et al. examined the records of 554 consecutive patients with CD, 95 of 
which had a family history of CD (17%). Sixty families were then analysed for 
concordance for site and type of CD. The authors found a high rate of 
concordance of 2 family members of 85% and 90% for site and type respectively 
(Bayless, Tokayer et al. 1996).  
 
Multiple genetic mutations have been identified that are associated with clinical 
disease locations. Mutations in the NOD2/CARD15 (IBD 1) gene on chromosome 
16 are associated with ileal disease and their frequency in colonic CD is no 
greater than unaffected individuals (Ahmad, Armuzzi et al. 2002). Localisation of 
CD to the colon has been associated with a low human beta-defensin 2 (HBD-2) 
gene copy number (Fellermann, Stange et al. 2006), in contrast to ileal disease, 
which is associated with reduced alpha-defensin expression (Wehkamp, Harder 
et al. 2004).  
 
Other genotypes have been associated with ileal CD, such as ATG16L1T300A GG 
genotype (Prescott, Fisher et al. 2007) and other ATG16L1 risk alleles (Van 
Limbergen, Russell et al. 2008). Similarly, the carriage of the HLA-DRB1*0103 
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allele is strongly associated with isolated colonic CD (Beckly, Hancock et al. 
2008).    
 
Ethnic background and smoking 
It is well documented that anatomical location of CD is linked to a patient’s 
ethnic background. One study investigated differences in CD phenotype between 
patients originating from South Asia and those with a Northern European 
background, but now all residing in Northwest London. The authors found a 
higher rate of isolated colonic disease in the South Asian patient cohort 
compared with the Northern European group (46.8% versus 34.8%, p=0.048) in 
whom ileocolonic disease was the most frequently affected location (40.5%) 
(Walker, Williams et al. 2011).  
 
Differences in CD phenotype between ethnic groups does not necessarily imply a 
genetic cause but may reflect variations in environmental factors related to 
lifestyle in different groups. One environmental factor that may be of importance 
in determining CD phenotype is smoking. The study above reported a 
significantly lower number of (self-reported) smokers in the South Asian cohort 
of patients compared to the Northern European cohort (10.6% versus 31.6%, 
p<0.0001).  
 
Smoking has been reported to be closely associated with disease location with a 
higher prevalence of ileal disease and a lower prevalence of colonic involvement 
in smokers (Lindberg, Jarnerot et al. 1992). Smoking is also associated with 
increased risk of complications, such as strictures or fistulae, and an increased 
risk or requiring surgery.   
 
Having identified that smoking leads to increased prevalence of ileal CD, and that 
smoking is more common in North European than South Asian communities, it 
seems that differences in the anatomical location of CD may be the result of 
genetic or environmental factors.  
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Age at diagnosis 
A study from 1996 found that a younger age of diagnosis (less than 20 years of 
age) correlated significantly with an increased frequency of ileal disease 
compared with patients diagnosed at an older age in whom colonic disease was 
more common (Polito, Childs et al. 1996). Despite this, more recent studies agree 
that isolated colonic CD is more common in paediatric patients with 76.5% of 
children < 5 years of age having Crohn’s disease limited to the colon (Paul, 
Birnbaum et al. 2006), dropping to 63% of children < 8 years of age (Heyman, 
Kirschner et al. 2005). 
 
 
Serological markers  
Specific disease locations have also been linked to serological markers such as 
serum antineutrophil cytoplasmic antibodies (ANCA). In UC, expression of 
pANCA occurs in 50-80% of patients and is associated with treatment-resistant 
left sided colitis and patients with aggressive disease.   
 
Serum ANCA has also been detected in patients with CD, albeit with a lower 
prevalence (between 10 and 30% in most studies). Vasiliauskas et al. 
investigated whether pANCA expression in patients with CD correlates with an 
identifiable clinical subgroup. The authors found that expression of pANCA is 
associated with left sided colonic CD and symptoms thereof (rectal bleeding and 
mucus discharge), while having an absence of small bowel inflammation. This 
‘UC-like’ CD phenotype correlated with pANCA expression in all cases 
(Vasiliauskas, Plevy et al. 1996).  
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3.2.2  Hypothesis and aims 
 
We hypothesised that alterations in the phenotype of circulating peripheral 
blood DC may contribute to the dysregulated immune response that underlies 
CD. In particular, an abnormal pattern of homing marker expression on 
circulating DC may correspond to the clinical phenotype (ie disease location) of 
the patient.  
 
 
Aims 
 
 To identify patients with active CD limited to specific anatomical 
compartments within the gastrointestinal tract. In addition, patients with 
cutaneous EIM of CD were identified, along with those with inactive CD.  
 
 To analyse homing marker expression of peripheral circulating blood DC 
on these groups of patients and relate the findings to their clinical disease 
phenotype. 
 
 To identify DC sub-populations (myeloid and plasmacytoid DC) and 
quantify relative expression of homing markers on DC sub-populations. 
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3.3  Methods 
 
Patients were recruited from IBD outpatient clinics and the endoscopy unit at St 
Mark’s Hospital between November 2010 and December 2011. All patients were 
recruited directly by the candidate to ensure standardisation of patient selection. 
A Microsoft Excel database was created containing phenotypical data for each 
patient recruited, including the following parameters: 
 
 Age 
 Gender 
 Number of years since diagnosis with CD 
 Montreal classification of CD 
 Disease activity (measured using Harvey Bradshaw Index, HBI) 
 Current medications 
 Date of most recent endoscopic examination 
 Date of most recent radiological examination 
 
Inclusion and exclusion criteria (outlined in methods, section 2.2.2) were applied 
to all patient recruitment.  
 
 
3.3.1   Crohn’s disease activity 
 
The Crohn’s Disease Clinical Activity Index (CDAI) was developed by Best and 
colleagues at the Midwest Regional Health Center, Illinois in 1976 (Best, Becktel 
et al. 1976). It is essentially a research tool used to quantify symptoms being 
experienced by a patient. The CDAI is considered the ‘gold standard’ for 
assessing disease activity in CD, although validation of the index has been varied. 
It is difficult to use in daily practice, for example in a busy outpatient clinic, as it 
requires complex calculations, biochemical and physical measurements 
(height/weight). In addition, patients need to record all the parameters in a diary 
for 7 days prior to assessment. A further criticism is that it does not incorporate 
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a subjective assessment of quality of life, endoscopic features of inflammation or 
systemic manifestations (such as fatigue).  
 
The Harvey Bradshaw Index (HBI) was devised in 1980 as a simpler and more 
user-friendly version of the CDAI (Harvey and Bradshaw 1980). It contains five 
simple clinical parameters as shown in table 6.  
 
 
Parameter Scoring 
Number of liquid 
stools per day 
Score 1 per liquid stool 
General well-
being 
0 = very well, 1 = slightly below par, 2 = poor, 3 = very poor, 
4 = terrible 
Abdominal pain 0 = none, 1 = mild, 2 = moderate, 3 = severe 
Abdominal mass 0 = none, 1 = dubious, 2 = definite, 3 = definite and tender 
Complications  Arthralgia, uveitis, erythema nodosum, pyoderma 
gangenosum, oral apthous ulceration, anal fissure, new 
fistula, abscess (score 1 per item) 
 
Table 6. The Harvey Bradshaw Index of disease activity in Crohn’s disease. The first 
three parameters are scored over the 24-hour period prior to assessment.  
 
 
The HBI has been shown to correlate well with the CDAI (Best 2006). For these 
reasons, the HBI was chosen as the disease activity index throughout this 
research project. Patients scoring ≤3 were classified as ‘in remission’ and those 
scoring ≥7 were classified clinically as having active inflammation.  
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3.3.2   Crohn’s disease phenotype 
 
Crohn’s disease phenotype was recorded according to the Montreal Classification 
of CD (table 1, section 1.1.3). All types of disease behaviour were included 
(inflammatory, stricturing and penetrating), as long as there were no 
complications relating to these (ie localised perforation or abscess formation in 
the case of penetrating CD).  
 
Disease location (the parameter being investigated) had been confirmed by 
endoscopic and radiological studies within 6 months of patient recruitment to 
the study. Patients with skin-related EIMs (erythema nodosum or pyoderma 
gangrenosum) were assessed by 2 separate consultant gastroenterologists, who 
agreed on the diagnosis, prior to patient recruitment. These patients did not 
have active luminal symptoms of CD.    
 
The following groups were recruited (individual demographic and clinical 
patient details provided later): 
 
 Active isolated small bowel (SB) CD, HBI ≥7 
 Active isolated colonic CD, HBI ≥7 
 Patients with active skin EIMs of CD 
 Patients with inactive ileocolonic CD, HBI ≤3 
 Healthy control subjects  
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3.3.3   Sample collection and processing  
 
Following venesection from the patient, samples were taken to the laboratory 
and processed within 30 minutes. Peripheral blood mononuclear cells (PBMCs) 
were separated from whole blood and labeled with fluorochrome conjugated 
antibodies, as described in sections 2.3.1 and 2.3.5 respectively. Four colour flow 
cytometry was used to identify peripheral blood DC populations and gating 
techniques (described in section 2.3.9) were used to quantify expression of 
homing molecules on total DC, mDC and pDC. Data was expressed as percentage 
homing molecule expression on DC (or DC subset) for each homing molecule 
studied.     
 
Homing molecules examined were β7 integrin, CLA, CCR4, CCR7, CCR9 and 
CCR10.  
 
 
3.3.4   Statistical analysis 
 
Statistical analysis was carried out using unpaired t-test. Correlation studies 
were performed using Pearson’s rank correlation coefficient test.   
 
P values of <0.05 were considered statistically significant.  
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3.4  Results 
 
3.4.1   Patient characteristics 
 
PBMCs were obtained from 33 subjects (9 with isolated SB CD, 5 with isolated 
colonic CD, 3 with skin EIMs, 7 with inactive ileocolonic CD and 9 healthy control 
subjects). Table 7 on the following page outlines the clinical and demographical 
patient information. 
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Case 
number 
Gender Age Years since 
diagnosis 
CD location HBI Current 
medications 
1 Female 56 4 Small bowel 10 5-ASA, AZA 
2 Male 46 15 Small bowel 7 5-ASA, AZA 
3 Female 53 36 Small bowel 7 6-MP, ENT 
4 Male 43 8 Small bowel 9 6-MP 
5 Female 19 9 Small bowel 8 5-ASA, AZA 
6 Male 34 11 Small bowel 12 5-ASA, 6-MP 
7 Male 27 2 Small bowel 10 AZA 
8 Female 32 2 Small bowel 9 5-ASA, AZA 
9 Male 29 5 Small bowel 11 5-ASA, AZA 
10 Female 31 24 Colon 8 AZA 
11 Male 55 12 Colon 14 5-ASA, AZA 
12 Female 26 6 Colon 14 5-ASA 
13 Male 22 2 Colon 12 6-MP, PROB 
14 Male 41 9 Colon 10 5-ASA, AZA 
15 Male 75 41 Ileocolonic 0 NIL 
16 Female 31 16 Ileocolonic 3 6-MP 
17 Female 52 26 Ileocolonic 2 AZA 
18 Male 61 26 Ileocolonic 1 5-ASA, AZA 
19 Female 36 11 Ileocolonic 1 5-ASA 
20 Female 53 8 Ileocolonic 0 NIL 
21 Male 48 17 Ileocolonic 2 5-ASA, AZA 
22 Female 30 5 EN (legs) 3 AZA 
23 Female 41 12 EN (legs) 4 5-ASA 
24 Male 62 26 PG (legs) 4 5-ASA, AZA 
25 Female 35 - HC - - 
26 Female 28 - HC - - 
27 Female 53 - HC - - 
28 Male 26 - HC - - 
29 Female 39 - HC - - 
30 Male 22 - HC - - 
31 Male 47 - HC - - 
32 Female 33 - HC - - 
33 Male 34 - HC - - 
 
Table 7. Clinical and demographical information of patients and healthy controls.  
EN = erythema nodosum, PG = pyoderma gangrenosum, HC = healthy control, 5-
ASA = 5-aminosalicylic acid, AZA = azathioprine, 6-MP = 6-mercaptopurine, ENT = 
polymeric diet, PROB = probiotic therapy,  
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3.4.2   Identification of dendritic cell sub-populations 
                        
DCs were identified in the PBMC pool as previously described in section 2.3.9.2 
(HLA DR+, lineage cocktail-). In order to identify DC subpopulations (mDC and 
pDC), a one parameter histogram was created identifying positive and negative 
expression of CD11c within the previously gated DC population (figure 18). Cells 
expressing CD11c are myeloid DC and those not expressing CD11c are the 
putative plasmacytoid population.  
 
 
Figure 18. Identification of mDC and pDC within total dendritic cell population. A) 
A single parameter histogram is created, identifying CD11c expression by DCs. B) 
Plasmacytoid DCs are negative for CD11c and are gated within region 4 (R4). C) 
Region 5 (R5) contains DCs expressing CD11c and therefore are taken as the mDCs.  
 
 
The WinList software programme allows ‘backgating’ of cell populations onto 
other histogram plots. Therefore it is possible to demonstrate the location of 
mDC and putative pDC within the total DC population (figure 19). The backgating 
plot shows the two cell subpopulations to be quite distinct when looking at HLA 
DR expression, with mDC expressing higher levels of HLA DR compared to pDC.  
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Figure 19. Distribution of mDC and pDC within the total dendritic cell population. 
A) CD11c- DCs are gated in region R4 (red) and CD11c+ DCs are gated in region R5 
(blue). B) Backgating of DC subpopulations onto HLA DR vs lineage cocktail plot. 
Myeloid DCs are seen to express higher levels of HLA DR compared to pDCs.  
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3.4.3   Expression of homing molecules on circulating dendritic cells  
 
3.4.3.1  β7 expression 
 
Expression of β7 surface integrin on circulating DC was high (80.6 ± 9.9%). DCs 
isolated from patients with active colonic CD had up-regulated β7 expression 
compared to DCs from HC or patients with inactive ileocolonic CD (figure 20). In 
view of its gut-homing significance, we were surprised to see that there was no 
significant difference in β7 expression on DCs isolated from patients with active 
SB CD.  
 
 
 
Figure 20. β7 expression on dendritic cells in different phenotypes of CD. A) FACS 
histograms demonstrating β7 expression on DCs and matched isotype control (Rat 
IgG 2a). B) Subtraction histogram, values indicating percentage β7 expression on 
all DCs and intensity ratio (IR) of expression on positive cells. C) Pooled results of 
β7 expression on DCs.  
HC = healthy control, SB = active small bowel CD, Colon = active colonic CD, EIM = 
extra-intestinal manifestations of CD, Inactive = inactive CD. 
Statistical analysis performed with unpaired t-test. 
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3.4.3.2  CLA expression 
 
We found quite wide variation in CLA expression across the different CD 
phenotypes, ranging from 1% up to 85%. DCs from patients with active SB CD 
have down regulated CLA expression compared to HC, patients with IA CD and 
patients with active colonic CD (figure 21). There are 4 patients in the EIM group 
(compared to 3 in the other markers) because an extra case of EIM was included 
in which only the CLA staining was successful.   
 
 
 
 
 
Figure 21. CLA expression on dendritic cells in different phenotypes of CD. A) FACS 
histograms demonstrating CLA expression on DC and matched isotype control (Rat 
IgM). B) Subtraction histogram, values indicating percentage CLA expression on all 
DCs and IR of expression on positive cells. C) Pooled results of CLA expression on 
DCs.  
HC = healthy control, SB = active small bowel CD, Colon = active colonic CD, EIM = 
extra-intestinal manifestations of CD, Inactive = inactive CD. 
Statistical analysis performed with unpaired t-test. 
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3.4.3.3  β7/CLA co-expression 
 
To further investigate gut versus skin homing phenotypes of DC in the clinical 
groups, we looked at co-expression of β7 and CLA homing markers on circulating 
DCs in each cohort of patients. 
 
This method of analysis demonstrated that, despite there being no increased 
expression of β7 on DCs from patients with active SB CD as there was on DCs 
from patients with active colonic CD, there was a reduction in CLA expression. 
This reduction in CLA expression renders increased single positive β7 
expression on DCs from patients with active SB CD compared to HC (figure 22).      
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Figure 22. β7 and CLA co-expression on DCs in different phenotypes of CD. A) 
Representative histogram plot demonstrating β7 and CLA on DC in a healthy 
control subject. B) Representative histogram demonstrating β7 and CLA expression 
on DCs in a patient with active SB CD. C) Pooled results of single positive β7, single 
positive CLA expression, double positive β7/CLA expression and double negative 
β7/CLA expression on DCs in different phenotypes of CD.  
HC = healthy control, SB = active small bowel CD, Colon = active colonic CD, EIM = 
extra-intestinal manifestations of CD, Inactive = inactive CD. 
Statistical analysis performed with unpaired t-test. 
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3.4.3.4  CCR9 expression 
 
CCR9 expression on circulating DCs was found to be relatively low (<40% in all 
groups except active SB CD). There was greater expression of CCR9 on DCs 
isolated from patients with active SB CD compared to HC, IA CD and active 
colonic CD. Patients with active colonic CD had very low CCR9 expression (1% in 
4 out of 5 patients), which was statistically significant when compared to the HC 
group.   
 
 
 
 
Figure 23. CCR9 expression on dendritic cells in different phenotypes of CD. A) FACS 
histograms demonstrating CCR9 expression on DCs and matched isotype control 
(Mouse IgG2a). B) Subtraction histogram, values indicating percentage CCR9 
expression on all DCs and IR of expression on positive cells. C) Pooled results of 
CCR9 expression on DCs.  
HC = healthy control, SB = active small bowel CD, Colon = active colonic CD, EIM = 
extra-intestinal manifestations of CD, Inactive = inactive CD. 
Statistical analysis performed with unpaired t-test. 
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3.4.3.5  CCR4 expression 
 
CCR4 expression was found to be >50% in most subjects studied. Circulating DCs 
isolated from patients with skin-related EIMs were found to have down-
regulated expression of CCR4 compared to the IA CD group and patients with 
active SB CD. CCR4 is a skin homing marker, and therefore this represents a 
surprising and paradoxical result.  However, only 3 patients were studied in this 
group and therefore further work is needed to confirm this finding. 
 
 
 
 
Figure 24. CCR4 expression on dendritic cells in different phenotypes of CD. A) FACS 
histograms demonstrating CCR4 expression on DCs and matched isotype control 
(Mouse IgG2b). B) Subtraction histogram, values indicating percentage CCR4 
expression on all DCs and IR of expression on positive cells. C) Pooled results of 
CCR4 expression on DCs.  
HC = healthy control, SB = active small bowel CD, Colon = active colonic CD, EIM = 
extra-intestinal manifestations of CD, Inactive = inactive CD. 
Statistical analysis performed with unpaired t-test. 
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3.4.3.6  CCR10 expression 
 
CCR10 expression was found to be very low on circulating DC across all the 
clinical groups (<16%). Despite this, CCR10 expression was found to be up-
regulated on DC from patients with skin EIMs compared to HC and patients with 
inactive CD (figure 25), albeit patient numbers in the EIM cohort were low.  
 
 
 
 
 
Figure 25. CCR10 expression on dendritic cells in different phenotypes of CD. A) 
FACS histograms demonstrating CCR10 expression on DC and matched isotype 
control (Rat IgG2b). B) Due to low CCR10 expression on DCs, the region gating 
method was utilised (region R6) to obtain values for percentage CCR10 expression 
on all DCs and IR of expression on positive cells. C) Pooled results of CCR10 
expression on DCs. HC = healthy control, SB = active small bowel CD, Colon = active 
colonic CD, EIM = extra-intestinal manifestations of CD, Inactive = inactive CD. 
Statistical analysis performed with unpaired t-test. 
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3.4.3.7  CCR7 expression 
 
CCR7 expression was found to vary between 30% and 80% in all subjects. There 
were no statistically significant differences in CCR7 expression between the 
clinical study groups (figure 26).   
 
 
 
 
 
Figure 26. CCR7 expression on dendritic cells in different phenotypes of CD. A) FACS 
histograms demonstrating CCR7 expression on DCs and matched isotype control 
(Mouse IgG2a). B) Subtraction histogram, values indicating percentage CCR7 
expression on all DCs and IR of expression on positive cells. C) Pooled results of 
CCR7 expression on DCs.  
HC = healthy control, SB = active small bowel CD, Colon = active colonic CD, EIM = 
extra-intestinal manifestations of CD, Inactive = inactive CD. 
Statistical analysis performed with unpaired t-test. 
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3.4.4  Expression of homing molecules on circulating dendritic cell sub-
populations  
 
Having found altered homing marker expression on total DCs in different 
phenotypes of CD, we examined whether the homing markers were expressed on 
both subpopulations of DC. Expression of the adhesion integrin, CD11c, was used 
to positively identify mDCs (figure 18, section 3.4.2). Putative pDCs were taken 
as the CD11c- DC population. Relative expression of each homing marker was 
quantified for both mDCs and pDCs in the 5 clinical CD groups.   
 
 
3.4.4.1  Myeloid dendritic cells 
 
Myeloid DC expressed greater levels of Beta7, CLA and CCR9 compared to pDC. 
This trend occurred regardless of the presence or location of CD (figure 27).   
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Figure 27. Expression of A) β7, B) CLA and C) CCR9 homing markers on mDCs and 
putative pDCs in different clinical phenotypes of CD.  
HC = healthy control, SB = active small bowel CD, Colon = active colonic CD, EIM = 
extra-intestinal manifestations of CD, Inactive = inactive CD. 
Statistical analysis performed with unpaired t-test. 
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3.4.4.2  Plasmacytoid dendritic cells 
 
With the exception of CCR9, chemokine receptors were expressed in greater 
amounts on pDCs (CCR4, CCR7 and CCR10), as shown in figure 28. Again, the 
differences did not alter according to the clinical phenotype of CD or healthy and 
diseased states. The only exception to this was CCR10 expression in the EIM 
group. However, as there was only one patient studied, this may represent an 
outlying result.   
 
 
Figure 28. Expression of A) CCR7, B) CCR4 and C) CCR10 chemokine receptors on 
mDCs and putative pDCs in different clinical phenotypes of CD.  
HC = healthy control, SB = active small bowel CD, Colon = active colonic CD, EIM = 
extra-intestinal manifestations of CD, Inactive = inactive CD. 
Statistical analysis performed with unpaired t-test. 
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3.4.5  Correlation of homing marker expression with clinical patient 
data 
 
After finding differences in the homing profile of DCs in different clinical 
phenotypes of CD, we studied whether such changes correlated with the 
demographical and/or clinical data collected on the patients. In order to study 
this, the expression of homing markers in all DCs, mDCs and pDCs was correlated 
with each clinical and demographical parameter, in each clinical phenotype of 
CD. Correlation studies on patients in the EIM patient group were not performed 
due to the low numbers in the EIM patient cohort.  
 
 
Small bowel CD correlation studies 
 
Correlation studies in patients with active SB CD indicated that there was 
reduced CLA expression on circulating mDCs with increasing age. Furthermore, 
as disease severity increased (measured by clinical indices making up the HBI), 
circulating mDCs had greater expression of CCR9 and pDCs had reduced 
expression of CCR4. Table 8 displays all correlation data in active SB CD.  
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Clinical parameter Age 
 
 
(r value 
p value
) 
Years since 
diagnosis 
 
(r value 
p value
) 
HBI 
 
 
(r value 
p value
) 
Gender:  
 
 
% expression (mean ± SD) 
male; female; p value 
Homing marker 
Beta7 
- All DCs 
- mDCs 
- pDCs 
 
r = -0.54 
ns
 
r = -0.03 
ns
 
r = +0.28 
ns
 
 
r = -0.27 
ns
 
r = +0.46 
ns
 
r = +0.42 
ns
 
 
r = -0.23 
ns
 
r = -0.51 
ns
 
r = -0.53 
ns
 
 
75.9±8.1; 73.4±6.5; ns 
94.7±1.8; 93.5±1.8; ns 
67.9±4.2; 56.2±13.2; ns 
CLA 
- All DCs 
- mDCs 
- pDCs 
 
r = + 0.23 
ns
 
r = -0.71 
p=0.03
 
r = -0.59 
ns
 
 
r = -0.30 
ns
 
r = -0.29 
ns
 
r = -0.35 
ns
 
 
r = -0.08 
ns 
r = +0.18 
ns
 
r = +0.11 
ns
 
 
19.1±7.6; 33.7±12.8; ns 
36.0±13.6; 38.1±13.7; ns 
31.4±10.9; 30.3±14.6; ns 
CCR9 
- All DCs 
- mDCs 
- pDCs 
 
r = +0.64 
ns 
r = -0.20 
ns
 
n/a 
 
r = +0.52 
ns
 
r = -0.64 
ns 
n/a 
 
r = -0.05 
ns 
r = +0.73 
p=0.02
 
n/a 
 
33.4±10.0; 37.5±10.6; ns 
39.0±7.2; 53.9±8.5; ns 
n/a 
CCR4 
- All DCs 
- mDCs 
- pDCs 
 
r = -0.49 
ns
 
r = -0.04 
ns 
r = +0.17 
ns
 
 
r = +0.34 
ns
 
r = -0.03 
ns 
r = +0.65 
ns
 
 
r = -0.15 
ns
 
r = -0.43 
ns
 
r = -0.71 
p=0.03
 
 
62.1±4.4; 66.1±3.7; ns 
59.3±4.3; 59.1±5.7; ns 
74.6±5.7; 63.0±3.2; ns 
CCR10 
- All DCs 
- mDCs 
- pDCs 
 
r = +0.13 
ns 
n/a 
r = -0.64 
ns
 
 
r = -0.32 
ns 
n/a 
r = -0.08 
ns
 
 
r = +0.14 
ns 
n/a 
r = -0.03 
ns
 
 
2.0±0.5; 6.5±2.5; ns 
n/a 
4.7±2.1; 2.6±1.1; ns 
CCR7 
- All DCs 
- mDCs 
- pDCs 
 
r = +0.39 
ns 
r = +0.17 
ns 
r = +0.12 
ns
 
 
r = +0.17 
ns
 
r = -0.40 
ns 
 
r = +0.24 
ns
 
 
r = +0.28 
ns
 
r = +0.25 
ns 
r = -0.26 
ns
 
 
49.0±6.1; 53.9±2.3; ns 
10.6±9.6; 40.4±19.6; ns 
70.6±2.1; 63.1±13.8; ns 
 
Table 8. Correlation studies between homing marker expression and clinical 
parameters in patients with active small bowel CD. Statistical analysis of age, years 
since diagnosis and HBI was performed using Pearsons correlation. Correlations in 
gender was performed using unpaired t-test.   
n/a = expression of homing marker falls below the detection limit in >80% of data 
points. 
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Colonic CD correlation studies 
 
Correlation studies in patients with active colonic CD identified a positive 
correlation between age and CCR4 expression on circulating mDCs (see table 9).  
 
Clinical parameter Age 
 
(r value p value) 
Years since 
diagnosis 
(r value p value) 
HBI 
 
(r value p value) 
Gender:  
 
% expression (mean ± SD) 
male; female; p value Homing marker 
Beta7 
- All DCs 
- mDCs 
- pDCs 
 
r = -0.85 ns 
r = +0.08 ns 
r = -0.81 ns 
 
r = -0.62 ns 
r = +0.02 ns 
r = -0.39 ns 
 
r = -0.05 ns 
r = -0.18 ns 
r = +0.21 ns 
 
86.9±3.5; 87.2±2.3; ns 
94.3±1.2; 94.9±0.7; ns 
71.7±3.6; 80.9±7.0; ns 
CLA 
- All DCs 
- mDCs 
- pDCs 
 
r = +0.80 ns 
r = +0.55 ns 
r = +0.63 ns 
 
r = -0.24 ns 
r = -0.47 ns 
r = +0.38 ns 
 
r = +0.35 ns 
r = +0.32 ns 
r = +0.37 ns 
 
72.4±8.9; 40.8±4.4; ns 
62.5±18.2; 55.2±37.0; ns 
41.7±16.9; 42.6±4.6; ns 
CCR9 
- All DCs 
- mDCs 
- pDCs 
 
n/a 
n/a 
n/a 
 
n/a 
n/a 
n/a 
 
n/a 
n/a 
n/a 
 
n/a 
n/a 
n/a 
CCR4 
- All DCs 
- mDCs 
- pDCs 
 
r = +0.10 ns 
r = -0.89 p=0.04 
r = -0.64 ns 
 
r = +0.52 ns 
r = -0.59 ns  
r = -0.17 ns 
 
r = +0.19 ns 
r = -0.02 ns  
r = -0.60 ns 
 
48.0±8.1; 68.9±0.8; ns 
66.8±3.5; 66.9±1.6; ns 
73.9±4.6; 72.2±2.8; ns 
CCR10 
- All DCs 
- mDCs 
- pDCs 
 
n/a 
n/a 
n/a 
 
n/a 
n/a 
n/a 
 
n/a 
n/a 
n/a 
 
n/a 
n/a 
n/a 
CCR7 
- All DCs 
- mDCs 
- pDCs 
 
r = -0.24 ns 
r = +0.65 ns  
r = -0.17 ns 
 
r = -0.57 ns 
r = +0.54 ns 
r = -0.40 ns 
 
r = +0.84 ns 
r = -0.26 ns  
r = +0.83 ns 
 
55.7±1.7; 58.6±7.5; ns 
39.8±9.3; 23.8±22.8; ns 
64.6±6.2; 70.4±11.1; ns 
 
Table 9. Correlation studies between homing marker expression and clinical 
parameters in patients with active colonic CD. Statistical analysis of age, years 
since diagnosis and HBI was performed using Pearsons correlation. Correlations in 
gender was performed using unpaired t-test.   
n/a = expression of homing marker falls below the detection limit in >80% of data 
points. 
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Inactive CD correlation studies 
 
There were no correlations seen between homing marker expression and clinical 
parameters in patients with inactive ileocolonic CD (see table 10).   
 
Clinical parameter Age 
 
 
(r value p value) 
Years since 
diagnosis 
 
(r value p value) 
HBI 
 
 
(r value p value) 
Gender:  
 
 
% expression (mean ± SD) 
male; female; p value 
Homing marker 
Beta7 
- All DCs 
- mDCs 
- pDCs 
 
r = -0.31 ns 
r = -0.44 ns 
r = -0.03 ns 
 
r = -0.30 ns 
r = -0.19 ns 
r = -0.28 ns 
 
r = +0.41 ns 
r = +0.22 ns 
r = -0.47 ns 
 
70.5±1.1; 74.3±1.5; ns 
91.8±2.9; 91.0±2.9; ns 
67.2±5.9; 65.2±7.6; ns 
CLA 
- All DCs 
- mDCs 
- pDCs 
 
r = -0.05 ns 
r = +0.21 ns 
r = +0.29 ns 
 
r = +0.26 ns 
r = +0.36 ns 
r = +0.63 ns 
 
r = +0.27 ns 
r = +0.02 ns 
r = +0.23 ns 
 
40.2±6.3; 57.3±12.3; ns 
50.5±23.5; 43.3±22.9; ns 
21.6±11.9; 27.0±17.8; ns 
CCR9 
- All DCs 
- mDCs 
- pDCs 
 
r = +0.44 ns 
r = -0.02 ns 
r = -0.15 ns 
 
r = +0.65 ns 
r = -0.14 ns 
r = -0.09 ns 
 
r = -0.09 ns 
r = -0.38 ns 
r = -0.20 ns 
 
19.2±4.7; 13.8±8.0; ns 
22.4±10.7; 17.4±11.6; ns 
14.1±6.6; 11.8±10.7; ns 
CCR4 
- All DCs 
- mDCs 
- pDCs 
 
r = +0.21 ns 
r = +0.59 ns 
r = +0.03 ns 
 
r = +0.49 ns 
r = +0.68 ns 
r = +0.29 ns 
 
r = -0.14 ns 
r = -0.35 ns 
r = -0.04 ns 
 
71.7±5.0; 67.2±3.1; ns 
66.3±7.0; 59.4±1.7; ns 
78.2±3.7; 72.3±4.6; ns 
CCR10 
- All DCs 
- mDCs 
- pDCs 
 
r = -0.03 ns 
n/a 
r = +0.51 ns 
 
r = -0.28 ns 
n/a 
r = +0.65 ns 
 
r = -0.47 ns 
n/a 
r = -0.02 ns 
 
1.5±0.3; 1.9±0.6; ns 
n/a 
8.7±2.8; 3.2±0.9; ns 
CCR7 
- All DCs 
- mDCs 
- pDCs 
 
r = -0.10 ns 
r = +0.33 ns 
r = -0.34 ns 
 
r = -0.03 ns 
r = +0.08 ns 
r = -0.47 ns 
 
r = -0.29 ns 
r = -0.02 ns 
r = -0.19 ns 
 
56.4±3.9; 60.3±6.0; ns 
41.5±7.1; 38.1±10.1; ns 
65.9±9.5; 81.8±6.8; ns 
 
Table 10. Correlation studies between homing marker expression and clinical 
parameters in patients with inactive ileocolonic CD. Statistical analysis of age, 
years since diagnosis and HBI was performed using Pearsons correlation. 
Correlations in gender was performed using unpaired t-test.   
n/a = expression of homing marker falls below the detection limit in >80% of data 
points. 
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Healthy control correlation studies 
 
There were no correlations seen between homing marker expression and clinical 
parameters in healthy control subjects (table 11). These findings are the same as 
those in patients with inactive ileocolonic CD.    
 
Clinical parameter Age 
 
 
(r value p value) 
Gender:  
 
 
% expression (mean ± SD) 
male; female; p value 
Homing marker 
Beta7 
- All DCs 
- mDCs 
- pDCs 
 
r = +0.29 
r = +0.52 
r = +0.16 
 
71.4±3.6; 81.7±4.2; ns 
80.4±8.7; 87.1±5.4; ns 
51.9±6.7; 63.5±2.8; ns 
CLA 
- All DCs 
- mDCs 
- pDCs 
 
r = -0.34 
r = +0.20 
r = -0.21 
 
54.2±6.5; 60.7±8.4; ns 
68.2±9.9; 71.4±4.5; ns 
54.2±4.6; 46.0±6.3; ns 
CCR9 
- All DCs 
- mDCs 
- pDCs 
 
r = -0.15 
r = -0.35 
n/a 
 
22.2±3.7; 16.6±2.2; ns 
21.1±5.1; 15.1±5.4; ns 
n/a 
CCR4 
- All DCs 
- mDCs 
- pDCs 
 
r = +0.17 
r = +0.02 
r = +0.29 
 
42.9±14.1; 59.7±2.8; ns 
57.7±2.0; 49.6±4.5; ns 
63.4±3.5; 62.8±4.4; ns 
CCR10 
- All DCs 
- mDCs 
- pDCs 
 
r = -0.42 
n/a 
r = +0.07 
 
1.6±0.6; 1.3±0.2; ns 
n/a 
2.6±0.9; 2.1±0.5; ns 
CCR7 
- All DCs 
- mDCs 
- pDCs 
 
r = +0.35 
r = -0.19 
r = -0.38 
 
47.3±3.7; 46.7±4.4; ns 
34.8±8.1; 31.5±2.9; ns 
75.9±6.9; 69.2±6.6; ns 
Table 11. Correlation studies between homing marker expression and clinical 
parameters in healthy control subjects. Statistical analysis of age was performed 
using Pearsons correlation. Correlations in gender was performed using unpaired 
t-test.   
n/a = expression of homing marker falls below the detection limit in >80% of data 
points. 
130 
 
3.4.6   Summary of results 
 
CD phenotype DC phenotype  
 
Isolated active colonic CD 
 
 
 
Increased expression of β7 
Reduced expression of CCR9 
 
Isolated active SB CD 
 
Increased expression of CCR9 
Reduced expression of CLA (renders increased single 
positive β7 expression) 
 
 
EIMs 
 
 
Increased expression of CCR10 
Reduced expression of CCR4 
 
 
Inactive ileocolonic CD 
 
 
DC phenotype same as in HC 
Table 12. Summary of DC phenotype in different clinical phenotypes of CD.  
 
 
 Myeloid DCs expressed greater levels of CLA, beta7 and CCR9 compared 
to plasmacytoid DC.  
 
 Plasmacytoid DCs expressed greater levels of CCR4, CCR7 and CCR10 
compared to myeloid DC. 
 
 There was a positive correlation between CCR9 expression on mDCs and 
negative correlation between CCR4 expression on pDCs with HBI in 
patients with active SB CD.  
 
 There was a negative correlation between CLA expression and age on 
mDCs in SB CD, and a positive correlation between CCR4 expression on 
mDCs and age in colonic CD. 
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3.5  Discussion  
 
Dendritic cell phenotype in Crohn’s disease 
 
We found distinctive phenotypic properties of circulating DCs in patients with 
active CD. DCs isolated from patients with active colonic CD expressed high 
levels of the β7 integrin. In these experiments, positive expression of β7 is taken 
to represent α4β7 integrin expression on cells, although this has already been 
identified as a limitation in the methodology (section 1.2.11). In healthy mucosa, 
MAd-CAM1 (the ligand for β7) is expressed on intestinal lamina propria venules, 
however this expression substantially increases in IBD. Furthermore, in CD, 
expression of MAd-CAM-1 is increased in inflamed tissue compared to non-
inflamed tissue (Arihiro, Ohtani et al. 2002). Indeed, studies have shown an 
increased density of α4β7+ cells in inflamed colonic lamina propria of patients 
with CD compared to controls (Souza, Elia et al. 1999).  
 
DCs from patients with isolated active SB CD, were found to have a different gut-
homing phenotype. These cells up-regulated CCR9 and down-regulated CLA 
expression. The reduced expression of CLA rendered the DCs with increased 
single positive β7 expression. 
 
In the small bowel, both the α4β7/MAd-CAM-1 and CCR9/CCL25/TECK 
pathways are important for lymphocyte migration. However, in the colon, 
expression of CCR9 and CCL25/TECK is limited. CCL25/TECK expression on 
epithelial cells in the small bowel has been shown to follow a gradient, with 
highest expression in the proximal small intestine and lowest expression in the 
ileum (Ericsson, Kotarsky et al. 2006). Studies have shown only a small subset of 
cells in the colon express CCR9 and there is no expression of the CCL25/TECK 
ligand (Papadakis, Prehn et al. 2000). This highlights an important role for CCR9 
and CCL25/TECK in small bowel homing, but only a limited role in colonic 
homing. This was demonstrated in a study using a T-cell receptor transgenic 
transfer model, which showed activated CCR9+ lymphocytes selectively localised 
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to the small intestinal mucosa, but following in vivo neutralisation of CCL25, 
there was a marked reduction in the ability of the lymphocytes to populate the 
small intestinal epithelium (Svensson, Marsal et al. 2002). Another study used 
both de-sensitisation of CCR9 as well as anti-CCL25 antibodies to demonstrate 
reduced migration of lymphocytes to the small bowel, but not the colon, in both 
inflamed and uninflamed conditions. They also identified increased expression of 
CCL25 in the presence of TNFα in the lamina propria of the small intestine, 
further underlining the importance of the CCR9-CCL25 interaction in CD (Hosoe, 
Miura et al. 2004).  
   
Overall, we have identified two DC homing markers that are associated with gut-
homing; β7 and CCR9. It also seems likely that the relative expression of β7 and 
CCR9 on circulating DCs and MAd-CAM-1 and CCL25/TECK expression in the 
intestinal tissue may determine preferential homing to either large or small 
bowel. These markers controlling anatomical compartmentalisation of the 
immune response in CD are increasingly being recognised as important 
therapeutic targets for new therapies, in the form of Vedolizumab (anti-α4β7) 
and Traficet-EN (anti-CCR9) currently undergoing trials for the treatment of CD. 
   
DCs isolated from patients with skin-related EIMs of CD had increased CCR10, 
reduced CCR4 and no change in CLA expression. Skin-related EIMs in CD often 
occur during episodes of active luminal CD, and therefore it has been suggested 
that primed effector immune cells are being recruited to the skin and away from 
the gut. CCR10 was traditionally thought of as a skin-homing marker, but more 
recent evidence suggests that it is a more ‘general’ mucosal homing receptor 
(Mora and von Andrian 2009), which may be more related to retaining T-cells in 
the skin after they have reached it, rather than actually guiding their migration 
(Mora 2008). This may be relevant in skin-related EIMs in CD, which can be 
refractory to treatment and chronic in their nature.  
 
Other skin-homing markers do exist on DCs (for example CCR8), which were not 
studied in this section. Furthermore, it is feasible that it is not the DC receptor 
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that is dysregulated in EIMs, but rather the ligand for that receptor. For example, 
in PSC (a liver-related EIM of CD), MAd-CAM-1 and CCL25 are upregulated in the 
liver (Eksteen, Grant et al. 2004) and provide a mechanism by which long-lived 
populations of memory lymphocytes are able to migrate to and infiltrate the liver, 
resulting in inflammatory damage. This may also be the case in other EIMs of CD, 
including the skin.  
 
Overall, it is difficult to draw any substantial conclusions from the EIM data in 
view of the low patient number recruited for the study. This is a reflection on the 
rarity of the condition and the rapid nature in which treatment is initiated in this 
patient group (usually with corticosteroids).  Future work could increase patient 
recruitment in this area, as well as studying any differences between EN and PG 
in terms of DC phenotype and immune cell homing in other EIMs (eg eyes, joints). 
 
DC subsets 
 
When examining homing marker expression on the two DC subsets (mDCs and 
pDCs), we found consistent differences. mDCs expressed relatively more β7, CLA 
and CCR9, while pDCs expressed relatively higher levels of the remaining 
chemokine receptors (CCR4, CCR7 and CCR10). These changes in relative marker 
expression were independent of the clinical disease phenotype, or indeed in the 
absence of a disease state. Both mDCs and pDCs have different distributions in 
vivo, with mDCs being found in both tissues and LN, while pDCs being mainly 
resident in LN. This may explain why the cell types have different expression of 
homing markers. 
 
It is also important to note that, the overall changes in homing marker 
expression between the different cohorts of patients and HC, were seen 
consistently on both mDC and pDC. For example, in the case of increased 
expression of CCR9 in patients with active SB CD, increased CCR9 expression was 
identified on both mDC and pDC groups separately.  
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Correlation studies 
 
The subject of changes in the immune system with increasing age is currently the 
source of much interest and research. The progressive deterioration in immune 
function that accompanies age (immunosenescence), is the result of alteration to 
both innate and adaptive immunity. Murine studies have demonstrated 
migration of DCs to secondary lymphoid organs (an essential function for DCs to 
exert their effect on T-cells) is significantly reduced in ageing. This is the result of 
both defective CCR7-signalling by mature DCs extracted from old mice compared 
to young mice and reduced chemotactic efficacy of CCL21 in old mice (Grolleau-
Julius, Harning et al. 2008). In addition, recent work carried out in our laboratory 
has identified reduced CCR7 expression on intestinal DCs with increasing age in 
a healthy control population [Dr David Bernardo, personal communication].  
 
We found that expression of CLA and CCR4 on circulating mDCs is reduced in 
patients with active small bowel and active colonic CD respectively, with 
increasing age. Changes in homing marker expression on circulating DCs may 
represent one way in which the immune system ‘ages’ with time and further 
work is needed to confirm these findings.  
 
In the active SB CD group, there were correlations between homing marker 
expression on DCs and disease severity (as measured by HBI). In addition to 
CCR9 expression being significantly increased on circulating DCs in patients with 
active SB CD compared to the other clinical groups, we found that CCR9 
expression on circulating mDCs positively correlates with disease severity. CCR9 
expression on pDCs is negligible, and this is likely to be masking a statistical 
correlation between CCR9 expression and disease severity in all DCs in the active 
SB CD group. These findings appear to underline the importance of CCR9 in 
playing a central role in the disease process in SB CD. Indeed, figure 23 (section 
3.4.3.4) identifies 4 patients with especially high CCR9 expression (>40%) and 
this correlated with the 4 patients with the highest disease severity (HBI≥10).  
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Furthermore, CCR4 expression on circulating pDCs has an inverse correlation 
with clinical disease severity, indicating a reduced skin homing potential of these 
cells in the presence of increased inflammation in the SB. We have previously 
shown that pDCs express relatively greater amounts of CCR4 compared to mDCs 
(figure 28, section 3.4.4.2).  
 
Finally, there were no correlations seen in the inactive ileocolonic CD group, 
perhaps expected in view of low disease burden. These findings were mirrored 
in the HC group, again, perhaps reflecting a return to ‘resting state’ of DCs in CD 
once the disease enters clinical remission.  
 
Tissue specificity of circulating DCs 
 
One striking observation from the results in this chapter is that circulating DCs in 
patients with CD display tissue specificity, which generally correlates with the 
anatomical location of inflammation. DCs originate from haematopoietic stem 
cells in the bone marrow and enter the blood stream. Fresh circulating DCs 
express both gut (β7) and skin (CLA) homing molecules and are therefore have 
the potential to migrate to any tissue and become ‘tissue-specific’ once there 
(Mann, Bernardo et al. 2012). When they encounter an antigen at the tissue site, 
they then migrate to the draining LN and present the antigen to the effector cell. 
Only a tiny minority of DCs will then pass via efferent lymphatics back to the 
thoracic duct. The vast majority of DCs end their lifecyle following antigen 
presentation.   
 
Despite this, our results indicate a high level of tissue specificity on circulating 
DCs in the disease state. In the case of gut homing, this specificity is not just to 
the gut, but also to different locations within the gut (ie small versus large 
bowel). There are two possible mechanisms by which this may occur:  
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 It may be that there are systemic changes in circulating plasma that cause 
or aid the imprinting of tissue specificity on DCs in CD. The cytokine 
milieu in plasma is the prime example, and it is possible that alterations in 
cytokine levels in circulating plasma is leading to changes in DC 
phenotype. An example of this is the function of IL-6 in patients with 
ulcerative colitis. Work in our laboratory has shown that elevated levels 
of IL-6 in plasma leads to a skin-homing phenotype on DCs and makes 
them more efficient at imprinting skin-homing onto T-cells (Bernardo, 
Vallejo-Diez et al. 2012). In CD, the presence of leptin has been shown to 
increase expression of CCR7 on intestinal DCs in a dose dependent 
manner (Al-Hassi, Bernardo et al. 2013). 
 
Furthermore, studies have identified other factors which are important 
for imprinting homing phenotype on cells. Retinoic acid (RA) can be 
generated by intestinal DCs by metabolising vitamin A and induces the 
expression of gut-homing molecules α4β7 and CCR9 on responding T-
cells, as well as concomitant suppression of skin-homing molecules E- and 
P- selectin (Iwata, Hirakiyama et al. 2004). Recent work in our laboratory 
has shown that, when cultured with different doses of RA, monocyte-
derived DC (MoDC) acquire expression of both β7 and CCR9 in a dose-
dependent manner, and increased phagocytic capacity (an important 
characteristic of immature DCs to allow for antigen sampling) (Bernardo, 
Mann et al. 2013). Vitamin D has also been shown to promote the 
development of DCs that stimulate T-cells to express skin-homing 
markers (Sigmundsdottir, Pan et al. 2007).      
 
 A further potential explanation for tissue-specificity of circulating DCs in 
CD centres on the regional draining lymph nodes. In healthy conditions, 
DCs do not generally recirculate via efferent lymphatics, however, this 
may not be the case in disease states. In the presence of cancer promoters, 
large numbers of epidermal Langerhans’ cells have been identified in 
efferent lymphatics, having traversed the regional lymph node (Dandie, 
137 
 
Watkins et al. 1994). The development of ‘leaky lymph nodes’ may also 
occur in other pathologies, such as CD, and lead to increased recirculation 
tissue-specific DCs. Further studies would be needed to confirm this.    
 
Another question raised by these results is whether CD occurs because of 
dysregulated homing of DCs or do DCs have dysregulated homing profiles as a 
consequence of CD? The latter explanation seems the most plausible, and is 
supported by several observations: 
 
 Recent work carried out in our laboratory has shown that the 
microenvironment of the gut (cell-free supernatant obtained following 
culture of colonic biopsies) can be used to condition fresh human blood 
DCs to acquire a gut-specific phenotype (Mann, Bernardo et al. 2012). 
Therefore, in the diseased state, the cell-free microenvironment of the 
inflamed gut will be polarising DCs towards developing a gut-homing 
phenotype, encouraging further recruitment of immune cells to the site of 
inflammation. Further studies conducted in our lab, using patients with 
active UC, used colonic biopsies from inflamed and non-inflamed areas of 
colon and cultured in vitro to obtain the cell-free supernatants. Human 
blood enriched DCs from HC subjects were conditioned with the cell-free 
supernatants. The results showed that DCs conditioned with non-
inflamed culture supernatants acquired a regulatory phenotype with 
decreased stimulatory capacity, whereas DCs cultured with inflamed 
biopsy supernatants acquired a pro-inflammatory phenotype with higher 
levels of stimulatory capacity (Bernardo, Vallejo-Diez et al. 2012). These 
studies indicate that the inflammatory process in IBD has a direct effect 
on DC phenotype and function.   
 
 During my work in the laboratory, one HC subject was recruited for 
research examining blood DC homing phenotype. The results of DC 
phenotyping showed high levels of CCR9 expression on circulating DCs 
and almost completely absent CLA expression (a significantly outlying 
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result). It subsequently transpired that the individual was suffering with 
viral gastroenteritis at the time the blood was taken, and repeat samples 
taken 2 weeks following the resolution of the illness showed complete 
normalisation of these results. These interesting but anecdotal results are 
shown in figure 29.    
 
 
 
Figure 29. Dendritic cell phenotype in an individual with viral gastroenteritis. A) A 
typical DC phenotype for a healthy individual, showing CLA/β7 expression in a two-
parameter histogram (percentage expression values shown) and one-parameter 
histograms showing CCR9 and CCR7 expression. B) The same DC phenotype data 
sets obtained from the individual with active viral gastroenteritis. C) DC 
phenotyping from same individual shown in B, performed 2-weeks following the 
resolution of viral gastroenteritis symptoms. 
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 Finally, our results showed no differences between patients with inactive 
ileocolonic CD and HC, in any of the homing markers studied. It seems 
very likely that patients with active ileocolonic CD would have 
dysregulation of DC homing phenotype (likely a combination of the active 
SB and active colonic CD groups from the previous results). This group of 
patients had inactive disease (HBI≤3) for at least three months prior to 
recruitment, and it seems that DC phenotypic changes have resolved over 
that period of time, and returned to a ‘resting state’. 
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Chapter 4 
 
 
Effect of infliximab on the phenotype of peripheral 
blood mononuclear cells 
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4.1  Abstract 
 
Background 
In health, the immune system maintains immune homeostasis in the gut. In 
inflammatory bowel disease, there is dysregulated immune activity resulting in 
mucosal inflammation. The inflammatory process may also involve other organs, 
such as the skin, eye, liver and joints (EIMs). The cause of EIMs is poorly 
understood. However compartmentalisation of inflammatory processes to 
specific organs may be linked to abnormalities in immune cell trafficking. Anti-
tumour necrosis factor alpha (anti-TNFα) therapies are effective treatments for 
IBD, but their precise mechanism of action is unclear. Paradoxical skin 
inflammation (e.g. psoriasis, eczema) has been reported in up to 20% of patients 
treated with anti-TNFα therapy. Antigen presenting cells and effector cells (T-
cells) are involved in tissue homing. In this study, we investigated the in-vitro 
effect of anti-TNFα on homing marker expression on peripheral blood 
mononuclear cells from healthy control subjects.  
 
Methods 
PBMCs were isolated from fresh blood from 8 healthy volunteers by performing 
a Ficoll gradient separation and cells were cultured in-vitro (1million PBMC/ml) 
with and without Infliximab (IFX, 100µg/ml) at 37.0°c for 24hours. Previous 
dosimetry studies had used 10ng/ml, 1µg/ml, 10µg/ml and 100µg/ml. DC (HLA 
DR+, CD3-, CD14-, CD16-, CD19-, CD34-), monocytes (CD14+), T-cells (CD3+) and B-
cells (CD19+) were identified by flow cytometry after culture. Expression of skin 
(CLA, CCR4, CCR10), gut (β7, CCR9) and lymph node (CCR7) homing markers 
were quantified after culture. Paired t-test was applied.  
 
Results 
Monocytes cultured with IFX increased CCR7 expression (p=0.023). T-cells 
increased CCR4 (p=0.028) and decreased β7 (p=0.029) and CCR7 (p=0.011) 
expression after culture with IFX. There were no significant differences in 
homing marker expression on DCs or B-cell populations.  
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Conclusions 
Up-regulation of CCR4 and reduced expression of β7 on T-cells incubated with 
IFX shows the acquisition of a skin-homing profile by T-cells, suggesting a 
possible mechanism for paradoxical skin inflammation observed in patients 
treated with anti-TNFα therapy. Increased expression of CCR7 on monocytes 
following incubation with IFX suggests an increased lymph node homing 
capacity. Targeting tissue-homing pathways provides a specific approach to IBD 
therapy. 
 
 
This abstract was presented at ECCO conference 2012 and subsequently published in JCC journal 
with the following reference. Request for permission to reprint in Appendix, section 10.3.  
 
Anti-TNFα induces a dysregulated tissue-homing profile on human immune cells in-vitro 
Peake ST, Bernardo D, Mann E, Al-Hassi HO, Landy J, Tee CT, Knight SC, Hart AL 
JCC 2012; 6(1):S15 
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4.2  Introduction 
 
4.2.1   Clinical application of infliximab in Crohn’s disease 
 
The development of monoclonal antibodies (mAb) to the TNFα cytokine over the 
last 15 years has revolutionised the medical treatment of immune diseases, 
including CD. IFX was the first mAb used for the treatment of patients with CD, 
approved by the US Food and Drug Administration in 1998 and subsequently 
introduced to the UK in 1999.  
 
The ability of IFX to induce and maintain remission, heal mucosa, reduce hospital 
admissions and surgical procedures and restore quality of life in patients with 
CD has led to the rapid adoption of IFX into clinical practice. It is now a widely 
used and efficacious treatment for CD and is an important addition to the 
physician’s medical armory.  
 
Subsequently, there has been great interest in the development of additional 
mAbs to block TNFα activity and other pro-inflammatory cytokines that play 
central roles in the activating and perpetuating inflammation in patients with CD. 
Despite this, IFX remains the drug of choice in the treatment of CD unresponsive 
to conventional therapies in most IBD units in the UK.  
 
 
4.2.2   Pharmacokinetic properties of infliximab  
 
IFX is administered intravenously. This enables administration of large volumes 
of the drug, achieves immediate central distribution (extracellular fluid) and 
reduces variability in drug levels between patients. The large loading doses and 
intravenous administration of IFX results high peak concentrations and low 
trough levels (Fasanmade, Adedokun et al. 2011). The exact mechanism of 
clearance of IFX from the system is not well understood, but is likely to be via 
proteolytic catabolism after receptor-mediated endocytosis in cells of the 
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reticuloendothelial system (Wang, Wang et al. 2008). Table 13 outlines the 
pharmacokinetic properties of IFX in CD. 
 
Maximum concentration 118 μg/ml 
Half Life 7.7 – 9.5 days 
Time to reach maximum plasma concentration <1 hour 
Volume of distribution 4.5 – 6 L 
Volume of distribution in central compartment 52.4 ml/kg 
Volume of distribution in peripheral 
compartment 
19.6 ml/kg 
Clearance 5.42 ml/kg/d (15.8ml/hr) 
 
Table 13. Pharmacokinetic properties of infliximab in Crohn’s disease (Ordas, 
Mould et al. 2012). 
 
 
4.2.3   Effects of infliximab on immune cells 
 
Our current knowledge of the mechanisms of action of IFX in CD has been 
detailed previously in the introduction section of this thesis (section 1.3). This 
subject remains the centre of much interest and ongoing work. To date, TNFα 
blockade by IFX has been shown to have beneficial effects on epithelial barrier 
integrity, immune cell apoptosis, mucosal angiogenesis, cytokine production, co-
stimulatory molecule expression and induction of cells with a regulatory 
phenotype.  
 
Despite all this data, there is still much work needed to clarify the modes of 
action of anti-TNFα agents. One area of potential interest is the effect of these 
therapies on homing marker expression. To date, the effect of anti-TNFα 
therapies on homing marker expression on DCs in CD has not been investigated.    
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4.2.4   Hypothesis and Aims 
 
Hypothesis 
 
We hypothesised that, following culture with IFX, there would be dysregulation 
of homing markers on circulating PBMCs. This change in homing marker 
expression may represent one novel mechanism of action of IFX therapy, by 
directing immune cells away from the site of inflammation. 
 
Aims 
 
 To identify changes in homing marker expression on circulating DCs, 
monocytes, B-lymphocytes and T-lymphocytes following culture with IFX 
in vitro.   
 
 To investigate the degree of IFX-induced immune cell cytotoxicity in vitro.    
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4.3  Methods 
 
In order to investigate these aims, PBMCs were isolated from 8 healthy control 
subjects as previously described (section 2.3.1).  
 
IFX was stored in manufacturer vials at 4°c and made up as per instructions 
immediately prior to use, to create a 10ml stock of IFX (100mg/ml). This was 
further diluted with complete cell medium to create aliquots of the test 
concentration (100μg/ml). Previous dosimetry experiments had been performed 
at other concentrations of IFX (10ng/ml, 1µg/ml, 10µg/ml and 100µg/ml). 
 
PBMCs (1 million PBMC/ml) were cultured with IFX and in complete medium 
alone as a paired internal control for 24hours at 37°c, 5% CO2, high humidity. 
Following culture, specific cell populations were identified and surface marker 
expression was quantified.  
 
 
Statistical analysis 
 
Statistical analysis was performed with paired t-test. P values of <0.05 were 
considered statistically significant.  
 
 
 
 
 
 
 
 
 
 
 
147 
 
4.4  Results 
 
Different cell populations within the PBMC group express different homing 
markers. For example, our studies have shown that circulating DCs co-express β7 
and CLA (Mann, Bernardo et al. 2012). However, the primary homing markers of 
interest in monocytes has been identified to be CCR9 and CCR7 (Bernardo, Mann 
et al. 2013). Therefore, based on previous experience from the laboratory, we 
have selected a different array of homing markers to be studied in each cell 
population.  
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4.4.1   Dendritic cells 
 
DCs were identified by a double gating strategy as described in the methods 
chapter (figure 14, section 2.3.9.2). Six homing markers were examined, 
including gut-homing markers β7 and CCR9, skin-homing markers CCR4, CCR10 
and CLA and the lymph node homing marker CCR7. All the markers studied had 
significant expression on DCs in basal conditions; β7 50.6±9.9%; CLA 
56.1±11.3%; CCR9 67.0±4.4%; CCR4 20.8±6.3% and CCR7 49.5±9.2%. The skin-
homing marker CCR10, was the only exception to this, and was expressed in very 
low numbers on circulating DCs (1.7±0.5%). There were no significant 
differences in homing marker expression on DCs following culture with IFX 
(figure 30). 
 
 
 
 
Figure 30. Expression of homing markers on dendritic cells following 24-hour 
culture with IFX (100μg/ml).  
Statistical analysis performed using paired t-test. 
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4.4.2   Monocytes 
 
Monocytes were identified by positive staining of CD14 on all PBMCs (figure 31).  
 
 
 
Figure 31. Identification of monocytes in PBMCs. A) Light scatter plot showing 
region R1 which contains all viable cells. A second histogram is made identifying 
cells with positive staining for CD14, gated in region R2. B) Histogram displaying 
the location of CD14+ve cells within the viable cell region by backgating.   
 
 
Previous work in our laboratory has identified CCR9 and CCR7 as being the 
primary homing markers in interest when studying monocytes (Bernardo, Mann 
et al. 2013). However, our results show low levels of CCR9 expression on 
circulating monocytes (3.9±2.9%). There were no changes in CCR9 expression 
following IFX culture (figure 32). 
 
There was greater expression of CCR7 on monocytes in basal conditions 
(13.1±3.8%). CCR7 expression was up-regulated on circulating monocytes 
following IFX culture (p=0.023), as shown in figure 32.  
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Figure 32. Expression of CCR7 and CCR9 on monocytes following 24-hour culture 
with IFX (100μg/ml).   
Statistical analysis performed using paired t-test. 
 
The increased expression of CCR7 on monocytes following culture with IFX 
indicates an increased lymph-node homing capacity. To further investigate the 
cell phenotype, we have examined level of HLA DR expression on CCR7+ 
monocytes following culture with IFX.  
 
Our results show that, following IFX culture, CCR7+ monocytes have a high 
expression of HLA DR (see figure 33), and therefore have a high capacity for 
antigen presentation. It is likely that this population of CD14+CCR7+HLA DRhigh 
cells are differentiating into DC-like cells of a myeloid lineage. Despite this, there 
were no significant changes in the intensity ratio of HLA DR expression on 
monocytes following culture with IFX.  
 
 
Figure 33. HLA DR expression on CCR7+ monocytes following IFX culture. A) Two-
parameter histogram showing CCR7 and HLA DR expression on monocytes in basal 
conditions B) The same staining histogram on monocytes following culture with 
IFX (100µg/ml) showing 38.3% of monocytes co-express CCR7 and the level of HLA 
DR expression on these cells is also high.  
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4.4.3   B lymphocytes 
 
B-cells were identified by positive staining for CD19 on cells within the gated 
lymphocyte population (figure 34). We examined the expression of two gut-
homing markers (β7 and CCR9) and two skin-homing markers (CLA and CCR4) 
on circulating B-cells following IFX culture.   
 
 
 
 
Figure 34. Identification of B-cell population in PBMCs. A) Light scatter plot 
showing region R1, which contains all lymphocytes. A one-parameter histogram is 
made identifying cells with positive staining for CD19, gated in region R2. B) 
Histogram displaying the location of CD19+ve cells within the lymphocyte region 
by backgating.   
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We found high levels of β7 expression on circulating B-cells (81.4 ± 3.2%). 
However, there was low level of expression of CLA, CCR4 and CCR9 on B-cells in 
basal conditions with values of 4.1±3.1%, 2.4±0.6% and 2.3±0.7% respectively.  
There were no significant changes in homing marker expression on B-cells 
following culture with IFX (figure 35).  
 
 
 
 
Figure 35. Expression of gut and skin homing markers on B-cells following 24-hour 
culture with IFX (100μg/ml).   
Statistical analysis performed using paired t-test. 
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4.4.4   T lymphocytes 
 
T-cells were identified by positive staining for CD3 on cells within the gated 
lymphocyte population (figure 36). We examined the expression of the gut-
homing marker β7, three skin-homing markers (CLA, CCR4 and CCR10) and the 
lymph node homing marker CCR7 on circulating T-cells following IFX culture.   
 
 
 
 
Figure 36. Identification of T-cell population in PBMCs. A) Light scatter plot 
showing region R1, which contains all lymphocytes. A one-parameter histogram is 
made identifying cells with positive staining for CD3, gated in region R2. B) 
Histogram displaying the location of CD3+ve cells within the lymphocyte region by 
backgating.   
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There was high levels of homing marker expression on circulating T-cells (β7 
70.2±2.7%; CLA 12.2±4.4%; CCR4 18.7±3.6% and CCR7 87.9±2.4%). Again, 
CCR10 was the exception, with low levels of expression on T-cells (6.2±4.5%).  
 
β7 and CCR7 expression were found to be down-regulated following 24-hour 
culture with IFX (p=0.029 and 0.011 respectively). CCR4 expression was 
significantly up-regulated on T-cells following IFX culture (p=0.028). These 
changes in the homing profile of circulating T-cells following 24hr IFX culture, 
appear to suggest a shift from a gut-homing profile (β7high CCR4low) to a skin-
homing profile (β7low CCR4high).  
 
 
 
Figure 37. Expression of gut and skin homing markers on T-cells following 24-hour 
culture with IFX (100μg/ml).   
Statistical analysis performed using paired t-test. 
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4.4.5   Cytotoxicity of infliximab in vitro 
 
In order to confirm whether the changes in homing marker expression following 
IFX culture are a true finding, we needed to check that the IFX drug was not toxic 
to cells in vitro, and that cell death was not responsible for our findings by 
inducing selective apoptosis on different cell populations expressing different 
homing markers.   
 
This was achieved by calculating and comparing absolute cell numbers in the 
basal and IFX conditions. Flow-countTM fluorospheres with a known density 
(depending on the batch) were used as a reference during flow cytometry 
analysis of human cells for calculation of absolute cell numbers. The 
fluorosphere counting beads can be identified on a light scatter plot and gating 
around this event allows us to calculate absolute cell numbers. Figure 38A-C 
demonstrates this method and also confirms that the presence of counting beads 
does not affect the results, as the beads are never located within the viable cell 
region when initial cell gating is performed.  
 
There were no changes in cell counts in basal conditions compared to IFX culture 
and therefore no significant IFX-associated cell cytotoxicity was detected (see 
figure 38D).   
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Figure 38. Calculation of absolute cell numbers of cell populations within PBMC 
group. A) Identification of monocytes as CD14+ cells in region R2. B) Two-
parameter histogram (FL1:FL2) with monocytes backgated onto plot (red) and the 
fluorosphere counting beads (blue) gated within region R3. C) Backgating of both 
the monocytes (red), which show up within the viable cell gate, R1, used for 
experiments, and the counting beads (blue) which are clearly seen outside the 
viable cell gate and therefore not interfering with results. D) Absolute cell numbers 
for each cell population in basal conditions and following 24-hour culture with IFX 
(100μg/ml).  
Statistical analysis performed using paired t-test. 
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4.4.6   Summary of results 
 
 No change in DC or B-cell phenotype post culture with IFX 
 
 Increased expression of CCR7 on monocytes following IFX culture 
 
 Reduced β7 and CCR7 expression and increased CCR4 expression on T-
cells following IFX culture 
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4.5  Discussion 
 
Human circulating DCs display a multi-homing β7+ and CLA+ phenotype. This is 
not shared by circulating monocytes which have previously been shown to 
express CCR9 and CCR7 as their main homing markers and virtually no β7 or 
CLA (Bernardo, Mann et al. 2013). These differences may account for the 
different tissue distributions of the cell types in vivo. In these experiments, 
positive expression of β7 is taken to represent α4β7 integrin expression on cells, 
although this has already been identified as a limitation in the methodology 
(section 1.2.11). 
 
Despite this, we found low levels of CCR9 expression on the circulating monocyte 
population. This may reflect on the HC status of the donor subjects and 
individual variability. The low levels of CCR9 expression on monocytes may also 
be explained by the 24hr time period that the cells have spent in culture prior to 
staining and acquisition. Studies which use monocyte-derived DCs have shown 
that during the 5-day cell culture phase required to produce DCs, monocytes 
gradually lose homing expression (see section 5.2.1, figure 39) (Bernardo, Mann 
et al. 2013). Therefore, it may be that the monocytes have down regulated CCR9 
expression during the period of time spent in cell culture in the absence of 
external stimuli.  
 
Our results showed up regulation of CCR7 on monocytes following 24-hour 
culture with IFX, indicating an increased lymph node homing capacity. Retention 
of APCs in the LN and tissue is an essential factor to maintaining immune 
homeostasis. Although the homeostatic/tolerogenic status of the monocytes was 
not studied, it is likely that they express a ‘regulatory’ phenotype in view of the 
fact that they were isolated from HC subjects. If this were found to be the case, 
the increased capacity for monocytes to migrate to the LN following culture with 
IFX may represent one way in which IFX acts. These findings would need to be 
confirmed in a larger study, including monocyte phenotype and functional 
studies in both HC and active CD.  
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We identified a significant change in T-cell phenotype following culture with IFX 
for 24 hours. CCR7 expression was down regulated, and therefore T-cells have a 
reduced LN homing capacity following IFX culture. This may serve to direct naïve 
T-cells away from the LN and therefore avoid exposure to antigen presenting 
cells and subsequent stimulation and proliferation of T-cells.  
 
Furthermore, T-cells down regulated their gut homing potential (reduced 
expression of β7) and up regulated skin-homing affinity (increased CCR4 
expression) following IFX culture. This appears to represent an overall change in 
T-cell migration, away from the gut and towards the skin. These findings are 
interesting and may represent a novel mechanism by which the phenomenon of 
paradoxical inflammation (PI), seen in some patients with CD treated with anti-
TNFα therapy, occurs.  
 
PI is a poorly understood process, although there have been several possible 
mechanisms described in the literature by which it may occur, including a 
genetic predisposition, autoimmune factors, effect of TNFα blockade on IFNα 
production by pDCs in the skin and the role of other cytokines. The effect of IFX 
on immune cell homing has not been previously studied with respect to PI. 
Future larger studies would need to identify the cellular and molecular 
mechanisms through which IFX is having its effect on T-cells. It is unclear 
whether the effect of IFX on T-cells is a direct action or via a different primary 
responding cell. It would also be interesting to examine the effect of IFX on T-
cells in the in vivo setting, using patients who develop PI while on anti-TNFα 
therapy. Indeed, this approach could be expanded to evaluate the evolution of 
homing marker expression in time in different phenotypes of CD, as well as the 
effects of different therapies on homing marker expression.  
 
We did not see any changes on DC or B-cell phenotype following IFX culture. In 
this chapter, these cell populations were examined in the setting of PBMCs. In the 
next chapters, we set out to enrich DCs in fresh blood and examine the effect of 
IFX on the phenotype and function of low density cells.   
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Chapter 5 
 
 
Effect of infliximab on the phenotype, intracellular 
cytokine production and cytokine profile of low density 
cells in Crohn’s disease and healthy controls. 
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5.1  Abstract 
 
Introduction 
DCs play a key role in discriminating between commensal microorganisms and 
potentially harmful pathogens. DC phenotype and cytokine production 
determine the type of immune response (immunity/tolerance) elicited by T-cells 
following antigen presentation. DCs also direct the T-cells to target tissues to 
perform their function via imprinting tissue-specific homing markers. In CD, 
dysregulation of the immune response to gut microbiota & aberrant immune cell 
trafficking play a central role in disease pathogenesis. IFX is a widely used and 
effective treatment for CD, but its mechanism of action is unclear.  
 
In this study, we investigated the in-vitro effect of IFX on phenotype and ongoing 
cytokine production of human blood-enriched DCs from patients with active CD 
and HC. 
 
Methods 
Low density cells (LDCs), which are enriched for DCs, were obtained following 
Ficoll and Nycoprep gradient separation of blood obtained from patients with 
active ileocolonic CD (HBI≥7) and HC. LDCs were cultured (0.5x106 cells/ml) 
with IFX (1μg/ml, 10μg/ml, 100μg/ml & basal) for 24 hours. Activation marker 
(CD40, CD80, HLA DR), TLR receptor (TLR2 and TLR4) and homing marker 
(CCR4, CCR5, CCR7, CCR8, CCR9, CCR10 and β7) expression was quantified by 
flow cytometry. Natural ongoing intracellular cytokine production (TNFα, TGFβ 
and IL-6, IL-10, IL-12 and IL-15) was assessed via intracellular staining and flow 
cytometry. Cytokine secretion was measured on cell-free culture supernatants 
via Multiplex.  
 
Unpaired t-test and one-way ANOVA statistical analysis with Dunnett’s multiple 
comparison tests were applied.  
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Results 
TNFα and IL-6 were increased in culture supernatants from patient with active 
CD (p=0.031 and 0.033 respectively) although their intracellular ongoing 
cytokine production was decreased (p=0.004 and 0.006 respectively). LDCs from 
CD had increased β7 (gut-homing integrin) expression compared to HC 
(p=0.032).  
 
Following IFX culture, LDCs decreased β7 expression (p<0.05) and reduced CCR9 
intensity ratio (p<0.01). There was a trend towards reduction in TLR2 and 4 
expression in CD. IL-12 production by LDCs from HC was increased following IFX 
culture (p<0.01). There was a marked reduction in TNFα in cell supernatant 
following culture with IFX (p<0.01) and a reduction in IL-2 at the highest IFX 
concentration in HC (p<0.05).   
 
Conclusions 
Increased TNFα and IL-6 in culture supernatants from CD patients coupled with 
a decrease in ongoing production by DC may suggest a negative cytokine 
feedback system. Reduced expression of β7 and CCR9 and elevated production of 
IL-12 in LDCs cultured with IFX, shows reduced affinity for gut-homing and 
increased immunogenicity and may suggest a possible mechanism for IFX-
induced paradoxical inflammation. The most dramatic effect of IFX was a 
reduction in TNFα in the supernatant, which is likely to represent neutralisation 
of the TNFα cytokine.  
 
 
This abstract was presented at BSG and ECCO conferences 2013 and subsequently published in Gut 
and JCC journals with the following references. Permissions to reprint in Appendix, section 10.2 and 
10.3 respectively.  
 
Unravelling the mechanism of action of infliximab in Crohn’s disease and healthy controls 
following in vitro culture with blood-enriched dendritic cells 
Peake ST, Bernardo D, Mann ER, Landy J, Al-Hassi HO, Knight SC, Hart AL 
Gut 2013; 62: A254 
JCC 2013; 7(1): S140-141 
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5.2  Introduction 
 
In the previous chapter, we have examined the effect of IFX on the phenotype of 
several cell populations in vitro. We found no changes in the phenotype of DCs 
following culture with IFX. However, that work had been carried out by 
identifying DCs from PBMCs as HLA DR +ve and lineage cocktail –ve cells. In 
order to specifically investigate the effect of IFX on DCs in vitro, we isolated and 
purified DCs from peripheral blood (low density cells, LDCs), and subjected this 
cell population to in vitro IFX culture.      
 
 
5.2.1   Low density cells  
 
Most studies to date investigating DCs have used DCs derived from either murine 
bone marrow or human monocyte-derived DC (MoDC). The latter are generated 
by in vitro culture of purified CD14+ peripheral blood monocytes for several 
days in the presence of GM-CSF and IL-4 at supra-physiological conditions. This 
drives DC differentiation, with up-regulation of HLA DR and down regulation of 
CD14. However, due to prolonged period of time in vitro, the cells lose homing 
marker expression (figure 39), likely due to the lack of ongoing exposure to 
tissue microenvironment required to condition DCs (Bernardo, Mann et al. 2013). 
In view of this, the use of MoDC to study DC homing markers and phenotype 
would likely yield inaccurate data.  
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Figure 39. Effect of differentiation of monocytes into MoDC on homing marker 
expression. Graphs showing the effect of prolonged culture (5 days) on MoDC 
homing marker expression in the absence of external stimuli (Bernardo, Mann et al. 
2013). 
 
 
In order to study homing marker expression, we have used LDCs as our in vitro 
‘cell model’ for human peripheral blood DCs. Despite the fact LDCs do not 
provide as pure a cell population as MoDC, because they have been in culture for 
a much shorter period of time, they provide a more physiological model to 
accurately study the effects of IFX on phenotype and function of DCs.  
 
LDCs are obtained from PBMCs, which initially undergo a period of in vitro 
culture, allowing immature DCs (small cells that resemble lymphoid cells) to 
acquire increased density buoyancy and monocytoid morphology. This period of 
in vitro culture also allows for depletion of monocytes, as these cells will adhere 
to the culture flask. DCs from human peripheral blood do also adhere transiently, 
but become non-adherent within 16 hours (Van Voorhis, Hair et al. 1982), and 
therefore, following in vitro culture, the non-adherent cell fraction contains a 
greater proportion of lymphocytes and DCs.  
 
In order to further enrich for DCs, the non-adherent cell fraction is exposed to a 
Nycoprep gradient. Nycoprep is a hyperosmolar solution that has useful 
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properties for DC enrichment. Lymphocytes are sensitive to Nycoprep and upon 
contact with Nycoprep, they undergo significant water loss from the cell cytosol 
and shrink. This has the effect of making them denser and hence they pass 
rapidly through the Nycoprep layer to form a pellet for discarding.   
 
Cell analysis has shown the isolated LDC population to be highly enriched for 
DCs with a high surface expression of HLA DR, CD11c, CD83 and CD86 (Knight, 
Farrant et al. 1986). Previous work from our laboratory has also shown that the 
enriched DC population isolated by this method is 98-100% positive for HLA DR 
expression and has morphological features of DC at both optical and electron 
microscopy (Holden, Bedford et al. 2008). Although the final cell population is 
only approximately 80% purified for cells with DC phenotype and morphology, 
the LDC population offers a ‘physiological’ model for in vitro experimental work 
with blood DCs, especially when compared with MoDC.  
   
A third method of obtaining human circulating DCs for in vitro work is by 
enriching circulating blood DCs via flow or magnetic sorting of the different DC 
populations. As well as being able to obtain ‘pure’ DCs, this method also allows 
the extraction of DC subpopulations, ie pDCs (CD11c-, CD123+, BDCA2+), type 1 
mDCs (CD11c+, CD123-, BDCA2-, CD1c+, CD141-) and type 2 mDCs (CD11c+, 
CD123-, BDCA2-, CD1c-, CD141+). At the time this work was carried out, our 
laboratory did not have a flow sorter, and the method of magnetic sorting had 
not been optimised. Therefore, these approaches were not possible.   
 
 
5.2.2   Activation and maturation markers on LDCs 
 
As previously discussed, TLRs are one type of pattern recognition receptor. TLRs 
are proteins expressed either on the cell surface or in the intracellular 
compartment of cells such as DCs and macrophages. They play a vital role in 
recognition of specific microbial products and therefore aid antigen acquisition. 
We have concentrated our studies looking at two cell-surface TLRs; TLR2 (gram 
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positive bacteria) and TLR4 (gram negative bacteria).  Work conducted in our 
laboratory has shown that, in CD, intestinal DCs isolated from areas of active 
inflammation express higher levels of TLR2 and TLR4 than uninflamed tissue 
(Hart, Al-Hassi et al. 2005).  
 
At the time of antigen presentation to naïve T-cells, DCs express the antigen 
presenting molecule (such as the MHC class II molecule, HLA DR) in addition to 
co-stimulatory molecules (eg CD40, CD80, CD86). The quality and quantity of 
these two markers (in addition to cytokines) will determine whether the 
response of tolerogenic (ie tolerance to food antigens and commensal 
microbiota) or immunogenic. Immature DC express low levels of these co-
stimulatory molecules (Banchereau, Briere et al. 2000), and up-regulation occurs 
after antigen acquisition in the intestine and during DC migration to the draining 
LN.   
 
 
5.2.3   Cytokines in Crohn’s disease 
 
Thirty years ago, two T-helper cell subsets (Th1 and Th2) were described 
(Mosmann, Cherwinski et al. 2005). Traditionally it was assumed that CD was 
mediated by Th1 cells, while UC was the result of Th2 cells. Th1 differentiation is 
mainly driven by IL-12 and IFNγ and Th1 cells produce IFNγ, with their primary 
role being protection against intracellular microbes (Brand 2009). At the onset 
of CD, mucosal T-cells appear to mount a typical Th1 response that resembles an 
acute infectious process, and is lost with progression to late CD (Kugathasan, 
Saubermann et al. 2007). There are several further observations that implicate 
Th1 cells as being major mediators of the pathogenesis of CD: 
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 Macrophages in CD produce increased amounts of IL-12 (Monteleone, 
Biancone et al. 1997). 
 Nuclear extracts from T-cells obtained from inflamed CD tissue contain 
high levels of Th1 associated transcription factors (STAT4 and T-bet) 
(Neurath, Weigmann et al. 2002). 
 Enhanced production of IL-18 (reinforces Th1 cell polarisation) in 
actively inflamed CD mucosa (Monteleone, Trapasso et al. 1999). 
 T-cells isolated from areas of active CD have high levels of the IL12Rβ2 
chain (found with Th1 cells) (Parrello, Monteleone et al. 2000). 
 T-cells isolated from areas of active CD express increased amounts of 
IFNγ and reduced amounts of IL-4 (Th2 cytokine) compared to healthy 
controls (Fuss, Neurath et al. 1996).   
 
 
However, it has now become clear that the Th17 pathway also plays a significant 
role in CD (Annunziato, Cosmi et al. 2007). While Th1 and Th2 differentiation 
depends on presence of their cytokines for differentiation (IFNγ and IL-4 
respectively), polarisation of Th17 cells does not require IL-17. Murine Th17 
cells originate from naïve CD4+ T-cells in the presence of IL-6 and TGFβ. Their 
development is then increased by IL-21 and IL-23 (Bettelli, Carrier et al. 2006). 
IL-12 and IL-23 share the same p40 subunit, and therefore antibodies have been 
developed to target the IL-12/IL-23p40 subunit in the hope of down-regulating 
both Th1 and Th17 pathways simultaneously.  
 
Following contact with foreign antigens, APCs release cytokines resulting in 
differentiation of T-cells. In addition, pro-inflammatory cytokines such as TNFα, 
IL-6 and IL-1β, which are predominately released from DCs and macrophages, 
have a direct role leading to intestinal inflammation in CD. TNFα is produced by 
both Th1 and Th17 cells in CD (Abraham and Cho 2009).   
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5.2.4   Hypothesis and Aims 
 
Hypothesis 
 
We hypothesised that, when cultured in vitro, IFX would modulate the phenotype 
and cytokine production of LDC, in a dose-dependent manner.  
 
Aims 
 
 To identify changes in LDC phenotype following culture with IFX, 
including: 
o Homing marker expression 
o Activation marker expression 
o Maturation marker expression 
 
 To identify changes in ongoing LDC cytokine production following culture 
with IFX.    
 
 To investigate changes in the cytokine content of the cell-free supernatant 
solution following culture with IFX.  
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5.3  Methods 
 
Patients were recruited from IBD outpatient clinics and the endoscopy unit at St 
Mark’s Hospital between October 2011 and June 2012. Patients had active 
ileocolonic CD (HBI ≥7), confirmed by endoscopic with or without radiological 
studies within 6 months or recruitment. Healthy control subjects were recruited 
in parallel to patient recruitment.  
 
All patients were recruited directly by the candidate to ensure standardisation of 
patient selection. A Microsoft Excel database was created containing 
phenotypical data for each patient recruited, including the following parameters: 
 
 Age 
 Gender 
 Number of years since diagnosis with CD 
 Montreal classification of CD 
 Disease activity (measured using Harvey Bradshaw Index, HBI) 
 Current medications 
 Date of most recent endoscopic examination 
 Date of most recent radiological examination 
 
Inclusion and exclusion criteria were applied to patient recruitment (outlined in 
section 2.2.2), to ensure an accuracy of data obtained.  
 
 
5.3.1   Enrichment of LDCs and preparation of IFX 
 
LDCs, enriched for DCs, were isolated on a Nycoprep gradient from non-adherent 
cells after overnight culture of PBMCs (described in section 2.3.2).  
 
IFX was prepared from a stock solution at 10mg/ml concentration. Aliquots of 
the desired test concentrations (1μg/ml, 10μg/ml and 100μg/ml) were made by 
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dilution of the stock with complete medium. LDCs were then cultured for a 
further 24 hours in 1ml of complete medium (0.5x106 cells/ml) with either a test 
concentration of IFX or in basal conditions (complete medium alone).   
 
Following culture, cell expression of homing, maturation and activation markers 
was determined by monoclonal antibody labeling and flow cytometry.  
 
 
5.3.2   Quantification of ongoing intracellular cytokine production 
 
To quantify ongoing cytokine production by LDCs, cells were incubated for 4 
hours with or without monensin. Monensin is a protein transport inhibitor that 
blocks secretion of proteins by cells via the Golgi apparatus, thereby causing an 
accumulation of cytokines at the endoplasmic reticulum or Golgi (figure 40). 
Cytokines being synthesised by LDCs incubated with monensin over the 4-hour 
period accumulate within the cell, whereas those cells incubated in basal 
conditions do not retain cytokines. Following the 4 hour culture period, LDCs 
were fixed and permeabalised to allow for intracellular cytokine staining and 
flow cytometry. LDCs cultured without monensin were taken as ‘control’ samples 
and subtracted from the LDCs cultured with monensin, to give an overall 
accurate picture of ongoing cytokine production by LDCs over the 4-hour period.     
 
 
 
 
Figure 40. Molecular structure of monensin. Monensin is an inhibitor of 
intracellular protein transport and was used to allow quantification of ongoing 
cytokine production by LDCs.   
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Although technically challenging and time consuming, the major advantage of 
this method is that it allows quantification of intracellular cytokine production in 
the absence of external stimuli, which may bias their cytokine profile. 
 
 
5.3.3   Quantification of cell-free supernatant cytokine profile 
 
The BD CBA Human Th1/Th2/Th17 Cytokine Kit uses bead array technology to 
simultaneously detect and quantify the concentration (in pg/ml) of multiple 
cytokine proteins in cell-free supernatant samples.  
 
Seven bead populations with distinct fluorescence intensities have been coated 
with capture antibodies specific for their specific cytokine (IL-2, IL-4, IL-6, IL-10, 
TNFα, IFNγ and IL-17a). The seven bead populations are then mixed together to 
form a bead array, which is analysed in the APC channel of the 6-colour flow 
cytometer.  
 
 
5.3.4   Statistical analysis 
 
Statistical analysis of differences between LDCs from patients with active CD 
compared to HC was performed using unpaired t-test. Analysis of the effect of 
IFX on LDC phenotype and cytokine profile was performed using and one-way 
analysis of variance (ANOVA) with Dunnett’s multiple comparison test.  
 
P values of <0.05 were considered statistically significant in all cases.  
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5.4  Results 
 
5.4.1   Patient characteristics 
 
Five patients with active ileocolonic CD, who met the inclusion and exclusion 
criteria previously outlined, were identified and recruited to provide blood 
samples for the study. Six healthy control subjects were recruited. 
Demographical and clinical data is shown in table 14.  
 
Case 
number 
Gender Age Years since 
diagnosis 
CD location HBI Current 
medications 
1 Female 27 2 Ileocolonic 11 6-MP 
2 Female 43 8 Ileocolonic 9 AZA 
3 Male 54 12 Ileocolonic 12 AZA 
4 Male 31 4 Ileocolonic 12 AZA 
5 Female 66 7 Ileocolonic 10 AZA 
6 Male 26 - HC - - 
7 Male 34 - HC - - 
8 Female 35 - HC - - 
9 Female 51 - HC - - 
10 Female 33 - HC - - 
11 Male 47 - HC - - 
 
Table 14. Patient and healthy control characteristics and demographical data.  
HC = healthy control, 6-MP = 6-Mercaptopurine, AZA = Azathioprine 
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5.4.2   Identification and purification of LDCs from blood 
 
Human blood low density mononuclear cells were identified at multi-colour flow 
cytometry using forward scatter (FSC) and side scatter (SSC) characteristics, as 
shown in figure 41. This figure also shows the efficacy of Nycoprep in the LDC 
enrichment process, by selecting the low density cells and excluding the smaller 
and denser lymphocyte population. Cells falling within the LDC region (region 
R1) are taken as the antigen presenting cells (APCs).     
 
 
 
 
Figure 41. Nycoprep gradient in the enrichment of LDC population. A) Pre-
Nycoprep histogram showing APC population (LDCs) in region R1 and lymphocyte 
population in region R2. These regions contain 8.7% and 79.5% of events 
respectively. B) Post-Nycoprep histogram in which the proportion of events within 
the APC region (R1) has increased to 85.7% and events in the lymphocyte region 
(R2) has fallen to 1.9%.  
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LDCs have previously been shown to comprise predominately DCs, but also 
contain other types of APC as well. Figure 42 below shows HLA DR and CD14 
staining of the LDC population. As expected, >90% of cells express HLA DR in 
both HC and CD, but we also found significant CD14 expression. Despite this, the 
LDC population shares several properties with DCs including the presence of 
veiled exteriors (Knight, Farrant et al. 1986) and the capacity to stimulate naïve 
(CD4+CD45Ra+) T-cells which is not true for monocytes.   
 
Culturing LDCs with IFX did not affect HLA DR or CD14 expression.   
 
 
 
 
Figure 42. HLA DR and CD14 expression on circulating LDCs in HC and patients 
with active CD.  
HC = healthy control, CD = active ileocolonic CD, ns = not significant 
Statistical analysis comparing HC and CD groups performed using unpaired t-test. 
Analysis of effects of IFX performed using one-way ANOVA with Dunnett’s multiple 
comparison test. 
 
 
 
 
 
 
 
175 
 
5.4.3   Activation and maturation markers 
 
To examine the effect of IFX culture on pattern recognition receptors on 
circulating blood LDCs, we investigated TLR2 and TLR4 expression (figure 43). 
Although there were no statistically significant differences in TLR2 and 4 
expression between HC and patients with active CD, there was a trend towards 
higher TLR expression in the active CD state. There also appeared to be a 
stepwise reduction in TLR2 and 4 expression in CD with increasing doses of IFX. 
However, this did not reach statistical significance.   
 
 
Figure 43. TLR2 and 4 expression by circulating LDC in HC and patients with active 
ileocolonic CD and effect of IFX culture on expression.  
HC = healthy control, CD = active ileocolonic CD, ns = not significant 
Statistical analysis comparing HC and CD groups performed using unpaired t-test. 
Analysis of effects of IFX performed using one-way ANOVA with Dunnett’s multiple 
comparison test. 
 
 
HLA DR expression on APCs (including LDCs) correlates with the cell activation 
potential. Over 90% of the LDC population express HLA DR, so in order to detect 
changes in HLA DR expression in HC and CD and the effect of IFX, we assessed 
the intensity ratio of staining on HLA DR+ cells There were no differences seen in 
the intensity ratio of HLA DR expression between HC and CD, or with the 
addition of IFX to the cell culture (figure 44). Similarly, there were no changes in 
the expression of the co-stimulatory molecules CD40 and CD80.  
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Figure 44. Expression of HLA DR and co-stimulatory molecules on circulating LDC 
in HC and patients with active ileocolonic CD and effect of IFX culture on expression. 
A) Intensity ratio of HLA DR expression on positive cells. B) Percentage expression 
of co-stimulatory molecules, CD40 and CD80, on LDCs.  
HC = healthy control, CD = active ileocolonic CD, ns = not significant 
Statistical analysis comparing HC and CD groups performed using unpaired t-test. 
Analysis of effects of IFX performed using one-way ANOVA with Dunnett’s multiple 
comparison test. 
 
 
5.4.4   Homing marker expression 
 
In order to investigate the expression of gut-homing markers on circulating LDCs 
and the effect of IFX culture, CCR9 and β7 were examined (figure 45).  
 
The expression of the β7 integrin was increased on LDCs isolated from patients 
with active ileocolonic CD compared to HC (p=0.032). This correlates with 
findings in the first results chapter, where β7 expression was increased on 
circulating DCs from patients with active colonic CD compared to HC. A reduction 
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in β7 expression was seen on CD LDCs cultured with the greatest concentration 
of IFX (p<0.05). There were no differences in the intensity ratio of β7 expression. 
 
There was a trend towards greater expression of CCR9 on LDCs from patients 
with active CD compared to HC, but this did not reach statistical significance. 
Following culture with IFX, the intensity ratio of CCR9 expression was reduced in 
both the 10μg/ml (p<0.05) and 100μg/ml (p<0.01) concentrations. 
  
 
 
Figure 45. Expression of gut homing markers on circulating LDCs in HC and 
patients with active ileocolonic CD and effect of IFX culture on expression. A) β7 
expression on LDCs in terms of percentage expression and intensity ratio of 
expression. B) CCR9 expression on LDCs in terms of percentage expression and 
intensity ratio of expression.  
HC = healthy control, CD = active ileocolonic CD, ns = not significant  
In basal conditions:  * = p<0.05 
In IFX conditions: * = p<0.05 when compared to basal condition  
** = p<0.01 when compared to basal condition  
Statistical analysis comparing HC and CD groups performed using unpaired t-test. 
Analysis of effects of IFX performed using one-way ANOVA with Dunnett’s multiple 
comparison test. 
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The expression of skin-homing markers on LDCs, and effect of IFX on this 
expression, was examined by investigating CCR4, CCR8 and CCR10 chemokine 
receptors (figure 46). We found relatively high expression of all 3 skin homing 
markers on circulating LDCs. There were no differences in expression between 
HC and CD and no differences seen following culture with IFX.  
 
 
 
Figure 46. Expression of skin homing markers on circulating LDCs in HC and 
patients with active ileocolonic CD and effect of IFX culture on expression.  
HC = healthy control, CD = active ileocolonic CD, ns = not significant 
Statistical analysis comparing HC and CD groups performed using unpaired t-test. 
Analysis of effects of IFX performed using one-way ANOVA with Dunnett’s multiple 
comparison test. 
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The final two homing markers examined were CCR7 (lymph node homing) and 
CCR5 (directs homing to sites of inflammation), shown in figure 47. There were 
no differences in expression of these markers in LDCs from active CD or HC or 
following culture with IFX.  
 
 
 
Figure 47. Expression of CCR7 and CCR5 on circulating LDCs in HC and patients 
with active ileocolonic CD and effect of IFX culture on expression. 
HC = healthy control, CD = active ileocolonic CD, ns = not significant 
Statistical analysis comparing HC and CD groups performed using unpaired t-test. 
Analysis of effects of IFX performed using one-way ANOVA with Dunnett’s multiple 
comparison test. 
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5.4.5   Ongoing intracellular cytokine production 
 
Due to limitations in the number of LDCs available for experimental work, six 
pathologically relevant cytokines were selected for the study (figure 48).  
 
Circulating LDCs isolated from patients with active ileocolonic CD had reduced 
ongoing production of TNFα (p=0.0043) and IL-6 (p=0.0066) compared to HC in 
basal conditions. There were no changes in the ongoing production of these 
cytokines when IFX was introduced into the cell culture.  
 
The production of the Th1-differentiating cytokine, IL-12, was increased in LDCs 
from HC following the addition of IFX to the cell culture (1μg/ml IFX, p<0.01; 
10μg/ml, p<0.01; 100μg/ml, p<0.05). There were no changes in LDCs isolated 
from patients with active CD.      
 
There were no statistically significant differences in production of TGFβ, IL-10 or 
IL-15 between HC and CD or following the addition to IFX to the cell culture.  
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Figure 48. Cytokine production by LDCs from HC and patients with active CD and 
the effect of IFX.   
HC = healthy control, CD = active ileocolonic CD, ns = not significant  
In basal conditions:  * = p<0.05, ** = p<0.01 
In IFX conditions: * = p<0.05 when compared to basal condition  
** = p<0.01 when compared to basal condition  
Statistical analysis comparing HC and CD groups performed using unpaired t-test. 
Analysis of effects of IFX performed using one-way ANOVA with Dunnett’s multiple 
comparison test. 
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5.4.6   Cytokine profile in cell-free supernatant  
 
In addition to assessing ongoing LDC intracellular cytokine production, we also 
quantified the presence of cytokines in the cell-free supernatant following cell 
culture with and without IFX. In order to do this, we used a Th1/Th2/Th17 
Multiplex kit, which included TNFα, IFNγ, IL-2, IL-4, IL-6, IL-10 and IL-17a 
(figure 49).  
 
 
 
 
Figure 49. Cytokine concentrations in cell-free supernatant samples following 
culture of LDCs with and without IFX.  
Detection limits (pg/ml): IL-2=6.0, TNFα=5.2, IL-6=4.8, IFNγ=4.1, IL17a=3.0,  
IL-4=6.6, IL-10=3.9 
HC = healthy control, CD = active ileocolonic CD, ns = not significant  
Statistical analysis comparing HC and CD groups performed using unpaired t-test. 
Analysis of effects of IFX performed using one-way ANOVA with Dunnett’s multiple 
comparison test. 
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We had previously found ongoing TNFα and IL-6 production by LDCs to be lower 
when isolated from patients with active CD compared to HC (figure 48). However, 
when the same cytokines were studied in the cell-free culture supernatants we 
found significantly increased cytokine levels in the LDC cultures obtained from 
patients with active ileocolonic CD compared to HC (p=0.031 and p=0.033 
respectively). Having identified these differences between LDCs from HC and CD, 
we moved onto examine the effect of IFX on LDC cytokine profiles in HC and CD.  
 
The concentration of free TNFα is reduced with increasing concentration of IFX 
in the cell culture (1μg/ml p<0.05 with p<0.01 with 10 and 100μg/ml 
concentrations of IFX). A similar trend towards reduced concentration of free IL-
6 in the supernatant with increasing amounts of IFX added is also seen, but this 
did not reach statistical significance.    
 
There were no differences seen in concentrations of IL-4, IL-10 or IFNγ when 
comparing CD to HC or with the addition of IFX to the cell culture. However, 
there was a reduction in free IL-2 concentration in the cell culture samples from 
HC LDCs at the highest concentration of IFX (p<0.05).  
 
 
5.4.7   Correlation studies 
 
We set out to examine whether there was any correlation between LDC 
properties (including surface marker expression, ongoing cytokine production 
and cytokine secretion) and the demographical and/or clinical data collected on 
the patients and HC.  
 
Surface marker correlation data in patients with active ileocolonic CD 
We found a positive correlation between the IR of HLA DR expression on 
circulating LDCs and percentage expression of β7 with disease severity 
(measured by the HBI) in patients with active ileocolonic CD. Full correlation 
data is shown in table 15.  
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Clinical parameter  
Age 
 
 
 
(r value 
p value
) 
 
Years since 
diagnosis 
 
 
(r value 
p value
) 
 
HBI 
 
 
 
(r value 
p value
) 
 
Gender:  
 
 
 
% expression (mean ± SD) 
male; female; p value 
Homing marker 
IR = intensity ratio 
% = % expression 
 
HLA DR  
- IR 
 
r = -0.55 
ns
 
 
r = -0.31 
ns
 
 
r = +0.94 
p=0.01
 
 
37.8±3.6; 18.1±9.7; ns 
Beta7  
- % 
- IR 
 
r = -0.01 
ns
 
r = +0.69 
ns
 
 
r = +0.48 
ns 
r = +0.02 
ns
 
 
r = +0.84 
p=0.06
 
r = -0.14 
ns
 
 
64.4±2.9; 66.0±3.7; ns 
1.9±0.2; 2.1±0.3; ns 
CCR9 
- % 
- IR 
 
r = -0.85 
ns 
r = -0.34 
ns
 
 
r = -0.50 
ns 
r = -0.25 
ns
 
 
r = -0.02 
ns
 
r = -0.77 
ns
 
 
74.6±6.5; 76.1±2.7; ns 
5.4±0.2; 6.2±1.2; ns 
CCR4 
- % 
 
r = -0.55 
ns
 
 
r = -0.05 
ns
 
 
r = -0.26 
ns
 
 
39.9±19.6; 54.7±12.5; ns 
CCR8 
- % 
 
r = +0.01 
ns
 
 
r = -0.46 
ns
 
 
r = +0.47 
ns
 
 
90.7±3.0; 83.1±7.1; ns 
CCR10 
- % 
 
r = -0.62 
ns
 
 
r = -0.47 
ns
 
 
r = +0.73 
ns
 
 
22.0±8.0; 26.9±9.9; ns 
CCR5 
- % 
 
r = +0.06 
ns
 
 
r = +0.52 
ns
 
 
r = +0.51 
ns
 
 
41.8±22.6; 33.1±17.6; ns 
CCR7 
- % 
 
r = +0.39 
ns
 
 
r = -0.01 
ns
 
 
r = -0.34 
ns
 
 
52.3±17.7; 54.9±14.6; ns 
TLR2 
- % 
 
r = -0.23 
ns
 
 
r = -0.21 
ns
 
 
r = -0.13 
ns
 
 
56.5±25.6; 22.5±17.9; ns 
TLR4 
- % 
 
r = +0.24 
ns
 
 
r = -0.27 
ns
 
 
r = +0.14 
ns
 
 
34.8±29.3; 23.9±21.3; ns  
CD40 
- % 
 
r = -0.32 
ns
 
 
r = +0.14 
ns
 
 
r = -0.08 
ns
 
 
68.9±13.7; 72.7±3.3; ns 
CD80 
- % 
 
r = +0.21 
ns
 
 
r = +0.59 
ns
 
 
r = -0.60 
ns
 
 
13.4±1.9; 30.0±13.0; ns 
 
Table 15. Correlation studies between low density cell surface marker expression 
and clinical parameters in patients with active ileocolonic CD. Statistical analysis of 
age, years since diagnosis and HBI was performed using Pearsons correlation. 
Correlations in gender were performed using unpaired t-test.  
 
185 
 
Surface marker correlation data in healthy control subjects 
No correlations were seen between surface marker expression and the age and 
gender of HC subjects, as shown in table 16.  
 
Clinical parameter Age 
(r value p value) 
Gender:  
% expression (mean ± SD) 
male; female; p value 
Homing marker 
IR = intensity ratio 
% = % expression 
HLA DR  
- IR 
 
r = -0.59 ns 
 
31.2±11.6; 33.2±26.0; ns 
Beta7  
- % 
- IR 
 
r = +0.01 ns 
r = -0.54 ns 
 
53.0±6.1; 48.7±9.3; ns 
1.8±0.3; 2.1±0.4; ns 
CCR9 
- % 
- IR 
 
r = -0.66 ns 
r = -0.32 ns 
 
69.4±5.9; 63.1±12.2; ns 
4.9±0.7; 5.2±0.8; ns 
CCR4 
- % 
 
r = -0.63 ns 
 
61.2±2.0; 53.7±2.5; ns 
CCR8 
- % 
 
r = +0.11 ns 
 
85.6±3.5; 63.9±26.8; ns 
CCR10 
- % 
 
r = -0.36 ns 
 
47.4±10.0; 25.0±4.7; ns 
CCR5 
- % 
 
r = +0.52 ns 
 
24.0±16.1; 54.8±5.6; ns 
CCR7 
- % 
 
r = -0.02 ns 
 
59.4±6.9; 63.2±8.6; ns 
TLR2 
- % 
 
n/a 
 
n/a 
TLR4 
- % 
 
n/a 
 
n/a 
CD40 
- % 
 
r = -0.37 ns 
 
70.9±7.9; 71.6±7.0; ns 
CD80 
- % 
 
r = +0.66 ns 
 
35.9±20.2; 56.4±18.5; ns 
 
Table 16. Correlation studies between low density cell surface marker expression 
and clinical parameters in healthy control subjects. Statistical analysis of age was 
performed using Pearsons correlation. Correlations in gender were performed 
using unpaired t-test.   
n/a = expression of surface marker falls below the detection limit in >80% of data 
points. 
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Ongoing intracellular cytokine production correlation data in patients with 
active ileocolonic CD 
We found that the amount of ongoing production of IL-6 by LDCs positively 
correlated with disease severity and HBI in patients with active CD. There was a 
negative correlation between ongoing production of TGFβ and the age of CD 
patients recruited (table 17). 
 
Clinical parameter Age 
 
 
 
(r value p value) 
Years since diagnosis 
 
 
(r value 
p value
) 
HBI 
 
 
 
(r value p value) 
Gender:  
 
 
 
% expression (mean ± SD) 
male; female; p value 
Cytokine 
 
 
 
TNFα 
 
 
r = -0.70 
ns
 
 
r = -0.51 
ns
 
 
r = +0.53 
ns
 
 
62.1±2.2; 65.3±3.0; ns 
 
TGFβ 
 
r = -0.94 p=0.01 
 
 
r = -0.67 ns 
 
 
r = +0.27 ns 
 
 
55.6±8.3; 56.5±6.1; ns 
 
IL-6 
 
r = -0.33 ns 
 
 
r = -0.38 ns 
 
 
r = +0.89 p=0.04 
 
 
62.6±2.1; 60.9±4.2; ns 
 
IL-10 
 
 
r = +0.37 ns 
 
r = +0.57 ns 
 
r = -0.37 ns 
 
52.9±31.0; 69.0±4.8; ns 
 
IL-12 
 
 
r = -0.67 ns 
 
r = -0.30 ns 
 
r = -0.41 ns 
 
57.3±4.9; 66.8±5.1; ns 
 
IL-15 
 
 
r = +0.12 ns 
 
r = -0.36 ns 
 
r = -0.24 ns 
 
68.9±11.0; 71.3±7.0; ns 
 
Table 17. Correlation studies between ongoing intracellular cytokine production by 
low density cells and clinical parameters in patients with active ileocolonic CD. 
Statistical analysis of age, years since diagnosis and HBI was performed using 
Pearsons correlation. Correlations in gender were performed using unpaired t-test.   
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Ongoing intracellular cytokine production correlation data in healthy 
control subjects 
No correlations were seen between ongoing cytokine production by circulating 
LDCs from HC subjects and age and gender of those subjects, as displayed in 
table 18. 
 
Clinical parameter Age 
 
 
 
(r value p value) 
Gender:  
 
 
 
% expression (mean ± SD) 
male; female; p value 
Cytokine 
 
 
 
TNFα 
 
 
r = -0.13 ns 
 
83.1±2.8; 72.6±6.9; ns 
 
TGFβ 
 
r = -0.03 ns 
 
 
52.7±9.3; 56.2±3.1; ns 
 
IL-6 
 
r = +0.04 ns 
 
 
83.4±4.5; 75.4±3.6; ns 
 
IL-10 
 
 
r = +0.67 ns 
 
74.5±5.0; 81.3±2.7; ns 
 
IL-12 
 
 
r = -0.48 ns 
 
50.7±10.4; 49.3±22.7; ns 
 
IL-15 
 
 
r = +0.09 ns 
 
82.3±3.7; 72.6±7.5; ns 
 
Table 18. Correlation studies between ongoing intracellular cytokine production by 
low density cells and clinical parameters in healthy control subjects. Statistical 
analysis of age was performed using Pearsons correlation. Correlations in gender 
were performed using unpaired t-test.   
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Cell-free supernatant cytokine concentration correlation data in patients 
with active ileocolonic CD 
There were no correlations between the cell-free cytokine concentrations 
following culture of LDCs from patients with active CD and patient 
demographical and clinic parameters, as shown in table 19. The concentration of 
three of the studied cytokines fell below detection limits (IFNγ, IL-4 and IL-17a) 
and therefore correlation analysis on these cytokines was not performed.   
 
Clinical parameter Age 
 
 
 
(r value p value) 
Years since 
diagnosis 
 
 
(r value p value) 
HBI 
 
 
 
(r value p value) 
Gender:  
 
 
concentration, pg/ml (mean±SD) 
male; female; p value 
Cytokine 
 
 
 
TNFα 
 
 
r = +0.17 ns 
 
r = +0.23 ns 
 
r = -0.07 ns 
 
12.9±1.2; 14.3±4.6; ns 
 
IFNγ 
 
n/a 
 
 
n/a 
 
n/a 
 
n/a 
 
IL-2 
 
r = +0.34 ns 
 
 
r = +0.76 ns 
 
 
r = +0.51 ns 
 
 
6.7±0.7; 20.4±13.3; ns 
 
IL-4 
 
 
n/a 
 
 
n/a 
 
 
n/a 
 
 
n/a 
 
 
IL-6 
 
 
r = +0.38 ns 
 
r = +0.45 ns 
 
r = +0.27 ns 
 
39.1±2.4; 28.9±10.1; ns 
 
IL-10 
 
 
r = +0.30 ns 
 
r = -0.84 ns 
 
r = +0.44 ns 
 
6.4±0.3; 7.6±1.2; ns 
 
IL-17a 
 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
Table 19. Correlation studies between cell-free supernatant cytokine concentration 
and clinical parameters in patients with active ileocolonic Crohn’s disease. 
Statistical analysis of age, years since diagnosis and HBI was performed using 
Pearsons correlation. Correlations in gender were performed using unpaired t-test.   
n/a = Cytokine concentration falls below the detection limit in >80% of data points. 
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Cell-free supernatant cytokine concentration correlation data in healthy 
control subjects 
There were no correlations between the cell-free cytokine concentrations 
following culture of LDCs from HC and age/gender of HC, as shown in table 20. 
Again, the concentration of IL-4 and IL-17a fell below detection limits and 
therefore correlation analysis on these cytokines was not performed.   
 
Clinical parameter Age 
 
 
 
(r value p value) 
Gender:  
 
 
concentration, pg/ml (mean±SD) 
male; female; p value 
Cytokine 
 
 
 
TNFα 
 
 
r = +0.40 ns 
 
7.4±1.3; 6.7±1.5; ns 
 
IFNγ 
 
r = -0.40 ns 
 
 
4.7±0.3; 6.0±1.9; ns 
 
IL-2 
 
r = +0.60 ns 
 
 
18.6±6.7; 30.1±22.3; ns 
 
IL-4 
 
 
n/a 
 
 
n/a 
 
IL-6 
 
 
r = -0.19 ns 
 
15.8±4.3; 8.8±1.1; ns 
 
IL-10 
 
 
r = -0.47 ns 
 
10.6±2.3; 10.4±3.4; ns 
 
IL-17a 
 
 
n/a 
 
n/a 
 
Table 20. Correlation studies between cell-free supernatant cytokine concentration 
and clinical parameters in healthy control subjects. Statistical analysis of age, years 
since diagnosis and HBI was performed using Pearsons correlation. Correlations in 
gender were performed using unpaired t-test.   
n/a = Cytokine concentration falls below the detection limit in >80% of data points. 
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5.4.8   Summary of results 
 
Differences between LDCs from patients with active CD compared to HC: 
 Increased β7 expression on LDCs from patients with active CD 
 
 Reduced ongoing production of TNFα and IL-6 in LDCs isolated from 
patients with active CD, but increased levels of the same cytokines (TNFα 
and IL-6) in the cell-free culture supernatant.  
 
Effect of IFX on LDC phenotype: 
 Reduced gut-homing affinity of LDCs from patients with active ileocolonic 
CD when cultured with IFX, as shown by reduction in β7 expression and 
reduction in intensity ratio of CCR9 on positive cells.  
 
 Trend towards reduced TLR2 and 4 expression on LDCs cultured with IFX 
in a dose-dependent fashion (p=ns).   
 
Effect of IFX on ongoing cytokine production and secretion: 
 Increased production of IL-12 by LDC (HC) cultured with IFX.  
 
 Reduction of TNFα (CD and HC) and IL-2 (HC) in the cell-free supernatant 
when cultured with IFX. Possible trend towards reduced IL-6 (CD) in 
supernatant with IFX (p=ns).   
 
Correlation studies 
 β7 expression, IR of HLA DR and ongoing production of IL-6 on LDCs from 
patients with active ileocolonic CD all display positive correlation with 
disease severity (as measured by HBI). 
 
 Negative correlation between ongoing production of TGFβ and the age of 
patients with active CD. 
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5.5  Discussion 
 
The study of human DCs is difficult due to low numbers of DCs in human samples 
and the absence of a single marker on DCs to allow for identification. In order to 
study the effect of IFX on the phenotype and cytokine profile of circulating DCs in 
CD and HC in vitro, our first challenge was to obtain a cell population which 
would accurately represent DCs in human blood. As previously discussed, our 
laboratory does not have access to a flow sorter and magnetic sorting was not 
possible due to lack of optimisation of the methods involved in this process. 
Other studies on blood DCs have utilised MoDCs, however this approach to study 
homing marker expression would yield inaccurate results, due to homing marker 
depletion that occurs during the 5-day culture required to produce MoDC 
(Bernardo, Mann et al. 2013).     
 
LDCs are highly enriched for DCs, with the majority of the cell population 
displaying DC phenotype (HLA DR+, CD11c+, CD83+, CD86+) and morphology at 
both optical and electron microscopy (Knight, Farrant et al. 1986). Isolating LDCs 
from human blood does involve a period of culture (24 hours) and therefore 
LDCs are more mature than DCs which have been identified as part of a PBMC 
population. Despite this, the LDC population enables us to perform in vitro 
experiments with a physiologically representative DC model.  
 
Differences between LDC phenotype and cytokine profile from patients 
active CD and HC 
 
LDCs from patients with active CD had elevated β7 expression compared to HC. 
In these experiments, positive expression of β7 is taken to represent α4β7 
integrin expression on cells, although this has already been identified as a 
limitation in the methodology (section 1.2.11). There was also a trend towards 
increased CCR9 expression in CD, but this did not reach statistical significance. 
This is consistent with the results from chapter 3, in which circulating DCs 
isolated from patients with active colonic CD had increased β7 expression (figure 
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20, section 3.4.3.1) those from patients with active SB CD had increased CCR9 
expression (figure 23, section 3.4.3.4) compared to HC. This indicates that the DC 
enrichment protocol has worked as the phenotype of LDCs from patients with 
active CD appears to mirror the phenotype of fresh circulating DCs.    
 
The patients with active CD recruited for this part of the study all had ileocolonic 
disease, hence up regulation of both β7 and CCR9. Unfortunately, the relative 
anatomical burden of disease (small bowel versus colonic) in each subject at the 
time of recruitment was not measurable. It is possible that this patient cohort 
had increased colonic inflammation compared to SB inflammation, which may 
account for the relatively increased ratio of β7:CCR9 expression compared to HC, 
but this is impossible to know.    
 
There was a trend towards increased expression of both TLR2 and TLR4 on LDCs 
from patients with active CD compared to HC. This did not reach statistical 
significance, although this is likely due to small sample size. The upregulation of 
TLR expression in active CD has previously been demonstrated in intestinal DC 
isolated from patients with active CD (Hart, Al-Hassi et al. 2005), likely leading to 
increased recognition of bacterial products and an enhanced response to them. 
Conversely, CD80 expression and the IR of HLA DR appeared to be reduced on 
LDCs from patients with active CD compared to HC (p=ns). Although surprising, 
this finding may be a reflection on the active recruitment of more mature 
circulating LDCs to the intestinal sites of inflammation in CD, leaving the 
immature LDCs in the circulation. This hypothesis could be further tested by 
performing the same phenotypic studies on paired blood and tissue (gut) 
samples from patients with active CD.  
 
Upregulation of TLR expression on LDCs in CD may be secondary to the presence 
of inflammatory factors in the diseased state. Studies have shown that the 
presence of pro-inflammatory cytokines such as TNFα, IL-6 and IFNγ can cause 
increased expression of TLR2 and 4 (Martins, Kallas et al. 2003). In addition, 
bacterial products may act directly via TLRs to upregulate further TLR 
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expression on DCs, as previously demonstrated in patients with UC (Hausmann, 
Kiessling et al. 2002). Increased levels of intestinal permability in CD may lead to 
greater exposure of DCs to microbial products and the subsequent bacterially-
driven increased TLR expression.   
 
LDCs isolated from patients with active CD had reduced ongoing production of 
TNFα and IL-6 compared to those from HC, but that the levels of the same two 
cytokines were increased in the cell-free supernatant. These two cytokines are 
integral in the pathogenesis of CD (Th1 and Th17 pathways respectively). The 
relationship between these two cytokines in terms of ongoing production versus 
content in the supernatant is an interesting finding and may be the result of two 
possible explanations.  
 
 Firstly, the method in which ongoing production of the cytokines is 
quantified may be relevant. The monensin method is a way of assessing 
ongoing intracellular cytokine production in the absence of external 
stimuli. The benefit of this is that no additional stimuli or molecules need 
to be added to the cells in order to obtain results, and therefore the 
results are not affected by any other extrinsic factor(s). However, the 
ongoing production of cytokines is measured after 24 hours of incubation, 
and therefore you obtain a 4 hour ‘snapshot’ of intracellular cytokine 
production after a substantial period of cell culture. The cells have been 
producing cytokines throughout that whole period, and this likely 
explains the elevated levels of TNFα and IL-6 in the CD supernatants. As a 
result of the culture period, it may be that the stimulating factors 
resulting in the pro-inflammatory LDC activity are reducing and therefore, 
the ongoing production of these cytokines is subsequently falling. Future 
experiments may address this hypothesis by repeated assessments of 
ongoing intracellular cytokine production and cell-free supernatant 
cytokine concentrations at multiple time points during the cell culture 
process (for example 2hrs, 4hrs, 6hrs etc until 24hrs post-initiation of cell 
culture).  
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 Another possibility may be a negative feedback mechanism whereby the 
elevated extracellular levels of TNFα and IL-6 are exerting a negative 
feedback on their own ongoing intracellular production. One study has 
shown that NKT-produced Th1/Th2 cytokine balance to be maintained 
under the control of a negative feedback loop through DCs, with Th1 
cytokine-pretreated DCs mainly inducing Th2 cytokine production and 
Th2 cytokine-pretreated DCs inducing Th1 cytokine production by 
stimulated NKT-cells (Onoe, Yanagawa et al. 2007). This type of negative 
feedback loop may be amplified in in vitro conditions due to the physical 
restrictions placed on the cells (ie the cells remain in 1ml volume 
throughout the culture period). Further work would be necessary to 
ascertain if this is the case.    
 
  
Effect of IFX on LDC phenotype 
 
Following 24 hours of in vitro LDC culture with the various test doses of IFX, 
there were significant changes in the phenotype of the LDCs. There was a 
stepwise reduction in expression of β7 as well as a similar reduction in the 
intensity ratio of CCR9 expression on positive cells. Changes in β7 expression 
and CCR9 IR were only seen in LDC from patients with active CD, apart from the 
maximum concentration of IFX, where we saw reduced CCR9 IR in LDCs from HC 
as well. This effect was not seen in the previous chapter when culturing PBMCs 
with IFX and assessing homing marker expression on a gated (HLA DR+, lineage 
cocktail-) DC population, and may be a reflection on LDCs comprising a different 
population of APCs than DCs isolated as part of PBMC population.   
 
The significance of this change in homing marker expression is a reduced gut-
homing affinity of LDCs from patients with active CD following culture with IFX, 
and the impression that the phenotype of these LDCs is becoming more ‘normal’, 
ie returning to a phenotype similar to that of LDCs from HC. Directing the pro-
inflammatory LDCs away from the gut may represent one mechanism of action of 
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IFX, albeit the effect was only studied in in vitro conditions in these experiments. 
It remains unclear if this effect is a direct result of the action of IFX on LDCs 
themselves or an indirect action via other molecules, such as cytokines. This 
hypothesis is further supported by our observation that the ongoing intracellular 
production of cytokines by LDCs and the cytokine milieu in cell-free supernatant 
samples were altered following culture with IFX.  
 
 
Effect of IFX on LDC cytokine profile   
 
There was increased ongoing production of IL-12 by LDCs from HC subjects 
following the addition of IFX to the culture (not observed with LDCs from active 
CD patients). It seems strange that the addition of IFX would cause greater 
production of IL-12 (a Th1 cytokine) by LDCs. However, there is ample evidence 
that TNFα blockade can cause upregulation of other pro-inflammatory pathways 
and cytokines in the literature. Notley et al. examined the effect of TNFα 
blockade on Th1 and Th17 cells in mice with collagen-induced arthritis (Notley, 
Inglis et al. 2008). The TNFα blockade was achieved using murine p75 TNFR-Fc 
or anti-mouse TNFα monoclonal antibodies. The authors found expanded 
populations of both Th1 and Th17 cells in the periphery, but also an 
improvement in joint inflammation. Additional experiments demonstrated that, 
while the numbers of Th1 and Th17 cells had increased, these were located 
mainly in the lymph nodes and did not accumulate in the joints, hence the 
improvement in arthritis. This may explain, to some extent, upregulation of IL-12 
by LDCs following TNFα blockade.  
 
In the cell-free CD LDC culture supernatant, we found a stepwise reduction in 
free TNFα with increasing doses of IFX (figure 49, section 5.4.6). Studies in CD 
have shown an increased number of lamina propria sTNF-producing cells and 
high concentrations of sTNF can be detected in the stool of patients with active 
inflammatory responses (Braegger, Nicholls et al. 1992; Breese and MacDonald 
1995). As with the other commercially available anti-TNFα antagonists, IFX is 
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known to effectively neutralise the bioactivity of sTNF. In light of the fact that we 
have shown there is no effect of IFX on ongoing intracellular TNFα production by 
LDCs in vitro, direct neutralisation of free TNFα in the cell-free supernatant by 
IFX is the likely explanation for this finding, and also explains the dose-
dependent effect observed.  
 
There were lower levels of TNFα seen in the cell-free supernatant from HC LDCs. 
And a further reduction in TNFα was observed following culture with IFX at the 
higher concentrations (p<0.05). Data suggests that there are differences in the 
sTNF neutralisation potency of IFX depending on the concentration of sTNF 
present, which might have important consequences in vivo. At high 
concentrations of sTNF (>2ng/ml, as measured in inflamed tissues in CD) (Van 
Deventer 1997), the potency of IFX was high (comparable with adalimumab and 
etanercept). However, at low sTNF concentrations (≈0.1ng/ml), the potency of 
IFX falls to levels equivalent to adalimumab, but 20 fold less potency than 
etanercept. This may explain the differences in reduction of TNFα with IFX 
between the active CD group and HC seen in the cell free supernatants.  
 
The concentration of IL-2 in the cell-free supernatant was also reduced in both 
CD and HC groups following culture with IFX in a dose-dependent way, although 
statistical significance was only achieved at the highest concentration of IFX in 
the HC group. Studies have shown that anti TNFα therapy has a broad impact on 
the immune system that exceeds the blockade of TNFα itself. One study, using 
CD45RB high T-cell transfer model of colitis, demonstrated that – in addition to 
inducing a marked improvement in colonic inflammation – anti-TNFα therapy 
down regulated IL-2 and IFNγ secretion by lamina propria T-cells, as well as 
significantly decreasing expression of IL-23p19 and IL-17 in the inflamed colon 
(Liu, Jiu et al. 2007).  
 
Early production of IL-2 by LDCs is essential for the development of an IFNγ-
secreting Th1 response and therefore very relevant in the pathogenesis of CD. 
The reduction in concentration of IL-2 that we observed in the cell-free 
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supernatant may be the result of ‘reverse signaling’ of IFX on LDCs, whereby 
binding of IFX to tmTNF causes suppression of pro-inflammatory cytokine 
production (in addition to reduced cell activation and upregulation of adhesion 
molecules). Further studies are required to investigate whether this is the case.   
 
 
Correlation studies  
 
We identified positive correlations between the intensity ratio of HLA DR 
expression, percentage expression of β7 and ongoing production of IL-6 by LDCs 
with disease severity (HBI). Greater IR of HLA DR and production of IL-6 implies 
LDCs have greater immunogenic potential and therefore are likely to lead to 
greater T-cell stimulation in more severe disease. Higher expression of β7 in 
severe disease implies a greater gut-homing potential of LDCs. The HBI is 
predominately a measure of luminal disease activity in CD, and therefore these 
two findings appear to match the clinical patient parameters. Indeed, we have 
also shown in this chapter that percentage expression of β7 on LDCs and the 
quantity of IL-6 in culture supernatants are reduced following the addition of IFX 
to cell cultures in a dose-dependent manner. This adds further weight to the 
importance of these molecules in CD.      
 
Previous studies have shown that age-related changes in the immune system 
contribute to increased susceptibility of elderly people to infection, vaccine 
failure and possibly autoimmunity and cancer (Pawelec 1999; Targonski, 
Jacobson et al. 2007). The effect of ageing on DC function specifically is still not 
fully understood. While in vitro generated MoDCs from elderly subjects are 
functionally intact regarding differentiation and maturation (Steger, Maczek et al. 
1996), they have been shown to have reduced ability for micropinocytosis and 
phagocytosis of apoptotic cells when compared to those from younger subjects 
(Agrawal, Agrawal et al. 2007). These two functional deficits are likely to 
contribute to reduced antigen uptake, and may also affect antigen processing and 
presentation by DCs, leading to an overall reduction in effective T-cells responses 
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in ageing (Weiskopf, Weinberger et al. 2009). Furthermore, CD40 and CD40L 
expression (co-stimulatory molecule and ligand, essential for efficient T-cell 
stimulation by DCs) are reduced in ageing and therefore the CD40-CD40L 
pathway becomes dysfunctional with age (Fernandez-Gutierrez, Jover et al. 
1999). We found a negative correlation between CD40 expression on LDCs and 
age, but this was non-significant.  
 
Finally, our data revealed a negative correlation between ongoing production of 
TGFβ by LDCs and age in patients with active CD. This correlation was not seen 
in the HC cohort. This raises the possibility of the phenomenon of 
immunosenescence affecting patients with CD to a greater extent than HC due to 
the disease state. Another possibility is that LDCs producing greater quantities of 
TGFβ have already been recruited to the inflamed tissue in patients with active 
CD. It is likely that greater patient numbers in future studies may reveal further 
correlations between LDC markers and cytokine production with age.  
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Chapter 6 
 
 
The effect of infliximab pre-treated human blood-
enriched dendritic cells from patients with active 
Crohn’s disease and healthy controls on subsequent 
human T-lymphocyte phenotype and cytokine 
production 
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6.1  Abstract 
 
Introduction 
DCs play a key role in discriminating between commensal microorganisms and 
potentially harmful pathogens. Expression of surface markers and cytokine 
production by DCs at the time of antigen presentation control T-cell 
differentiation, cytokine profile and homing properties imprinted on stimulated 
T-cells. This process defines the type of immune response that occurs 
(regulatory/inflammatory) and its anatomical location. In CD, dysregulation of 
the immune response to gut microbiota and aberrant immune cell trafficking 
play a central role in disease pathogenesis. IFX is a widely used and effective 
treatment for CD, but its precise mechanism of action is unclear.  
 
In this study, we investigated the effect of IFX pre-treated blood-enriched DCs, 
isolated from patients with active Crohn’s disease and healthy control subjects, 
on human T-cell proliferation, phenotype and cytokine content. 
 
Methods 
LDCs, which are enriched for DCs, were obtained following Ficoll and Nycoprep 
gradient separation of fresh blood obtained from patients with active ileocolonic 
CD (HBI≥7) and HC. LDCs were cultured (0.5x106cells/ml) with IFX (1μg/ml, 
10μg/ml, 100μg/ml & basal) for 24 hours.  
 
T-cells were enriched from allogeneic HC blood by negative immunomagnetic 
bead separation, selecting CD3+ cells, and labelled with CFSE. LDCs were added 
to T-cells in complete medium (400,000cells/ml) at basal, 1%, 2% and 3% 
concentrations and incubated for 5 days.   
 
Following incubation, T-cell proliferation, expression of β7 & CLA surface 
homing markers and intracellular cytokine content of stimulated T-cells (TNFα, 
TGFβ, IFNγ, IL-10, IL-15 and IL-17) was quantified by flow cytometry on 
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stimulated T-cells. Unparied t-test, one-way and two-way ANOVA statistical 
analysis with Dunnett’s multiple comparisons tests were applied.  
 
Results 
In basal conditions, LDCs from HC and CD patients did not differ in their 
stimulatory capacity for allogeneic T-cells or in the cytokine profile acquired by 
T-cells. However, T-cells stimulated by LDCs from CD patients increased β7 
intensity ratio (p<0.05).  
 
Following culture with IFX, LDCs decreased their stimulatory capacity in a dose-
dependent, stepwise fashion in both HC and CD (p<0.001 in both conditions).  
 
Culture with IFX did not have any effect on the acquired homing profile of 
stimulated T-cells, although these T-cells had a trend (p=ns) towards lower 
TNFα and higher IL-17 content when stimulated by LDCs from CD patients.  
 
Conclusions 
The marked reduction in the ability of LDC to stimulate T-cells following culture 
with IFX represents one plausible explanation for the efficacy of anti-TNFα 
therapies in the treatment of CD. This effect was dose-dependent (within our 
range of test concentrations) suggesting that higher doses of IFX further reduce 
T-cell stimulation and may provide one explanation of the clinical benefits of 
dose escalation in refractory CD.  
 
This abstract was presented at BSG and ECCO conferences 2013 and subsequently published in Gut 
and JCC journals with the following references. Permissions to reprint abstract in Appendix, section 
10.2 and 10.3 respectively.  
 
The effect of infliximab pre-treated human blood-enriched dendritic cells from patients with 
active Crohn’s disease and healthy controls on subsequent human T-lymphocyte phenotype and 
cytokine production in vitro 
Peake ST, Bernardo D, Mann ER, Landy J, Al-Hassi HO, Knight SC, Hart AL 
Gut 2013; 62: A253-A254 
JCC 2013; 7(1): S150 
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6.2  Introduction 
 
Intestinal DCs are constantly sampling the luminal microenvironment of the gut 
for antigenic material. Once an antigen is detected, it is processed within the 
endoplasmic reticulum of the DC to form a small peptide that is subsequently 
presented on MHC class II molecules to lymphocytes in the mesenteric lymph 
nodes. In order to migrate to the draining mesenteric lymph nodes, DCs undergo 
a process of maturation as previously described in section 1.2.6.  
 
Circulating naïve T-cells express high levels of L-selectin and CCR7 that allow 
them to enter secondary lymphoid tissue through interactions with their ligands  
(L-selectin ligand and CCL21 respectively) on endothelial vessels (Cyster 1999). 
The end result of this process is a high concentration of naïve T-cells in lymphoid 
tissue, awaiting presentation of antigenic material by DCs. 
 
These interactions between DCs and lymphocytes regulate several aspects of the 
immune response. DCs have several roles in this respect; to activate and imprint 
antigen specificity on the lymphocyte and also to direct lymphocytes to the site 
where the antigen is most likely to be encountered by (tissue-specificity). 
Lymphocyte priming by intestinal DCs in mucosal tissue increases the expression 
of the two main gut-homing markers, α4β7 and CCR9 (Stagg, Kamm et al. 2002; 
Mora, Bono et al. 2003). Expression of α4β7 and CCR9 by mucosal lymphocytes 
also requires the presence of retinoic acid.  
 
Furthermore, DCs determine the nature of the immune response. Early 
production of IL-2 is essential for the development of an IFNγ-secreting Th1 
response, whereas production of IL-1, IL-6 and IL-23 will drive a Th17 response. 
Antigen presentation taking place in the presence of IL-10 or TGFβ will lead to 
the induction of regulatory T-cells with an anti-inflammatory phenotype. 
Retinoic acid – in addition to being required for imprinting of gut-homing 
receptors of lymphocytes – can also synergise with TGFβ to induce T-cells with a 
regulatory phenotype and gut-homing properties (Coombes, Siddiqui et al. 2007).    
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The process of lymphocyte priming in lymphoid tissue includes changes in 
lymphocyte homing phenotype. Activated effector lymphocytes down-regulate 
CCR7 and L-selectin expression and up-regulate markers required for migration 
to target tissues.  
 
 
6.2.1   Hypothesis and Aims 
 
Hypothesis 
 
We hypothesised that LDCs pulsed with IFX would have a reduced T-cell 
stimulatory capacity, and that the reduction in stimulation would correlate with 
the concentration of IFX used during LDC culture. Furthermore, we hypothesised 
that there would be dysregulated T-cell phenotype and cytokine content 
following stimulation by IFX-pre-treated LDCs.   
 
Aims 
 
 To identify changes in the stimulatory capacity of LDCs following pre-
treatment with IFX.   
 
 To identify changes in T-cell phenotype and cytokine content following 
stimulation by IFX-pre-treated LDCs.  
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6.3  Methods 
 
6.3.1   Isolation of allogeneic T-cells 
 
In order to assess the stimulatory capacity of IFX-pre-treated LDCs and the effect 
of these cells on T-cell phenotype and cytokine profile, LDCs (the ‘stimulators’) 
were incubated with allogeneic T-cells (the ‘responders’) in a mixed leukocyte 
reaction (MLR).  
 
PBMCs were obtained from a healthy control, as previously described in section 
2.3.1, and re-suspended in 0.5ml of MiniMACS buffer (sterile PBS containing 
0.5% BSA and 2mM EDTA). The cells were then labelled with anti-CD14, anti-
HLA DR and anti-CD19 immunomagnetic beads (30μl each) on ice for 20 minutes.  
 
Cells were then washed twice with miniMACs buffer and passed through the 
magnetic cell sorting system (VarioMACSTM Separation System, Miltenyi Biotech, 
Bisley, UK), followed by 4ml of miniMACs buffer at 4°c. The resultant solution is 
depleted of CD19+, CD14+ and HLA DR+ cells. In order to increase T-cell purity, a 
new depletion column was setup and the T-cell solution was run through the 
column for a second time.  
 
The final solution has a CD3+ T-cell purity of >98% (Bernardo, Al-Hassi et al. 
2012). The cells were washed twice in cold PBS at 4°c and re-suspended in 3ml 
PBS. The enriched T-cell solution is then labelled with carboxyfluorescin 
diacetate succinimidyl ester (CFSE) to permit quantification of T-cell 
proliferation following the MLR process.  
 
A trypan blue cell count was then performed to determine the T-cell 
concentration. Once the cell count was known, the solution was further diluted 
with complete medium, to give a final concentration of 4 million T-cells/ml.  
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6.3.2   Mixed leukocyte reaction 
 
0.5x106 stimulator cells (LDCs) per ml were cultured with the different test 
concentrations of IFX in 1ml complete medium for 24 hours. LDCs in complete 
medium only served as a control. Following the 24-hour culture period, the 
stimulator cells were washed twice in complete medium to remove any traces of 
IFX from the solution.  
 
The CFSE-labelled responder T-cells were plated out in a 96-well round bottom 
plate at a concentration of 400,000 cells in 200µL complete medium. The 
stimulator cells were added at 1% (4000 LDCs), 2% (8000 LDCs) and 3% 
(12,000 LDCs) concentrations and each well was made up to 200μl total volume 
with complete medium. Negative control tubes contained T-cells with 200µL of 
complete medium, without LDCs. 
 
After 5 days culture at 37°c, 5% CO2 and high humidity, cells were recovered and 
T-cell proliferation, phenotype and cytokine content was analysed by flow 
cytometry.       
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6.3.3   Quantification of T-cell proliferation 
 
Prior to the MLR process, all responder T-cells were labelled with CFSE (figure 
50).  Dividing T-cells were identified by the dilution in CFSE staining intensity, 
therefore allowing for quantification of T-cell proliferation.  
 
 
 
Figure 50. Quantification of T-cell proliferation. A) Two-parameter FSC:SSC 
histogram with region R1 identifying all viable PBMCs negative for HLA DR, CD14 
and CD19 expression. B) One-parameter histogram gated on region R1 identifying 
all CD3+ cells (region R2). C) A one-parameter histogram gated on regions 1 and 2 
identifying cells that are negative for CFSE staining and therefore have undergone 
cell division following stimulation by LDCs (region R3).  
 
 
6.3.4   Statistical analysis 
 
T-cell proliferation was analysed using two-way analysis of variance (2-way 
ANOVA) with Dunnett’s multiple comparison test.  
 
Differences in T-cell phenotype and cytokine profile between HC and CD was 
analysed using unpaired t-test. The effect of IFX on phenotype and cytokine 
profile was analysed using one-way ANOVA with Dunnett’s multiple comparison 
test.  
 
P values of <0.05 were considered statistically significant in all cases.  
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6.4  Results 
 
6.4.1   Patient characteristics 
 
Samples from healthy control subjects (n=4) and patients with active ileocolonic 
CD (HBI ≥ 7) (n=3) were obtained. These were the same individuals as used in 
the previous chapter. Demographic and clinical data is shown in table 21.  
 
Case 
number 
Gender Age Years since 
diagnosis 
CD location HBI Current 
medications 
1 Female 27 2 Ileocolonic 11 6-MP 
2 Male 31 4 Ileocolonic 12 AZA 
3 Female 66 7 Ileocolonic 10 AZA 
4 Male 34 - HC - - 
5 Female 35 - HC - - 
6 Female 33 - HC - - 
7 Male 47 - HC - - 
 
Table 21. Patient characteristics and demographical data.  
HC = Healthy control subject, 6-MP = 6-Mercapopurine, AZA = Azathioprine 
 
Inclusion / exclusion criteria were applied for all patient recruitment, as outlined 
in section 2.2.2. 
 
 
6.4.2   T-cell stimulation 
 
LDCs from HC and patients with active CD stimulated and led to proliferation of 
the allogeneic responder T-cells in the MLR experiment (figure 51). In all 
conditions, the percentage of proliferating T-cells increases as the concentration 
of stimulating LDCs added increases.  
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There is a stepwise reduction in the stimulatory capacity of LDCs with increasing 
concentrations of IFX added to the LDC culture. This trend is apparent in both HC 
and active CD conditions. Statistical significance was achieved at several points 
regarding this trend, as shown below in figure 51.   
 
 
Figure 51. Stimulatory capacity of LDCs following pre-treatment with IFX in HC 
and active CD. Concentrations of IFX used in LDC culture shown in coloured key. 
A) LDCs isolated from HC (n=4).  
1μg/ml IFX: p=ns 
10μg/ml: p<0.05 at 2% LDC; p<0.01 at 3% LDC 
100μg/ml: p<0.05 at 1% LDC; p=ns at 2% LDC; p<0.001 at 3% LDC 
B) LDCs isolated from patients with active ileocolonic CD (n=3). 
1μg/ml and 10μg/ml IFX: p=ns 
100μg/ml: p<0.05 at 1% LDC; p=ns at 2% LDC; p<0.001 at 3% LDC 
Statistical analysis performed using two-way ANOVA with Dunnett’s multiple 
comparison test. 
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There was no statistically significantly difference in T-cell proliferation between 
LDCs from HC compared to those from patients with active CD. Figure 51 
appears to show increased T-cell proliferation with LDCs from HC compared to 
CD, however this appearance is the result of one outlying LDC sample in the HC 
cohort which did indeed show a very high stimulatory capacity. This may be the 
result of a wide difference in HLA profile of this HC subject and the donor of the 
allogeneic T-cells in this particular case, which has led to increased T-cell 
stimulation.      
 
 
6.4.3   Phenotype of stimulated T-cells  
 
To examine the phenotype of stimulated T-cells, we investigated the surface 
expression of β7 (gut-homing) and CLA (skin-homing) markers on proliferating 
T-cells, as identified by negative CFSE expression following LDC stimulation 
(figure 52).  
 
We found a high percentage expression of β7 on proliferating T-cells following 
MLR (46.7±9.8% in HC; 63.7±14.0% CD; 55.8±7.4% overall). There was a trend 
towards higher expression of β7 on T-cells stimulated by LDCs from patients 
with active CD compared to HC, but this did not reach statistical significance 
(p=0.08). However, the intensity ratio of β7 expression on positive cells was 
significantly greater on T-cells following stimulation by LDCs from patients with 
active CD compared to HC (p<0.05). These findings correlate with those from the 
previous chapter, where the same LDCs isolated from patients with active CD 
had significantly greater β7 expression than those from HC. Pre-treating LDCs 
with IFX prior to MLR did not affect β7 expression on proliferating T-cells.  
 
CLA expression on proliferating T-cells following LDC stimulation ranged from 
20.7±4.4% in HC to 35.3±11.0% in CD with overall mean expression being 
26.9±5.6%. There were no differences in CLA expression between T-cells 
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stimulated by LDCs from patients with active CD compared to HC. Pre-treating 
LDCs with IFX prior to MLR stimulation also did not affect CLA expression.  
  
 
 
Figure 52. T-cell phenotype following stimulation. A) Percentage expression and 
intensity ratio (IR) of β7 expression on proliferating T-cells stimulated by IFX-pre-
treated LDCs from patients with active CD and HC. B) Percentage expression and IR 
of CLA expression on proliferating T-cells stimulated by IFX-pre-treated LDCs from 
patients with active CD and HC. 
HC = healthy control, CD = active ileocolonic CD, ns = not significant, * = p<0.05 
Statistical analysis comparing HC and CD groups performed using unpaired t-test. 
Analysis of effects of IFX performed using one-way ANOVA with Dunnett’s multiple 
comparison test. 
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6.4.4   Cytokine profile of stimulated T-cells 
 
Following MLR stimulation, we assessed the intracellular cytokine content of 
proliferating T-cells (figure 53). There was a trend towards reduced TNFα and 
increased IL-17 in T-cells stimulated by LDCs from patients with active CD 
compared to HC, but this did not reach statistical significance (p=0.10 and 0.07 
respectively). There were no differences when analysing the effect of IFX-pre-
treatment of LDCs on the intracellular cytokine content of stimulated T-cells.    
 
 
Figure 53. Intracellular cytokine content of proliferating T-cells. Graphs showing 
cytokine content of T-cells stimulated by LDCs from patients with active ileocolonic 
CD and HC in addition to the effect of IFX-pre-treatment of LDCs prior to T-cell 
stimulation.  
HC = healthy control, CD = active ileocolonic CD, ns = not significant  
Statistical analysis comparing HC and CD groups performed using unpaired t-test. 
Analysis of effects of IFX performed using one-way ANOVA with Dunnett’s multiple 
comparison test. 
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6.4.5   Summary of results 
 
Differences between CD and HC states 
 
 Increased intensity ratio of β7 expression on positive T-cells stimulated 
by LDCs from patients with active CD compared to HC.  
 
 Trend towards reduced TNFα and increased IL-17 content of T-cells 
primed by LDCs from patients with active CD compared to HC (p=ns). 
 
Effect of IFX-pre-treatment on stimulatory capacity and T-cell phenotype 
and intracellular cytokine content  
 
 Dose-dependent reduction in T-cell proliferation when stimulated by IFX-
pre-treated LDCs from both patients with active CD and HC.  
 
 No effect of IFX-pre-treatment on phenotype or intracellular cytokine 
content of stimulated T-cells.  
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6.5  Discussion 
 
Differences between T-cells stimulated from LDCs from CD and HC states 
 
There was increased intensity ratio of β7 expression on proliferating T-cells that 
had been stimulated by LDCs from patients with active CD compared to HC. In 
the previous chapter, we found elevated β7 expression on the same CD LDCs that 
we used for stimulation in this chapter (figure 45, section 5.4.4). In these 
experiments, positive expression of β7 is taken to represent α4β7 integrin 
expression on cells, although this has already been identified as a limitation in 
the methodology (section 1.2.11).  
 
Previous studies designed to investigate the ability of DCs to imprint gut-homing 
properties on T-cells used murine DC from the mesenteric lymph nodes or 
Peyer’s patches (with gut-homing phenotype) to stimulate T-cells from different 
sources. The results showed that α4β7 expression was induced on the T-cells, 
thereby directing them back to intestinal tissue (Stagg, Kamm et al. 2002; Mora, 
Bono et al. 2003). Conversely, T-cell stimulation by DCs from other tissues 
resulted in the expression of skin-homing molecules on the T-cells (Mora, Cheng 
et al. 2005). Our results indicate that, in CD, there is greater β7 expression on 
circulating LDCs and this leads to greater β7 expression on stimulated T-cells. 
The α4β7 : MAdCAM-1 axis has been repeatedly shown to be central in 
development and persistence of chronic intestinal inflammation in CD. One 
recent study demonstrated overexpression of MAdCAM-1 in the gut endothelium 
in patients with active CD. However, 10 weeks following treatment with IFX, 
patients who responded to therapy had significantly decreased expression of 
MAdCAM-1 in the gut, and a corresponding increase in circulating β7+ T-cells 
(Biancheri, Di Sabatino et al. 2013). This study suggests that IFX itself is able to 
exert an inhibitory effect on T-cell recruitment in the gut, and this may 
contribute to reducing chronic inflammation in active CD.  
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There was a trend towards a reduction in TNFα and increased IL-17 content in 
proliferating T-cells that had been stimulated by LDCs from patients with active 
CD compared to HC, albeit these results did not reach statistical significance. In 
the previous chapter, we observed a reduction in ongoing production of TNFα by 
LDCs from patients with active CD (figure 48, section 5.4.5), and this effect 
appears to have been passed on to the stimulated T-cells. We did not assess the 
concentration of TNFα in the cell-free supernatant in this part of the study.  
 
Elevated IL-17 content in T-cells that have been stimulated by LDCs from CD 
patients supports the involvement of the Th17 pathway in the pathogenesis of 
CD. Although IL-17 is not required for Th17 pathway polarisation (this process 
occurs in the presence of IL-6 and TGFβ and amplified by IL-21 and IL-23), Th17 
cells are characterised by increased expression of IL-17a and IL-17F (Wilson, 
Boniface et al. 2007). Studies have consistently shown that IL-17 is highly 
expressed in the mucosa and serum of patients with active CD (Fujino, Andoh et 
al. 2003), therefore supporting their role in CD pathogenesis. Furthermore, the 
receptors for IL-17 are expressed on intestinal epithelial cells (Awane, Andres et 
al. 1999), and Th17 cells are known to have a significant action on the epithelial 
barrier in CD.  
 
 
Effect of IFX-pre-treated LDCs on T-cell stimulation, phenotype and 
ongoing cytokine production  
 
As expected, there was a clear correlation between the quantity of LDCs present 
in the culture and T-cell proliferation. The greater the number of LDCs 
(stimulator cells), the greater the amount of T-cell (responder cell) proliferation 
that occurs. IFX was shown to have a marked effect on the T-cell stimulatory 
capacity of LDCs. This was observed with both LDCs from HC subjects and those 
with active ileocolonic CD. 
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IFX reduces the stimulatory capacity of LDCs from HC and patients with active 
ileocolonic CD in a dose-dependent stepwise manner. This pattern achieved 
statistical significance at several concentrations in both conditions. The 
mechanism by which IFX exerts this action is unclear, especially as we have 
previously shown no changes in activation markers or co-stimulatory markers 
on LDCs following the addition of IFX to in vitro cell culture. The reduction in 
stimulatory capacity may occur as a result of alterations in the cytokine milieu 
produced by LDCs in which antigen presentation is taking place. In the previous 
chapter we observed that cell-free culture supernatants from CD have 
significantly higher concentrations of pro-inflammatory cytokines such as TNFα 
and IL-6 when compared to HC supernatants (figure 49, section 5.4.6). 
Furthermore, cytokines have previously been shown to be the most important 
factor affecting the induction of effector functions in T-cells (de Jong, Smits et al. 
2005). 
 
Clinically, patients treated with IFX may ‘lose response’ to the drug during the 
maintenance treatment phase. Looking across the trials of anti-TNFα therapy use 
in CD, the cumulative loss of response after 12 months ranges between 23-46% 
for both IFX and ADA (Ben-Horin and Chowers 2011). The disease process can 
often be ‘recaptured’ by increasing the amount if IFX given, either by reducing 
the interval between scheduled doses or increasing the amount of the drug given 
at each interval (Katz, Gisbert et al. 2012) thereby increasing the serum 
concentration of IFX. The reduction in the stimulatory capacity of LDCs with 
increasing doses of IFX that we have observed in vitro may go some way towards 
explaining why such dose-escalation works in vivo. Further studies are needed to 
identify the mechanism of reduced LDC stimulatory capacity with IFX. 
 
Finally, there were no changes in T-cell phenotype or intracellular T-cell 
cytokine content following culture with IFX-pre-treated LDCs. This was a 
surprising finding, especially in light of the changes observed on LDCs following 
IFX culture shown previously in chapter 5. IFX has been shown to induce clinical 
remission and achieve immune tolerance in patients with active CD in vivo. 
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Immune tolerance can be achieved by passive or active mechanisms. Passive 
immune tolerance occurs by reduction in stimulatory capacity of DCs, whereas 
active immune tolerance is achieved by induction of a generation of T-cells with 
regulatory phenotype. Based on these results, it seems likely that IFX induces 
regulatory properties in a passive way.  
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Chapter 7  
 
 
Discussion 
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7.1  General discussion 
 
DC phenotype in CD 
 
The first line of investigation was to examine the phenotype of circulating DCs in 
patients with CD. CD is a heterogeneous condition in which inflammation can 
occur at any point along the GIT from mouth to anus, or in extra-intestinal sites. 
We know that DCs express tissue-specific homing markers (Mann, Bernardo et al. 
2012), and have the capacity to imprint these homing markers on effector T-cells. 
Therefore, we hypothesised that DCs were dictating the location of inflammation 
in patients with active CD, and hence their homing phenotype would be altered 
in patients with different anatomical locations of CD inflammation. 
  
Circulating DCs obtained from patients with isolated active colonic CD showed 
up regulation of β7 expression with low levels of CCR9 expression. This gives 
rise to an overall increased gut-homing potential but reduced small bowel 
homing, therefore these DCs are programmed to migrate to the colon. The ligand 
for β7 (Mad-CAM-1) is expressed on intestinal lamina propria high endothelial 
venules, and it’s expression increases significantly in the presence of active 
intestinal CD (Arihiro, Ohtani et al. 2002). Conversely, DCs obtained from 
patients with active SB CD, had high expression of CCR9 and low expression of 
CLA (leading to increased single positive β7 expression). Murine studies have 
shown that CCR9 expression confers SB homing properties on DCs (Hart, Ng et al. 
2010) and the corresponding ligand (CCL25/TECK) is highly expressed on 
epithelial cells in the SB but almost absent in the colon (Papadakis, Prehn et al. 
2000). Furthermore, we found a strong correlation between CCR9 expression on 
mDCs and disease severity in patients with active SB CD. DCs isolated from 
patients with skin-related EIMs had increased CCR10 and reduced CCR4 
expression, but no change in the gut-homing markers (β7 and CCR9) compared 
to HC.  
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These results appear to indicate that the homing profile on circulating DCs does 
correlate with the anatomical location of inflammation in CD. Exactly how this 
occurs remains unclear. The expression of homing markers on DCs is a dynamic 
process and studies have previously identified the importance of constituents of 
the local microenvironment in determining DC homing phenotype (Mann, 
Bernardo et al. 2012; Bernardo, Mann et al. 2013). It may be that inflamed tissue 
in patients with CD secretes factors into the microenvironment which modulates 
DC homing profile, thereby ‘attracting’ them to their own site of inflammation.      
 
There were no differences between the phenotype of circulating DCs when 
comparing healthy controls and patients with ileocolonic CD that had been 
inactive for ≥3 months. Although patients with active ileocolonic CD were not 
studied in this section, it seems likely that they would have a dysregulated DC 
phenotype based on the above observations. This suggests that when patients 
with CD enter clinical remission and the burden of inflammation falls, the DCs 
phenotypically return to a ‘resting state’, which mirrors that of the healthy 
individuals.  
 
 
Effect of IFX on DC phenotype 
 
Having revealed that the phenotype of circulating DCs correlates with the 
anatomical location of active CD, we moved on to investigate the effect of IFX on 
the phenotype of peripheral blood mononuclear cells. The PBMC population was 
chosen (as opposed to solely a DC population) to investigate whether IFX 
modulated homing marker expression on other immune cells in addition to DCs. 
In these in vitro studies, we used a physiological concentration of IFX (100µg/ml) 
which is similar to the concentration found in vivo when patients are treated 
with IFX in clinical practice (Ordas, Mould et al. 2012).     
 
Following culture with IFX, we found increased expression of CCR7 on 
circulating monocytes. The ligands for CCR7 (CCL19 and CCL21) are expressed in 
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lymph nodes and therefore monocytes appear to up regulate their lymph node 
homing capacity, where they are able to perform antigen presentation to effector 
T-cells. If these cells expressed a tolerogenic phenotype then this may indicate 
one potential way in which IFX works.  
 
T-cells appeared to inherit a skin-homing phenotype following culture with IFX 
(reduced β7 and CCR7 expression and increased CCR4 expression). This novel 
finding may represent a previously undescribed mechanism by which 
paradoxical inflammation (PI) occurs, when patients with active CD are treated 
with anti-TNFα therapies in vivo and develop cutaneous psoriatic or eczematous 
inflammation. This exciting finding warrants further investigation by recruiting 
and examining immune cell homing phenotype in patients who develop PI after 
IFX treatment (with a matched control group). The reported incidence of PI in 
patients with IBD is 5-9% (Fidder, Schnitzler et al. 2009; Rahier, Buche et al. 
2010) and therefore recruiting enough patients to find changes in immune cell 
phenotype would be challenging, especially when applying exclusion criteria for 
the study.      
 
There were no changes seen on DC phenotype following culture with IFX. 
However, these experiments were carried out in the setting of freshly isolated 
PBMCs and therefore we moved onto examining the effects of IFX on enriched 
human DCs. 
 
 
Effect of IFX on blood-enriched DCs 
 
Most studies to date investigating human DCs have used monocyte-derived DCs 
(MoDC). As previously discussed, DCs produced by this method cannot be used 
to study homing markers, due to the gradual loss of homing marker expression 
on cells during the 5 day cell preparation and culture phase (figure 39, section 
5.2.1), likely due to the lack of ongoing exposure to tissue microenvironment 
required to condition DCs (Bernardo, Mann et al. 2013). Our laboratory does not 
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have access to a flow sorter and magnetic sorting was ruled out by lack of 
optimisation of the techniques involved.  
 
Therefore, we have used low density cells (LDCs) as our in vitro model of 
circulating human DCs. Cell analysis has shown the isolated LDC population to be 
highly enriched for DCs with a high surface expression of HLA DR, CD11c, CD83 
and CD86 (Knight, Farrant et al. 1986). Previous work from our laboratory has 
also shown that the enriched DC population isolated by this method is 98-100% 
positive for HLA DR expression and has morphological features of DC at both 
optical and electron microscopy (Knight, Farrant et al. 1986; Holden, Bedford et 
al. 2008). The use of LDCs as a model of circulating DCs is further supported by 
our results which showed elevated β7 expression and a trend towards elevated 
CCR9 expression on LDCs from patients with active ileocolonic CD when 
compared to HC. These findings are mirrored by the previous work when we 
found up regulation of β7 and CCR9 on DCs from patients with active colonic and 
SB CD respectively, when we examined DC phenotype as part of PBMCs (figures 
20, section 3.4.3.1 and figure 23, section 3.4.3.4, respectively).  
 
We found further differences between LDCs from patients with active ileocolonic 
CD and HC in terms of cytokine profiles. The ongoing intracellular production of 
TNFα and IL-6 was reduced in LDCs from patients with CD, however the 
concentration of the same two cytokines was increased in the cell-free culture 
supernatant. This may be the result of the experimental methodology we used to 
quantify ongoing cytokine production, in which we measured cytokine 
production over a 4 hour period following 24 hours of cell culture. This process 
means we are only seeing a ‘snapshot’ of cytokine production within this time 
frame. Another possibility is the existence of a negative feedback mechanism 
whereby the high levels of extracellular TNFα and IL-6 that have been produced 
and accumulated during the cell culture phase exert a negative feedback message, 
thus reducing intracellular production. A similar system has previously been 
observed with NKT cells and Th1/Th2 cytokine balance (Onoe, Yanagawa et al. 
2007), but further studies would be needed to confirm this finding in LDCs.  
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Following culture with IFX, we found that the elevated levels of TNFα, IL-6 and 
IL-2 in the culture supernatant were significantly reduced. These 3 cytokines are 
integrally involved in the development of Th1 and Th17 responses that 
characterise CD. The reduction in the concentration of these cytokines following 
culture with IFX is likely to be one of the ways in which IFX works in patients 
with active CD.        
 
We also found changes in LDC phenotype following IFX culture. The most 
significant of these was a reduction in gut-homing affinity, as shown by down 
regulation of β7 expression and a reduction in the intensity ratio of CCR9 
expression on positive cells following the IFX culture period. As previously 
hypothesised, directing immune cells away from the gut may be one way in 
which IFX works in patients with active luminal inflammation. Interestingly, 
there was also a trend towards down regulation of TLR2 and TLR4 expression on 
LDCs, but this did not reach statistical significance. TLRs are used by DCs to 
sense microbes and pathogens which then lead to maturation of the DC. In health, 
TLR2 and 4 expression by human colonic DCs is low (Hart, Al-Hassi et al. 2005) 
and this contributes to their tolerogenic function and prevents unnecessary 
activation of the immune system to commensal microbiota. In IBD, expression of 
TLR2 and 4 by colonic DC is up regulated (Hart, Al-Hassi et al. 2005) and this is 
likely to drive dysregulated immune response to bacterial components of the gut 
lumen. Down regulation of TLR2 and 4 on LDCs following culture with IFX may 
again be another mechanism by which IFX exerts its action.  
 
Overall, the main effects of IFX on LDCs appear to be two-fold. Firstly, there is a 
reduction of pro-inflammatory Th1/Th17 cytokines in the cell-free culture 
supernatant and secondly there is a reduced affinity of LDCs for gut homing. The 
importance of these two factors in the disease process in patients with active CD 
was further reinforced when analysing the patient correlation data. We 
identified that both β7 expression and the ongoing production of IL-6 by LDCs 
positively correlate with disease severity. This overall gives the impression that 
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β7 expression and IL-6 production are of particular importance when examining 
the effect of IFX on LDCs and this warrants further investigation in the future.  
 
 
Effect of IFX pre-treated LDCs on T-lymphocytes 
 
Having proved that human enriched blood DCs are modulated in vitro by IFX, we 
wanted to investigate the functional consequences of this. In order to study this, 
we examined the stimulatory capacity of IFX pre-treated LDCs, and the 
phenotype and cytokine profile of stimulated effector T-cells in vitro.  
 
A major finding arising from this section of the project was the marked reduction 
in LDC stimulatory capacity following culture with IFX. This effect was dose-
dependent and was observed following culture with LDCs from both patients 
with active CD and HC subjects.  Interestingly, we did not observe any changes in 
activation or co-stimulatory markers on the LDCs that may lead to this reduction 
in stimulatory capacity. It seems likely that this may – in part – be due to the 
cytokine milieu in which antigen presentation is occurring. We have shown that 
cell-free supernatant when LDCs have been cultured with IFX contains 
significantly less TNFα and IL-2 with a trend towards lower IL-6 concentration 
(figure 49, section 5.4.6). It is possible that the reduced levels of these pro-
inflammatory cytokines in the milieu are responsible for the reduction in T-cell 
stimulation seen with IFX-pre-treated LDCs, although further studies would be 
needed to confirm this.      
 
The stimulating LDCs from patients with active CD have previously been shown 
to have higher expression of the β7 integrin compared to those from HC, and this 
appears to have been transferred to the responding T-cells, which had higher β7 
intensity ratio than T-cells stimulated by LDCs from HC. It therefore seems that 
LDCs from patients with active ileocolonic CD have an enhanced capacity to 
imprint gut-homing onto responding T-cells. If this effect also occurs in vivo, it 
may highlight one method by which LDCs are triggering gut inflammation.  
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7.2  Experimental limitations  
 
As mentioned during this thesis, one clear methodological limitation is the 
assumption that β7 expression on immune cells is equivalent to α4β7 expression 
and therefore represents a gut-homing phenotype. A tiny proportion of 
circulating lymphocytes (2%) express αεβ7 and therefore will also stain positive 
for β7 expression. The ligand for αεβ7 is e-cadherin and this is expressed on 
epithelial surfaces such as the gut, but also including the lungs and skin, hence 
the cells have a different homing phenotype. However, in view of the scarcity of 
circulating lymphocyte αεβ7 expression, cells which express β7 in the 
experimental work in this thesis are assumed to have gut-homing properties. 
 
When recruiting patients with CD for inclusion in the studies, we included 
patients taking a stable dose of azathioprine. Previous work carried out in our 
laboratory has shown that concurrent use of azathioprine does not affect or alter 
homing marker expression on immune cells. Furthermore, thiopurine therapy is 
widely used in patients with CD, and exclusion of these patients would have 
significantly hindered recruitment to the studies. However, recent studies have 
identified Vδ2 T-cells to play a role in the pathogenesis of CD, by secreting pro-
inflammatory cytokines and stimulating enhanced IFNδ by intestinal CD4+ T-
cells (McCarthy, Bashir et al. 2013). Further work by the same group has shown 
that these cells are ablated in the blood and tissue from CD patients who are 
receiving azathioprine, and post-treatment Vδ2 T-cell recovery correlates with 
time when the drug is withdrawn (McCarthy, Hedin et al. 2015). In view of this, it 
may be that azathioprine is a confounding factor, and its effects on immune cells 
would need to be established in future studies.         
 
Another potential methodological limitation relates to the control groups used 
when studying effects of IFX.  When performing further work examining the 
effect of anti-TNFα therapy in vitro, it would be sensible to add in a further 
control group to allow for non-specific effects of the antibody therapy, using a 
control human IgG.          
225 
 
7.3  The future of targeted biological therapy for CD  
 
Current evidence suggests that a dysregulation of mucosal immunity in the gut of 
patients with CD leads to an overproduction of pro-inflammatory cytokines and 
trafficking of effector leukocytes to the bowel, resulting in gut inflammation. The 
pivotal role of cytokines in this process has led to therapies designed to target 
specific molecules or steps in the inflammatory cascade, for example anti TNFα 
therapies. To date, Infliximab and Adalimumab are the only biological agents 
licensed to treat CD in Europe. Although often efficacious, these therapies have 
clinical drawbacks, such as primary and secondary non-response, the 
development of neutralising antibodies or side effects and complications 
associated with therapy. Golimumab (another human monoclonal antibody that 
targets the TNFα cytokine) has been shown to bind TNFα to a higher affinity 
than IFX or ADA (Shealy, Cai et al. 2010) and is currently in Phase III placebo-
controlled trials for treatment of moderate to severely active UC patients.  
 
Increasing knowledge of the pathogenesis of IBD and the mechanisms, pathways 
and molecules involved in the inflammatory process has led to the identification 
of new potential targets for therapy. These new biological agents are at various 
stages of clinical trials and include: 
 
 Antibodies targeting integrins 
o Natalizumab (anti-α4) 
o Etrolizumab (anti-β7) 
o Vedolizumab (anti-α4β7) 
 
 Compounds targeting integrin receptors 
o PF-00547659 (anti-MAdCAM) 
o Alicaforsen (anti-ICAM-1) 
 
 Compounds targeting chemokine receptors 
o Traficet-EN (anti-CCR9) 
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 Inhibitors of T-cell activation 
o IDEC-131 (anti-CD40L) 
o cM-T412 (anti-CD4) 
o Visilizumab (anti-CD3) 
 
 Inhibitors of T-cell polarization 
o Fontolizumab (anti-IFNγ) 
o ABT-874/J695 (anti-IL12) 
o Basiliximab / Daclizumab (anti-IL2) 
 
 
Targeting integrins, receptors and cytokines is not an exact science and can be 
associated with serious complications. Natalizumab (anti-α4 integrin) showed 
efficacy in moderate to severe CD by blocking gut-homing (Targan, Feagan et al. 
2007) as well as in the treatment of multiple sclerosis by blocking the brain 
homing VLA-4 (α4β1) (Miller, Khan et al. 2003). However, the program had to be 
halted by the manufacturers when there were several cases of re-activation of 
latent JC virus and progressive multifocal leukoencephalopathy (PML). 
Natalizumab inhibits the shared α4 integrin component of both α4β7 and α4β1, 
and this is likely to have a much broader impact on the immune system, 
including impairment of lymphocyte trafficking leading to reactivation of viruses 
when dysregulated immune cell homing is no longer tissue-specific, but overlaps 
with other organs. PML was also reported in patients treated for psoriasis with 
Efalizumab (an adhesion molecule targeting αLβ2), and was subsequently 
withdrawn from the market (Kothary, Diak et al. 2011).  
 
At the time of submitting this thesis (2015), anti-integrin therapy (Vedolizumab) 
is being increasingly used in clinical practice in both anti-TNFα naïve patients 
and those that have failed conventional biological treatment. Vedolizumab (anti-
α4β7 integrin) has shown to be efficacious in clinical trials for UC (Feagan, 
Rutgeerts et al. 2013) and CD (Sandborn, Feagan et al. 2013). A major theme that 
has run through this thesis is the importance of β7 expression on immune cells 
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in CD. This feature has been consistent in all results chapters, both in terms of 
anatomical location of inflammation and correlation with disease severity. The 
effectiveness of anti-α4β7 integrin therapy in CD further underlines the 
relevance of β7 expression on immune cells in CD and it is clear that targeting 
this integrin is going to be a major development in the medical treatment of CD 
in the future.    
 
In this way, an improved understanding of homing markers and integrins in CD 
has the potential to lead to unique and personalised therapy. For example, we 
have shown that patients with isolated active SB CD have dysregulated 
expression of CCR9 on circulating immune cells, while the same cells from 
patients with isolated active colonic CD preferentially express β7. Therefore, it 
may be that patients with isolated SB CD can be treated with anti-CCR9 therapy 
(Vercirnon, also known as Traficet-EN or CCX282) while those with colonic 
disease receive Vedolizumab. This form of personalised therapy may be more 
effective with fewer side effects, as well as being more cost-efficient for the 
health service.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
228 
 
7.4  Future directions for this research 
 
This work has identified some interesting differences in homing marker 
expression on circulating DCs in different phenotypes of CD. There appears to be 
a specific homing marker profile which is unique to the anatomical location of 
inflammation in patients with CD. There are also correlations between the 
quantity of expression of some homing markers and disease severity, for 
example CCR9 expression on circulating mDCs positively correlates with HBI in 
patients with active SB CD (table 8, section 3.4.5). These findings may have a 
significant impact on our understanding of the inflammatory process in CD and 
furthermore may represent important areas of study when looking at targets for 
new therapeutic agents for CD in the future. It is clear that DCs play a 
fundamental role in directing migration of immune cells to target tissues in CD, 
although there is still some uncertainty about how exactly DCs know where to 
migrate to.  
 
The answer to this may lie in the constituents of the microenvironment in which 
DC conditioning occurs. It is known that IL-6 modulates DC homing profile and 
stimulatory capacity in UC (Bernardo, Vallejo-Diez et al. 2012), and a variety of 
other cytokines and vitamins have also been shown to affect immune cell homing 
and phenotype (eg retinoic acid, TGFβ and vitamin D, described in section 
1.2.11). We found significantly elevated levels of IL-6 in LDC culture 
supernatants from patients with active CD compared to HC as well as a 
correlation between IL-6 production by LDCs and disease severity. In light of 
these findings, future work should examine the role of plasma constituents in the 
development of DC homing profiles. One method of studying this would be to 
assess the cytokine and vitamin concentrations in plasma from patients with CD 
and then use the plasma to condition DCs isolated from a HC. The homing profile 
of these conditioned DCs could be compared to those conditioned with plasma 
obtained from a separate HC and potential differences between the two DC 
homing profiles identified. If this process were to identify soluble factors 
responsible for aberrant immune cell homing profiles, it may be possible to block 
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the factors responsible and prevent pathological alterations to homing profiles. 
This approach may represent a future direction for the development of targeted 
therapy in CD.  
 
We have identified several effects of IFX on the homing and cytokine profiles of 
circulating LDCs. Although widely used in clinical practice, the precise 
mechanism of action of IFX remains unclear and there is little published 
literature on its effect on human DCs. We found that LDCs have a reduced gut-
homing affinity (reduced β7 and CCR9 expression) and reduced levels of the pro-
inflammatory cytokines TNFα and IL-2 in the supernatant following culture with 
IFX. There were no changes in surface expression of ‘activation markers’ such as 
HLA DR, CD80 and CD40 on LDCs.  Despite this, we found that IFX pre-treated 
LDCs have a significantly reduced T-cell stimulatory capacity which is dose-
dependent. Taken together, these findings reinforce previous observations that 
cytokine profile is the most important factor effecting the induction of T-cell 
effector function (de Jong, Smits et al. 2005). Further work is needed to examine 
and identify the molecular and cellular mechanisms through which IFX is 
exerting its effect on immune cells.    
 
The work carried out in this thesis was performed using circulating human DCs 
and blood-enriched DCs in vitro. This approach has several advantages when 
setting out to study DC homing marker expression. For example, there are high 
numbers of immune cells in fresh blood, thereby providing ample cell numbers 
to test a wide range of homing markers and cytokines. Previous work has shown 
that intestinal DCs only compromise a very small proportion (0.5-1%) of viable 
cells obtained from fresh human gut biopsies [Dr David Bernardo, personal 
communication]. In view of the limited cell numbers obtainable for experimental 
work, we felt it would have been useful to have already identified markers of 
interest to study from blood work. Our original study design was to identify 
patients with active CD involving distal colon, who were being worked up for 
treatment with IFX. In addition to acquiring blood samples, we planned to 
perform a flexible sigmoidoscopy to obtain fresh colonic biopsies from inflamed 
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areas of mucosa. DCs would be isolated and phenotyped from both blood and 
intestinal mucosa. The process would have been repeated after the 8 week IFX 
induction course had been administered.         
 
Unfortunately, we found it difficult to recruit patients for a longitudinal in vivo 
study, as described above, for a number of reasons. Concurrent medications was 
an issue, as patients had often had their immunomodulator therapy increased 
recently (within 3 months) prior to starting biological therapy or were taking 
corticosteroids, thereby being excluded from the study. Another problem was 
lack of distal colonic inflammation which we could sample with flexible 
sigmoidoscopy (ie those patients with isolated SB or ileocaecal CD would be 
excluded). Only two patients were recruited over a 6 month period. Blood and 
gut samples were taken and analysed on both, but unfortunately one patient 
withdrew consent for the second round of sample acquisition and the other was 
prescribed a course of corticosteroids before the 8 week IFX induction period 
had finished. The natural next step would be to confirm our findings using fresh 
intestinal DCs isolated from patients with active CD and HC in a prospective, 
longitudinal study providing paired data for analysis. In particular, it would be 
interesting to correlate changes in DC phenotype following IFX therapy to 
particular cohorts of patients, such as primary non-responders, patients with 
EIMs or those that develop paradoxical inflammation as a consequence of IFX 
therapy. 
 
Finally, all the work on the effect of anti-TNFα therapy on immune cells in this 
thesis was carried out using IFX. Future work may investigate effects of other 
anti-TNFα therapies on immune cells in the same setting, in particular ADA and 
CZP, both of which are widely used for the treatment of CD, albeit the latter is not 
yet licensed in the UK. Studies have shown the IFX, ADA and CZP share several 
mechanisms of action (neutralisation of TNFα and upregulation of Treg 
population). However, they have different molecular structure and this can 
result in functional variations. For example, CZP lacks an Fc region and therefore 
does not induce cytotoxicity of tmTNF-bearing cells by antibody- or 
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complement- dependent cell cytotoxicity, whereas IFX and ADA were shown to 
be very effective in this manner (Scallon, Cai et al. 2002). The differential effect of 
these therapies on DCs has not previously been studied and may be of interest in 
the future.  
 
In conclusion, we found that homing marker expression on circulating human 
DCs correlates well with anatomical location of inflammation in patients with CD. 
In vitro culture with IFX effects homing marker expression, cytokine profiles and 
the stimulatory capacity of LDCs and this is likely to represent one mechanism 
by which anti-TNFα therapies work in vivo.   
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